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Abstract 
 
Introduction 
Triple negative breast cancers are defined by their lack of expression of HER, oestrogen receptors 
and progesterone receptors.  They account for around 10-24% of cases.  To define a cancer by the 
biomarkers it does not express is unsatisfactory.  Triple negative breast cancer has been linked to 
aspects of metabolism and metabolic disorders such as diabetes.  There are several biomarkers 
that are of interest and overlap in both their roles in breast cancer and in aspects of metabolism.  
Fatty acid binding protein 7 (FABP7) is one of 9 FABPs that is involved in the transport, 
solubilisation and regulation of metabolism of various fatty acids.  Expression profiling and 
immunohistochemistry (IHC) studies have identified FABP7 to be over-expressed in a subtype of 
breast cancer that can be considered almost synonymous with triple negative breast cancer; 
basal-like breast cancer, so called because it expresses cytokeratins that are characteristic of basal 
epithelial cells.  The role of FABP7 in breast cancer is not fully understood and studies have given 
conflicting results in regards to the relation to prognosis.  Evidence suggests that FABP7 can be 
regulated by methylation acetylation and exposure to fatty acids.  Insulin like growth factor 
binding protein-2 (IGFBP-2) is a member of the IGF-axis that is responsible for altering cell growth 
and metabolism.  IGFBP-2 has been found to be over-expressed in many cancers including those 
of the prostate and breast.  Phosphotensin homolog (PTEN) is a tumour suppressor gene that is 
responsible for dephosphorylating PIP3 to inhibit the Akt pathway and thus inhibit cell growth and 
promote apoptosis.  IGFBP-2 has IGF independent actions; it can down-regulate PTEN through 
binding of an integrin receptor and therefore have mitogenic and anti-apoptotic effects.   
Aims 
To study the expression of the metabolic biomarkers FABP7, IGFBP-2 and PTEN in clinical cases of 
Malaysian TN breast cancer.  To use appropriate cell lines in order to more fully understand 
whether epigenetic mechanisms and FAs regulate FABP7 expression. To over-express FABP7 in a 
breast cancer cell lines and to further understand the role of FABP7 in breast cancer. 
Methods 
IHC was used to assess FABP7, PTEN and IGFBP-2 expression in a cohort of triple negative breast 
cancer cases.  FAs, a demethylation agent-AZA and a histone deacetylase inhibitor-TSA were used 
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to investigate what regulated FABP7 in cell lines.  Over-expression experiments were used to 
understand the effect of FABP7 in breast cancer cell lines. 
Results 
FABP7 expression in patient samples was associated with lower grade, basal-like phenotype, FAS 
expression and although not significant, improved patient survival.  Treatment of BT-20 and MDA-
MB-231 cell lines with AZA and TSA resulted in increases in FABP7 mRNA expression.  Fatty acid 
treatment led to changes in FABP7 mRNA expression.  Combinations of AZA and fatty acids gave 
large increases in FABP7 mRNA expression.  Over-expression of FABP7 in BT-20 cells resulted in 
increased cell viability and although not significant changes in expression of survivin, caspase 9 
and their splice variants.  IGFBP-2 expression was associated with poor patient survival though 
this was not significant.  PTEN loss was a frequent event in the cohort of triple negative breast 
cancer cases; 48.3% of cases had PTEN loss.  PTEN loss was associated with poor patient survival 
though this was not significant.  PTEN loss was associated with expression of IGFBP-2. 
Discussion & Conclusions 
FABP7 is likely to play a role in patient survival as demonstrated in the patient samples.  FABP7 
over-expressing BT-20 cells tended to have increased survivin FL and ΔEX3 expression. Both 
increased mitochondrial activity and survivin expression have been found to be associated with 
improved prognosis in breast cancer and this may explain some mechanisms by which FABP7 
results in better prognosis in the TN breast cancer cases in this study.  Since FABP7 mRNA 
expression was not increased to fold changes comparable to oestrogen receptor re-expression 
after AZA and TSA treatment, it is unlikely that the FABP7 gene is methylated or regulated by 
acetylation.  It is possible that there are genes upstream of FABP7 such as transcription factors 
that are regulated my methylation and acetylation and therefore impact on FABP7 expression 
after treatment with AZA and TSA.  This is the first study that demonstrates the significant 
relationship between IGFBP-2 expression and PTEN loss in patient samples.  PTEN loss is a 
frequent event in TN breast cancer.  IGFBP-2 and PTEN loss may be useful markers of prognosis in 
TN breast cancer. 
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1 Introduction 
 
1.1 The Breast and Breast Cancer 
Breast cancer is the most common type of cancer in the UK with over 45,000 new cases each year 
(Cancer Research UK, 2010).  Worldwide it is one of the leading causes of cancer deaths with 
approximately 519, 000 dying each year from the disease with incidence increasing with age 
(World Health Organisation, 2009).   
The human breast is comprised of fatty and fibrous tissues or stroma, with ducts and lobes.  The 
lobes, also called glands produce milk during lactation (figure 1.1).  The breasts, or mammary 
glands, are one of the few tissues that are subjected to major morphological changes during 
developmental phases such as puberty and pregnancy.  For instance, nulliparous women had 
significantly less lobular development and differentiation than women who had children (Russo et 
al., 2005).  The network of ducts are formed before birth by branching out throughout the fat 
pad; they comprise of a basal layer of myoepithelial cells and a layer of specialized epithelial cells 
(Dontu et al., 2003) (figure 1.1).  Epithelial, mesenchymal and stromal interactions occur under 
the influence of hormones from the pituitary and the ovaries, such as oestrogen and 
progesterone; these interactions and hormones are essential for breast development during life 
(Robinson et al., 1999; Howard & Gusterson, 2000). 
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Figure 1.1 A diagram showing the main structures of the breast and in situ and invasive breast 
cancer 
The breast is comprised of fatty tissue and milk ducts.  The lobes or glands produce milk during 
lactation.  Ducts comprise of a basement membrane with a layer of myoepithelial or basal cells 
and a layer of epithelial cells that line the inside of the ducts, a cross sectional representation is 
shown above.  Breast cancer can be contained within the duct, in situ, or invasive.  Diagram 
adapted from http://cancerhelp.cancerresearchuk.org 
 
Breast cancer is a heterogeneous group of diseases that usually originate from the epithelial cells 
lining the ducts or glands, however, it can also develop from the layer of myoepithelial cells in the 
duct or within the surrounding tissues of the glands and ducts.  Breast cancer originating from the 
ducts can be in situ (DCIS) i.e. contained within the duct or invasive where tumour cells have 
invaded outside of the duct (figure 1.1).  The multistep theory of breast cancer development helps 
explain how breast cancer arises and progresses (Thompson et al., 1992; Beckmann et al., 1997); 
Redacted due to copyright
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a schematic representation is shown in figure 1.2.  More recently mechanisms other than an 
accumulation of genetic abnormalities have been shown to be important in carcinogenesis and 
tumour progression.  For example epigenetic alterations such as methylation or acetylation, 
leading to changes in gene expression, and posttranslational modification of proteins that lead to 
differences in function or activity, are important factors in tumourigenesis (Cancer Genome Atlas 
Network, 2012; Sharma et al., 2010).  
 
 
 
Figure 1.2 A schematic representation of the multi-step theory of carcinogenesis 
This figure represents the multistep theory of carcinogenesis.  It begins with an initiating event, 
for example, a mutation in an oncogene or tumour suppressor gene.  The abnormal cell then 
divides at a faster rate than the normal cells leading to benign hyperplasia.  Further mutations 
occur eventually leading to highly abnormal and invasive cells. 
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The initiating event in the development of breast cancer can be caused by inherited gene 
mutations, such as mutations in BRCA1 or 2 (discussed in section 1.3.5); BRCA1 and 2 mutations 
are frequent in familial breast cancer, i.e. breast cancer that can be traced through generations of 
women.  It is estimated that carriers of BRCA1 or BCRA2 mutations have around an 80% risk of 
developing breast cancer by age 70.  However BRCA1 and BRCA2 mutations are present in only 
around 5-10% of all breast cancers (Ford et al., 1998; Oesterreich & Fuqua, 1999; Peto et al., 
1999).  The remaining breast cancers are sporadic and can be initiated by environmental 
exposures such as diet and lifestyle which are to be discussed further; as mutations accumulate, 
the abnormal cells become more invasive and grow out of the ducts.  Due to the proximity of the 
breast to the lymphatic system, breast cancer can invade other tissues in the body through this 
network.   
 
1.2 Diagnosis and screening of breast cancer 
In the UK there is a breast cancer screening programme.  Women between the age of 50 and 70 
are invited for a mammography every 3 years, by the year 2016 this will be extended to ages 47 to 
73 (Cancer Research UK).  A mammography is an X-ray of the breast that can help detect 
calcification or other changes in tissue density that are indicative of breast cancer.  In addition to 
this women are educated to check their breasts for lumps or changes on a regular basis.  An early 
study found that breast self examination was associated with a lower stage of cancer at the time 
of diagnosis compared to women who never undertook self examination; it was predicted that 
breast self examination would lead to a 10% reduction in 5 year mortality rates (Feldman et al., 
1981).  However there is much debate over the use of mammography and reduction in mortality 
rates.  One study found by looking over a 20 year period in Sweden before and after screening 
was introduced breast cancer mortality rates significantly reduced in the women who were 
routinely screened; this was not due to changes in incidence or clinical practice (Tabar et al., 
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2003). Another study in Denmark had similar findings with a 25% reduction in mortality due to 
screening (Olsen, et al., 2005).  In contrast to this, a different group in Denmark found no 
reduction in mortality due to screening; they also compared their results to other countries 
including the UK and stated there were similar findings (Jorgensen et al., 2010).  Over diagnosis of 
breast cancer due to mammography screening is also an issue; breast cancers that would 
otherwise not have been detected nor given any harm to patients, as they would have died from 
other causes first, are treated unnecessarily (Jorgensen et al., 2009; Zackrisson, et al., 2006). On 
detection of an abnormality a biopsy or fine needle aspiration is taken; these methods collect cells 
for microscopical examination.  The samples are studied by a pathologist who can distinguish 
abnormal cancer cells from normal breast cells.  If breast cancer is confirmed, surgery is 
undertaken to remove the tumour.  The surgery can be a lumpectomy, where just the tumour and 
some surrounding breast tissue is removed, or a mastectomy, where the whole breast is removed.  
The expression of markers such as oestrogen receptors, progesterone receptors and human 
epidermal growth factor receptor are used to determine targeted therapy options and prognosis; 
these are to be discussed further.   
 
1.3 Breast cancer types and incidence 
The most common type of breast cancer is ductal carcinoma arising from the epithelial cells or less 
commonly the myoepithelial cells of the duct.  Approximately 70-80% of breast cancers diagnosed 
in the UK are invasive ductal carcinoma (Cancer Research UK, 2010).  Breast cancer can also arise 
in the lobes from epithelial cells, as in figure 1.1; like ductal carcinoma, lobular carcinoma can be 
in situ or invasive.  Rarer types of breast cancer include medullary, so called because the 
macroscopic appearance resembles the medulla in the brain; mucinous, where cancer cells are 
surrounded by mucin, and tubular breast cancer, named after the tube-like structures observed 
under the microscope.  As mentioned breast cancer can also develop within the tissues 
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surrounding the breast ducts and glands; this type of breast cancer is also rare accounting for less 
than 1% of breast cancers, it is called angiosarcoma of the breast (Gallager, 1984).  These different 
types of breast cancer encompass histological classification; invasive types have poorer prognosis 
than those in situ; though there are other more recent means of classifying breast cancer for 
example at the molecular level. 
Breast cancer can be classified according to stage and grade.  Grade is based on microscopic 
appearance of the cancer cells for example, cell morphology, nuclear pleomorphism and numbers 
of mitotic figures; a score of 1-3 is applied depending on the extent of how abnormal the cancer 
cells are for each criteria; these scores are combined leading to a grade of 1-3 (Blamey et al., 2007; 
Bloom & Richardson 1957) (table 1.1) 
 
 
 
 
 
 
 
 
Table 1.1 Breast cancer grading 
Breast cancer is graded according to tubule formation, nuclear pleomorphism and mitotic count; 
the score for each of these is combined to give the final grade.  Information from Blamey et al., 
(2007); Bloom & Richardson (1957) and Elston & Ellis, (1991). 
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Stage takes into account tumour size and extent of invasion; (table 1.2).  Breast cancers with lower 
grade and stage tend to have a better outcome; for instance in a study by Henson et al., (1991); 
the outcomes of over 20,000 breast cancer cases were compared to grade and stage; grade 1 
breast cancers had an overall survival rate of 93% compared to grade 3 with 65% survival at 5 
years (Henson et al., 1991). 
 
 
 
 
 
 
 
Table 1.2 Staging criteria for breast cancer tumours 
Breast cancer is staged according to the tumour size (T), amount of invasion to lymph nodes (N) 
and surrounding tissues (M); the higher the stager the poorer the prognosis. This table represents 
the current ‘TNM’ staging criteria (information from Cancer Research UK) 
 
1.3.1 Hormone receptor positive breast cancer 
Breast cancer can be classified according to the positivity of the hormone receptors for oestrogen 
(ER) and progesterone (PR) as demonstrated by immunohistochemistry (IHC).  The proportion of 
hormone receptor over-expressing cases is between 70-80% but varies with age, with the highest 
proportion in western populations being in those over 65; individuals may also not necessarily be 
positive for both ER and PR as demonstrated using IHC (Rhodes et al., 2000; Li et al., 2003; Rakha 
et al., 2007b; Rhodes & Jasani, 2009).   
Stage Features 
1 <2cm in size. No invasion anywhere. 
2A 
<2cm in size some lymph node involvement OR 2-5cm in size no lymph 
node involvement OR No tumour in breast but tumour in lymph nodes 
under armpit. 
2B 
<5cm in size and lymph node involvement OR >5cm in size but no lymph 
node involvement. 
3A 
No tumour in breast but clumps of tumour cells in lymph nodes OR <5cm in 
size and lymph nodes contain clumps of tumour cells OR >5cm in size 
lymphnodes contain clumps of cells but no further invasion. 
3B 
Tumour has attatched to chest wall or skin; lymph nodes may or may not 
contain tumour cells but no metastasis. 
3C 
Any size; invasion in lymph nodes and under breast bone or to nodes 
around the collar bone. No further invasion. 
4 
Any size and lymph node involvment; tumour has invaded other tissues of 
the body, for example lungs, liver or bone. 
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Oestrogen has been implicated in carcinogenesis in a number of circumstances (figure 1.3); 
oestrogen metabolites can induce DNA damage though binding to guanine or adenine to form 
unstable DNA adducts, or by oxidative damage to DNA (Yager & Davidson, 2006). Oestrogen can 
also drive carcinogenesis in the breast through activation of the ER and downstream signalling 
pathways; the activated ER can also bind to transcription factors to activate them and to ER 
response elements in DNA to recruit or prevent binding of activators or co—activators; as a result 
gene expression is altered.  For example, ER can interact with transcription factors including 
activating protein 1 (AP1), specificity protein 1 (SP1) and nuclear factor-κB (NF—κB) (Fox et al., 
2009; Thomas et al., 2010).  Breast cancer cells that express ER are over stimulated by oestrogen 
and so apoptosis is inhibited and proliferation is promoted.  ER over-expression can occur through 
hypomethylation of the gene or, in a small number of cases, amplification of the gene (Fantl et al., 
1990; Piva et al., 1990). 
 
 
 
 
 
 
 
Figure 1.3 The mechanisms of oestrogen carcinogenesis 
Oestrogen can drive breast cancer through either its metabolites damaging DNA and altering 
expression through direct binding, or through binding to the ER to directly or indirectly activate or 
inhibit transcription of genomic or mitochondrial DNA.  This leads to increased proliferation and 
decreased apoptosis.  Diagram adapted from (Yager & Davidson, 2006). 
Redacted due to copyright
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Patients with ER positive breast cancer tend to have better survival than patients with ER negative 
breast cancer.  One early study found that 2 year survival rates were around 70% in ER positive 
patients compared to approximately 60% survival in ER negative patients (Bishop et al., 1979); 
another study found that beyond 2 years survival differences between ER positive and negative 
patients was more marked (Stewart et al., 1981).  However in more recent years, overall breast 
cancer survival rates have improved; in 2009 the five year survival was 85.1% (Cancer Research 
UK).  This improvement is a result of improved therapy which will be discussed further.  ER 
positive tumours tend to metastasize to the bone unlike ER negative tumours which spread more 
often to the brain and liver (Stewart et al., 1981).  More recently metastases in ER positive breast 
cancers have been linked to acquired regions of ER binding and that FOXA1, a DNA binding 
protein, reprograms the binding of ER in metastatic breast cancer (Ross-Innes et al., 2012).  
Initially, PR status was used as an indicator of ER function as the receptors are expressed in 
response to ER signalling pathway activation (Lange, 2008).  Breast cancers can be PR positive and 
ER negative; it was originally thought this may be a technical artefact but recent work has 
demonstrated otherwise (Ng et al., 2012).  More recently it has been found that the PR is involved 
in carcinogenesis independently of the ER signalling pathways; PR signalling can sensitize cells to 
growth factors.  In addition post-translational modifications, such as phosphorylation of PRs, are 
important in cell signalling within breast cancer (Knutson et al., 2012).  PR is also useful for 
predicting mortality in breast cancer; a retrospective study found that PR positivity was associated 
with an improved prognosis and was particularly useful in predicting outcome when combined 
with factors such as ER and lymph node status in patients that had received endocrine therapy 
(Bardou et al., 2003). 
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1.3.2 Treatment of hormone receptor positive breast cancer 
The main drug utilised that targets hormone receptor positive breast cancer is tamoxifen.  
Tamoxifen can be used in conjunction with chemotherapeutic agents and works by binding to the 
ER (figure 1.4), therefore preventing activation of proliferative and anti-apoptotic genes.  A recent 
clinical trial evaluated the effectiveness of tamoxifen combined with everolimus, a drug that 
inhibits mTOR signalling pathways.  The combination of tamoxifen with everolimus lead to 
improved overall survival and increased time to breast cancer progression than tamoxifen used 
alone (Bachelot et al., 2012).  Due to the effectiveness of tamoxifen against breast cancer 
preventative use has been suggested; one study gave tamoxifen or a placebo to women for 5 
years, they found that the incidence of breast cancer in the tamoxifen group was 24.8 per 1000 
women compared to 42.5 for the placebo group (Fisher et al., 2005).  Another group of drugs 
used against hormone receptor positive breast cancer are aromatase inhibitors; they work by 
inhibiting the enzyme complex that converts hormones, such as testosterone, to oestrogens, thus 
reducing the production of oestrogen so there is less oestrogen to bind to ERs and stimulate the 
cancer cells (figure 1.4).  It has been suggested that aromatase inhibitors can be used to prevent 
breast cancer, particularly in women with high plasma oestrogen levels (Goss & Strasser, 2001; 
Smith & Dowsett, 2003; Johnston & Dowsett, 2003). 
Despite targeted therapies for ER positive breast cancers, some do not respond or become 
resistant to treatment.  Mechanisms for this include loss of ER expression or a mutation that 
results in loss of ER function and tolerance of tamoxifen through increased metabolism of the 
drug (Ring & Dowsett, 2004). 
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Figure 1.4 The action of targeted therapies for ER positive breast cancer 
There are 2 types of targeted therapy for oestrogen receptor (ER) positive breast cancer.  
Tamoxifen prevents the binding of oestrogens to the ER so that in turn gene promoters that 
contain regions of ER binding, i.e. ER response elements (EREs), are not activated.  These EREs of 
promoter regions are upstream of ER target genes that when activated increase cell proliferation.  
Aromatase inhibitors work by preventing the production of oestrogens by inhibiting the 
aromatase enzyme complex from converting androstenedione and testosterone to oestrogens 
such as oestrone and oestradiol.  Both tamoxifen and aromatase inhibitors prevent activation of 
EREs in promoter regions upstream of ER target genes so that proliferation is inhibited.  Adapted 
from Johnston & Dowsett (2003). 
Redacted due to copyright
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1.3.3 Human epidermal growth factor receptor 2 positive breast cancer 
Human epidermal growth factor 2 (Her2) is an important biomarker used in the prognosis of 
breast cancer.  It is an epithelial growth factor receptor (Egfr) related tyrosine kinase and is part of 
the HER/ErbB2/Neu family.  In the normal breast, Her2 is involved with development and growth.  
Activation occurs through dimerisation of two Her2 receptors to form a homodimer, or through 
dimerisation of Her2 and another receptor from the Her family to form a heterodimer.  The 
homodimers or heterodimers phosphorylate substances such as themselves or other signalling 
molecules such as Phosphoinositide 3-kinase (PI3K) (Yarden & Sliwkowski, 2001), that lead to 
intracellular signalling causing increased cell proliferation and survival (Yarden, 2001; Dean-
Colomb & Esteva, 2008).  The glycoprotein receptor is over expressed in 20-30% of invasive breast 
carcinomas (Slamon et al., 1987; Yarden, 2001; Nunes et al., 2008).  HER2/neu is the gene that 
encodes Her2; it is found on chromosome 17 and is a proto-oncogene.  Amplification of this gene 
is responsible for Her2 over-expression in 90% of Her2 positive cases (Slamon et al., 1987; 
Popescu et al., 1989).  The remaining Her2 over-expressing cases are due to gene deregulation at 
a post-transcriptional level (Miller et al., 1994).  Most Her2 positive tumours are ER and PR 
negative and are associated with a poorer prognosis than breast cancers with hormone receptor 
over-expression (Tandon et al., 1989; Cheang et al., 2009).  More recently it has been found that 
polymorphisms in the IGF-I gene can differentiate between good or poor survival within Her2 
positive breast cancer (Muendlein et al., 2013). 
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1.3.4 Treatment of Her2 positive breast cancer 
Like ER and PR, Her2 over-expression can be demonstrated by IHC.  Cases are scored on the 
amount and intensity of membrane staining; this is used to help determine response to treatment 
with the drug trastuzumab (herceptin).  Cases that are 1+ or negative are considered not to 
benefit from targeted therapy whereas those that are 3+ are offered the drug (Nahta & Esteva, 
2006).  Equivocal cases, i.e. those with a 2+ score (figure 1.5), where membrane staining is not 
complete or as intense as a 3+ case, are tested further with fluorescence in situ hybridisation 
(FISH), chromogenic in situ hybridisation (CISH) or more recently silver enhanced in situ 
hybridisation (SISH).  The FISH, CISH and SISH techniques use nucleic acid probes that bind to 
specific sequences of DNA or RNA is tissue sections.  The probes are labelled so that they can be 
visualised when bound to the DNA or RNA.  Using these techniques it is possible to visualise how 
many copies of the HER2/neu gene are present within the breast cancer (Hicks & Tubbs, 2005).  
This determines whether the HER2/neu gene is amplified (Dietel et al., 2007; Nunes et al., 2008; 
Shousha et al., 2009).  If the gene is amplified in Her2 positive equivocal cases the patient will 
receive trastuzumab therapy. 
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Figure 1.5 The range of Her2 expression in invasive breast cancer 
Cases that are 0 or 1+ will not receive therapy as Her2 is not over-expressed.  Cases that are 2+ 
have intermediate intensity staining that is present in more than 10% of the tumour but is 
incomplete around the cells.  These cases will be subjected to in situ hybridisation to determine 
treatment.  Cases that are 3+ have strong staining that is complete in greater than 10% of the 
tumour forming a “chicken wire” pattern.  These cases are most likely to benefit from 
trastuzumab therapy.  (Images from “latest breast cancer” website). 
 
Trastuzumab is a monoclonal antibody that works by preventing dimerisation of the Her2 
receptors with other Her2 receptors or members of the Her family such as epidermal growth 
factor receptor (Egfr).  Trastuzumab can lead to activation of the immune system to initiate a 
response against the cells over-expressing Her2 and prevent the tyrosine kinase activity of Her.  
This prevents phosphorylation of itself and activation of other signalling molecules.  These actions 
in turn lead to decreased proliferation and increased apoptosis (figure 1.6). 
Redacted due to copyright
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Figure 1.6 The action of trastuzumab 
Trastuzumab prevents dimerisation of Her2 receptors with each other or other members of the 
Her2 family.  This blocks activation of signalling pathways leading to induction of apoptosis and 
decreased proliferation.  Trastuzumab can also lead to immune activation and decreased tyrosine 
activity to prevent phosphorylation of other Her2 and other signalling molecules.  Adapted from 
Burstein (2005). 
Redacted due to copyright
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Trastuzumab can be used in conjunction with chemotherapeutic agents such as docetaxel, and 
has been shown to improve survival of breast cancer patients; this improvement was noticeable 
even after only one year of follow up (Stebbing et al., 2000; Smith et al., 2007).  Recently, a clinical 
trial has investigated the combined use of trastuzumab and docetaxel with another monoclonal 
antibody that targets Her2.  Pertuzumab targets a different subdomain of Her2 than trastuzumab.  
The findings of the trial showed that pertuzumab in combination with trastuzumab and docetaxel 
resulted in a reduction of breast cancer progression and increased survival compared to cases 
treated with only trastuzumab and docetaxel.  The study highlighted the importance of blocking 
Her2 dimerisation with other Her family members by targeting more than one region of the Her2 
receptor at once (Baselga et al., 2012). 
Despite over-expressing Her2, some breast cancers are resistant or become resistant to 
trastuzumab.  One resistance mechanism is the truncation of the Her2 receptor, trastuzumab 
cannot bind to Her2 because the extracellular domain is not present (Pohlmann et al., 2009). 
Another drug used against Her2 positive breast cancer is Lapatinib, a molecule that inhibits Her2 
and EGFR dimerisation thus blocking downstream signalling of these receptors.  Lapatinib has 
been found particularly effective against breast cancers that are resistant to trastuzumab 
(Konecny, et al., 2006). 
 
1.3.5 Other targeted therapies for breast cancer 
More recently other targeted therapies for breast cancer have been developed.  One example is 
Avastin.  Avastin is a monoclonal antibody that targets vascular endothelial growth factor (VEGF).  
VEGF stimulates the growth of blood vessels and can be over-expressed in many cancers including 
those of the breast.  In a tumour, targeting VEGF is useful, as it slows blood vessel growth and 
thus prevents gas exchange and nutrients reaching the tumour cells (Ferrara et al., 2005; Rugo, 
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2004).  Clinical trials have shown that Avastin is effective in improving relapse free survival but not 
overall survival (Bear et al., 2012).  Due to these trial results there has been much debate over the 
use of Avastin; recently the National Institute and Clinical Excellence (NICE) has said it should not 
be used in advanced metastatic breast cancer because of the added cost as Avastin did not show 
any added benefit compared to current drugs alone (Cancer Research UK 2012 news). 
Another group of drugs that are classed as targeted therapy are Poly (ADP-ribose) Polymerase 
(PARP) inhibitors.  PARP is an enzyme involved in the repair of single strand breaks (SSBs) in DNA.  
PARP inhibitors block the repair of SSBs (Virag & Szabo, 2002) which, if left unrepaired, convert to 
double strand breaks (DSBs).  BRCA1 and BRCA2 are known as breast cancer susceptibility genes 
because mutations in these genes result in a high probability of developing breast or ovarian 
cancer.  BRCA1 acts as a tumour suppressor gene and encodes a protein that is involved with 
maintaining genetic stability.  The exact functions of BRCA1 and the pathways it is involved with 
are complex; recently Brca1 has been implicated in the regulation of fatty acid synthesis through 
acetyl-coA carboxylase (ACC) (Brunet et al., 2008).  Brca1 binds to the phosphorylated or inactive 
form of ACC, the rate limiting enzyme in fatty acid synthesis, and stabilises phospho-ACC.  If Brca1 
is abnormal or present in low levels, ACC is more abundant in its active form, thus impacting on 
cell metabolism through fatty acid synthesis (Brunet et al., 2008).  The interaction of ACC with 
Brca1 occurs through protein interaction motifs, called BRCT domains; these domains can be 
affected when BRCA1 is mutated (Magnard et al., 2002).  With regards to action on DNA repair, 
Brca1 and Brca2 interact with RAD51 to repair DNA by forming a macromolecular complex.  In 
addition Brca1 is also a transcriptional regulator; reviews have outlined how Brca1 can bind to 
enzymes involved in transcription to activate them.  Brca1 can also bind directly to promoter 
regions of genes; for example p21 a cell cycle regulator, to activate cell cycle checkpoints to allow 
DNA repair or ensure cell death if repair is not possible (Welcsh et al., 2000; Yoshida & Miki, 
2004).  Inactivating mutations in BRCA1 and 2 lead to an accumulation of DNA damage and cell 
cycle deregulation including DSB that are usually repaired by homologous recombination.  PARP 
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inhibitors are useful in tumours that have BRCA inactivating mutations or where BRCA is lost as 
they prevent SSB repair so DSBs occur leading to synthetic lethality or cell death.  However cells 
can overcome PARP inhibition when they retain one copy of BRCA1 or become resistant through 
functional mutations in BRCA or when mutations occur in other genes that enable restoration of 
DNA repair (figure 1.7 and figure 1.8) (De Soto et al., 2006; Lord & Ashworth, 2008; Underhill et 
al., 2011; Polyak & Garber, 2011). The pathways that PARP is involved with SSB repair and BRCA is 
involved in DSB are outlined in more detail in figure 1.8. 
 
 
 
 
 
 
 
 
Figure 1.7 The action of PARP inhibitors in breast cancer 
PARP inhibitors prevent the repair of single strand breaks (SSBs) leading to double strand breaks 
(DSBs) that will be lethal to tumour cells lacking Brca protein (caused by loss of heterozygosity 
(LOH) of the BRCA genes).  Tumours or normal cells (that carry BRCA abnormalities) retaining one 
copy or a functional mutated form of BRCA and normal cells will be resistant to death by PARP 
inhibition. Figure from Polyak & Garber (2011). 
Redacted due to copyright
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Figure 1.8 The role of PARP in SSB repair and the role of BRCA in DSB repair 
A: PARP is recruited to the site of the single strand break which in turn recruits the scaffold 
protein XRCC1.  DNA polymerase β (polβ) replaces the damaged nucleotide and DNA ligase III 
(LigIII) is recruited to ligate the nick.  If PARP is inhibited this process cannot occur and the SSB 
leads to DSB. B:DSBs are repaired by homologous recombination.  This figure shows how BRCA is 
involved in the repair of DSB. Phosphorylation of BRCA1 leads to complex formation with BRCA2, 
BRCA1-associaated RING domain protein 1 (BARD1) and RAD51.  This complex is relocated to the 
area of DNA replication after damage marked by proliferating cell nuclear antigen (PCNA).  In 
normal cells this leads to DNA repair and normal cell cycle.  In cells with BRCA dysfunction DNA 
repair is not possible; in cells with normal tumour suppressor gene expression such as p53 and 
cell cycle checkpoint gene expression such as p21, cell cycle arrest and apoptosis occurs. In cells 
with abnormal p53 or checkpoint genes cell proliferation can occur. Adapted from Arnold & 
Goggins (2001) and Curtin (2005). 
Redacted due to copyright
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Despite such targeted therapies some breast cancers do not respond or become resistant and 
currently research is being undertaken to understand why and to develop alternatives. Moreover 
there are a group of breast cancers that do not express ER, PR of Her2 and consequently do not 
respond to targeted therapy such as aromatase inhibitors, tamoxifen or trastuzumab. 
 
1.4 Triple negative breast cancer 
There are 10-24% of breast cancers that do not over-express ER, PR or Her2, so called triple-
negative (TN) breast cancers due to their lack of expression of these key biomarkers.  These breast 
cancers tend to be of a higher grade and stage than other breast cancers (Rakha et al., 2007b); 
they also tend to have poorer survival, as in figure 1.9, and are more likely to metastasize to 
distant sites (Kaplan & Malmgren, 2008; Dent et al., 2009; Hernandez-Aya et al., 2011).  Compared 
to other breast cancers TN breast cancers occur in a younger age group, for example a median age 
of diagnosis of 48 was reported in a TN cohort and another group found that TN breast cancer was 
more common in those under the age of 40 (Bauer et al., 2007; Hernandez-Aya et al., 2011). 
 
 
 
 
 
Figure 1.9 The survival probability of triple-negative breast cancers 
This graph shows the survival probability of TN breast cancers in years after diagnosis.  TN 
patients have poorer survival probability, decreasing over time compared to other hormone 
receptor positive and Her2 positive breast cancer (Dent et al., 2009). 
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TN breast cancers are less likely to be diagnosed by screening methods such mammography or 
ultrasound; suggestions for this include the rapid growth rate of TN tumours or differences in 
tumour density of TN breast cancers compared to other breast cancer types leading to difficult 
detection through imaging of the breast (Dent et al., 2007).  Currently, patients with these highly 
aggressive tumours have a poor prognosis, with no specific therapy available for their treatment 
as there is for hormone receptor and Her2 positive breast cancer (Reis-Filho & Tutt, 2008).  To 
define TN breast cancers by markers they do not express is an unsatisfactory way of classifying and 
studying these important tumours.  Fortunately, expression profiling has identified a group of 
breast carcinomas that are somewhat synonymous with triple negative breast cancer, in that the 
majority of them are negative for ER, PR and Her2.  
 
1.4.1 Basal-like breast cancer 
Breast cancers have been traditionally defined by their histological nature i.e. their appearance or 
markers they express with IHC.  Molecular profiling techniques are becoming more commonplace 
in defining breast cancer types.  Molecular profiling involves looking at protein, mRNA or DNA on 
a level where many comparisons are made at the same time.  One technique in particular, 
microarray analysis, involves a microarray of DNA probes for specific genes of interest.  The cDNA 
samples, converted from mRNA, bind to these probes and a signal is emitted reflecting the levels 
of expression of a gene of interest (DeRisi et al., 1996; Liotta & Petricoin, 2000; Morris & Carey, 
2007).  These types of techniques are not without their disadvantages; they do not necessarily 
take into account any post-translational modifications of proteins; these can have significant 
effect on the function of the protein.  Molecular profile techniques also do not take into account 
any mechanisms for over-expression of a gene, for example, gene amplification or epigenetic 
changes; tumour heterogeneity can also be overlooked (Morris & Carey, 2007).  Despite these 
disadvantages molecular profiling is an extremely useful tool and has resulted in new ways of 
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classifying breast cancer.  The different molecular subtypes of breast cancer reflect distinct gene 
patterns.  Luminal subtypes of breast cancer tend to express hormone receptors and have 
properties of luminal epithelial cells such as expression of low molecular weight cytokeratins; 
ERBB2+ breast cancer over-express HER2 and ‘normal breast’ cancers were found to express 
genes associated with adipose tissue and non-epithelial cells such as lipoprotein lipase and 
integrin-α7 (Perou et al., 2000; Sorlie et al., 2001).  Basal like breast cancer (BLBC) is so named 
due to expression of genes typical of basal/myoepithelial cells, such as high molecular weight 
cytokeratins (CK) demonstrated by expression arrays (Perou et al., 2000; Sorlie et al., 2001; Rakha 
et al., 2008).  The consensus is that these types of breast cancer originate from the myoepithelial 
or basal layer of cells within the duct.  Cytokeratins (CKs) are intermediate filament proteins that 
help comprise the mammalian cell cytoskeleton.  The expression of particular CKs reflects the 
type, differentiation state and function of the epithelial cell.  The expression of CKs can aid the 
classification of breast cancer (Perou et al., 2000; Sorlie et al., 2001; Abd El-Rehim et al., 2004; 
Nielsen et al., 2004; Rakha et al., 2006).  For example, luminal epithelial cells, and therefore 
breast cancers of luminal type, typically express low molecular weight CKs such as CK7, CK8, CK18 
and CK19; whilst myoepithelial or basal cells tend to express high molecular weight CKs such as 
CK5/6, CK14 and CK17 (Abd El-Rehim et al., 2004; Rakha et al., 2008).  However, there is a debate 
as to whether BLBC actually originate from the myoepithelial/basal cells or just share a similar 
phenotype (Livasy et al., 2006).  Since molecular profiling is not currently cost efficient and 
feasible to carry out on a large scale, in particular on routine surgical specimens, IHC staining of 
the basal CKs such as CK5/6 CK14 and CK17 has been found to be an effective alternative to 
identify BLBC (El-Rehim et al., 2004; Nielsen et al., 2004; Reis-Filho & Tutt, 2008; Kuroda et al., 
2009).  From molecular profiling and IHC studies there is an overlap between TN and BLBC; 56-
84% of TN cases express basal markers however not all BLBCs are TN (Perou et al., 2000; Sorlie et 
al., 2001; Rakha et al., 2007; Rakha et al., 2008; Reis-Filho & Tutt, 2008). BLBC also tend to be 
associated with poorer survival (figure 1.10).  Rakha et al, (2006) reported similar findings; BLBC 
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was associated with the poorest survival rates in both lymph node negative and positive cases.  
The development of BLBC has been associated with certain risk factors; for example, early 
menopause and multi-parity and not breast feeding; similarly to TN breast cancer, breast cancer 
at a younger age was also more likely to be BLBC (Millikan et al., 2008).   
Figure 1.10 Survival probabilities of the molecular subtypes of breast cancer 
Molecular profiling has led to the definition of 6 subtypes of breast cancer; luminal A, luminal B, 
luminal C, normal breast-like, ERBB2+ (Her2+) and basal like. Basal-like breast cancers have the 
poorest survival probability. Adapted from Sorlie et al. (2001). 
Molecular profiling has identified biomarkers associated with BLBC; for instance expression of 
HER1/EGFR in approximately 50% of cases, mutation of the P53 gene and expression of the C-KIT 
gene (Rakha et al., 2006; Rakha et al., 2007; Kreike et al., 2007).  There is also overlap between 
breast cancers with BRCA1 mutations, sometimes called hereditary or familial breast cancer, with 
BLBC and TN breast cancer; nearly all BRCA1 cases are of basal like phenotype and more than 60% 
of medullary and metastatic (breast cancers that have spread in to tissues beyond the breast) 
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BLBCs have BRCA1 gene promoter methylation (Lakhani et al., 2005; Turner & Reis-Filho, 2006; 
Turner et al., 2007; Reis-Filho & Tutt, 2008; Saal et al., 2008).  Not all BLBC express these markers 
or have such genetic alterations.  To define TN and BLBCs by the markers they do express would 
be more useful; particularly if there are targeted therapies available for those markers or related 
pathways. 
1.5 Metabolism and candidate biomarkers in triple negative breast cancer 
Obesity is on the increase worldwide particularly in western countries such as the UK and USA and 
it is estimated to increase healthcare costs by around £2 billion by 2030 in the UK (Wang et al., 
2011) due to the increased risk of developing diseases such as diabetes, heart disease and cancer.  
Postmenopausal women with a body mass index (BMI) of over 30 have a 31% increased risk of 
developing breast cancer compared to postmenopausal women with a BMI below 25; obese 
women who develop breast cancer also tend to have poorer overall survival and increased breast 
cancer progression and metastasis than women of a healthy weight (van den Brandt et al., 2000; 
Morimoto et al., 2002; Calle et al., 2003; Lahmann et al., 2004; Berclaz, et al., 2004; Lorincz & 
Sukumar, 2006).  One study reviewed the evidence behind the link between obesity and breast 
cancer and proposed the involvement of several pathways (figure 1.11).  Increased fat levels or 
adiposity can increase circulating levels of insulin and insulin-like growth factor-I (IGF-I to be 
discussed further), tumour necrosis factor-α (TNF-α) and adipokines such as leptin (Lorincz & 
Sukumar, 2006).  TNF-α is an inflammatory cytokine that is secreted by adipocytes that can lead 
to increased expression of aromatase, thus activating hormonal dependent tumourigenic 
pathways.  Leptin is also secreted by adipocytes and regulates food intake by acting on the 
hypothalamus.  Leptin can act as a growth factor in breast cancer cell lines, resulting in a more 
aggressive phenotype (Hu et al., 2002).  Lorincz & Sukumar, (2006) used the evidence to propose 
the mechanisms by which obesity is linked to breast cancer; however the majority of mechanisms 
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are proposed to occur through the ER, this does not take into account the link between obesity 
and breast cancers that do not express ER such as many Her2 positive and TN breast cancers. 
Figure 1.11 The proposed link between obesity and breast cancer 
Adiposity can result in increased levels of insulin, IGF-I and TNF-α and leptin.  IGF-I activates the 
IGF-1 receptor (IGF-1R) leading to phosphorylation of IRS and SHC.  IRS-1, IRS-2 and SHC activate 
the PI3K and MAPK signalling pathways leading to increased cell proliferations. Adiposity leads to 
increased ER signalling through a number ways.  For instance IGF-I can interact with oestradiol to 
increase cell proliferation by activation of the ER and IGF-1R.  The high levels of the inflammatory 
cytokine TNF-α and the growth factor leptin in adiposity lead to increased aromatase activity and 
thus oestrogen synthesis.  Consequently ER signalling pathways are activated that result in 
increased cell growth and invasion in breast cancer.  This diagram is from Lorincz & Sukumar 
(2006). 
Definitions: E2, oestradiol; E1, oestrone; T, testosterone; Δ4A, Δ4A-androstenedione; ApN, 
adiponectin; PI3K, phosphoinositide 3-kinase; IRS, Insulin receptor substrate; SHC, Src homology 2 
domain containing transforming protein 1.  
Lorincz A M , and Sukumar S Endocr Relat Cancer
2006;13:279-292
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Type 2 diabetes is also associated with an increased breast cancer risk; insulin resistance leads to 
increased levels of circulating insulin that can activate signalling pathways such as RAS and PI3K 
(to be discussed further), through the insulin receptor and cause increased proliferation and 
decreased apoptosis (Wolf et al., 2005). 
There is evidence linking together aspects of metabolism and TN breast cancer, these are outlined 
in detail below and in figure 1.12.  For instance, metabolic syndrome is a combination of medical 
disorders such as central obesity, raised triglyceride levels in the blood and high blood pressure, 
which substantially increase an individual’s risk of developing heart problems or diabetes.  
Investigation has taken place linking breast cancer with the metabolic syndrome and its 
associated diseases; metabolic syndrome is more common in patients with TN breast cancers than 
other breast cancers but it is yet to be determined whether metabolic syndrome increases the risk 
of TN disease (Maiti et al., 2010).  There is also conflicting evidence as to whether obesity 
increases the risk of developing TN breast cancer; one study found that a high BMI increases the 
risk of developing TN breast cancer (Pierobon & Frankenfeld, 2012), in contrast to this another 
found that there was no difference between obesity and physical activity and the subtype of 
breast cancer (Phipps et al., 2011).  Breast cancers with BRCA1 abnormalities tend to be of 
TN/basal like phenotype; Brca1 has recently been shown to be involved in the regulation of fatty 
acid synthesis through interaction with acetyl-coA carboxylase (ACC) (Brunet et al., 2008).  Brca1 
binds to the phosphorylated or inactive form of ACC, the rate limiting enzyme in fatty acid 
synthesis, and stabilises it.  If Brca1 is mutated or present in low levels, ACC is more abundant in 
its active form, thus converting acetyl coA to malonyl coA to increase fatty acid synthesis by fatty 
acid synthase (FAS) (section 1.3.5).  It has been suggested that women with BRCA1 mutations 
could be treated with drugs used for diabetes such as metformin or through calorie deprivation 
and exercise, as this would increase AMP-activated protein kinase (AMPK) levels that would in 
turn inhibit ACC (Magnard et al., 2002).  Fatty acid synthase (FAS) is another biomarker linking 
metabolism and cancer; FAS is up-regulated in many cancers including those of the breast, 
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prostate, colon and endometrium but it is not fully understood why or how (Kuhajda, 2000).  FAS 
expression was associated with an increased risk of breast cancer reoccurrence (Alo' et al., 1996) 
and up-regulation of FAS confers chemotherapy resistance; down regulation of FAS caused breast 
cancer cell lines to become more sensitive to chemotherapy drugs (Liu et al., 2008; Zeng et al., 
2010).  Insulin-like growth factor (IGF) -I has been shown to up-regulate FAS in malignant breast 
cancer cells and when FAS was suppressed, IGF-I mediated cell growth was inhibited and the cells 
were no longer resistant to palmitate induced death (Zeng et al., 2010).  Figure 1.12 shows the 
interaction of breast cancer biomarkers and aspects of metabolic pathways.  For instance liver 
kinase B1 (LKB1) is a tumour suppressor gene that can phosphorylate AMPK to activate it; this 
prevents fatty acid synthesis (Shaw et al., 2004).  The biomarkers of interest in the present study 
that will be discussed further are fatty acid binding protein 7 (FABP7), insulin-like growth factor 
binding protein 2 (IGFBP-2) and phosphatase and tensin homolog (PTEN). 
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Figure 1.12 The interaction of metabolic pathways and breast cancer 
The interaction of PTEN and IGFBP-2 is outlined further in section 1.7.1 (1).  The PI3K pathway 
phosphorylates PIP2 to PIP3; PIP3 is an important activator of the Akt pathway, which impacts on cell 
growth and proliferation.  PTEN dephosphorylates PIP3 to the inactive form PIP2 so the Akt pathway is 
not activated and thus cell proliferation is inhibited (Panigrahi et al., 2004) (2).  It has been found that 
in the breast cancer cell line MDA-MB-231 palmitate inhibits the PI3K pathway so in turn the Akt is 
inhibited; oleate activates the PI3K pathway in turn promoting cell proliferation (Hardy et al., 2000).  
Palmitate can induce apoptosis by its conversion to ceramide and also independently of ceramide 
conversion (de Pablo et al., 1999; Listenberger et al., 2001).  When FAS is up-regulated some breast 
cancer cells are resistant to palmitate induced apoptosis (Zeng et al., 2010) (3).  FABP7 binds to FAs 
such as palmitate and oleate to transport them and regulate FA metabolism (4).  The binding of IGF-I 
to the IGF-receptor (IGFR) has been shown to up-regulate the expression of FAS (Zeng et al., 2010) 
(5).Acetyl-CoA Carboxylase-α (ACC- α) is the rate limiting step in FA synthesis, it converts AcetylCoA 
to MalonylCoA. One study found that by inhibiting ACC- α apoptosis of cancer cells was induced 
(Chajes et al., 2006) (6). When ACC- α is phosphorylated (pACC- α) it become inactive.  Studies have 
shown that Brca1 binds to pACC- α and stabilizes it; therefore in cancers with BRCA1 mutations, 
Brca1 can no longer bind to pACC- α and stabilize the inactive form (Brunet et al., 2008; Magnard et 
al., 2002; Moreau et al., 2006).  This means that there is more active ACC- α and thus more 
conversion of AcetylCoA to MalonylCoA for FA synthesis (7).  Phosphorylated AMPK (pAMPK) is 
responsible for phosphorylating ACC- α to inactivate it.  Under low energy conditions there is an 
increased AMP: ATP ratio; AMPK responds to this by preventing fatty acid synthesis and thus 
prevents the consumption of ATP until the balance is corrected (Shaw, 2006).  One study, 
immunohistochemically staining for pAMPK, found evidence to suggest that AMPK can be 
dysfunctional in primary breast cancer and thus reactivation of the AMPK pathway may be of 
therapeutic benefit (Hadad et al., 2009) (8).  LKB1 is a tumour suppressor gene. LKB1 has been found 
to phosphorylate AMPK activating it and this preventing fatty acid synthesis (Shaw et al., 2004) (9). 
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1.6 Fatty acid binding protein 7 
Fatty acid binding protein 7 (FABP7) is involved in aspects of metabolism and may be a useful 
biomarker in the investigation of TN breast cancer.  FABP7 is also known as brain lipid binding-
protein (BLBP/FABP-B) as it was first discovered in the brain.  There are 9 FABPs, all around 15kDa 
in size, that have a role in the solubilisation of various fatty acids (FAs) and their transport, storage 
and FA metabolism.  The exact function and mechanisms of action of FABPs are not fully 
understood, however much work has been carried out examining their structure in order to 
uncover their function.  For example FABPs have a β-barrel tertiary structure that forms a cavity 
where FAs bind; additionally FABPs also have a helix-loop-helix motif which is thought is the point 
of entry for the FAs.  Gene expression analysis has revealed that FABP7 is over expressed in BLBC 
(Sorlie et al., 2001).  IHC has also demonstrated that FABP7 is associated with BLBC and TN breast 
cancer though there is conflicting evidence as to whether FABP7 is associated with poor or good 
prognosis; one breast cancer study using IHC concluded that FABP7 was associated with improved 
survival probability (Zhang et al., 2010); another concluded that FABP7 was associated with poor 
survival (Tang et al., 2010).  Such differences could be a reflection of the cohorts being unselected 
and different in size (Zhang et al., 2010; Tang et al., 2010).  Studies have shown that  FABP7 
inhibits cancer cell growth; over expressing FABP7 in the MDA-MB-231 breast cancer cell line 
significantly inhibited cell growth and promoted differentiation (Shi et al., 1997).  This effect was 
synergised with docosahexaenoic acid (DHA) supplementation (Wang et al., 2000).  In contrast a 
study on FABP7 in melanoma found that down-regulating FABP7 expression decreased cell 
proliferation and invasion and when it was over-expressed, cell proliferation and invasion were 
increased (Goto et al., 2006).  A continuation of this demonstrated, using IHC, that expression of 
FABP7 was associated with poorer survival and relapse of melanoma, although FABP7 expression 
was lost when patients progressed from primary melanoma to metastatic melanomas (Goto et al., 
2010).  Loss of heterozygosity of the FABP7 gene in metastatic melanomas may be responsible for 
the loss of FABP7 expression and thus improved prognosis (Goto et al., 2010).  In glioblastomas 
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FABP7 is also associated with poor prognosis and dietary supplementation of DHA has been found 
to increase FABP7 mRNA in rat brain (Kaloshi et al., 2007; Nasrollahzadeh et al., 2008).  These 
studies demonstrate the possibility of using FABP7 as a biomarker of prognosis in TN breast 
cancer.  A recent study by Mita et al. (2010) indicated that it was the relative abundance of FAs 
that influenced the role of FABP7 in gliomas.  Figure 1.13 illustrates how the relative abundance of 
arachidonic acid (AA) and DHA alter how FABP7 aids induction or inhibition of pro-migratory 
genes through activation of cyclooxygenase 2 (COX2) and PPAR-γ pathways.  Such results may link 
in with indications that the binding of a FABP to a FA induces a conformational change in the FABP 
that enhances or decreases its ability to bind and interact with other proteins and thus affect its 
function (Storch & McDermott, 2009).  Additionally the relative expression of FABP7 with COX2 or 
PPAR-γ could be predictive of prognosis. 
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Figure 1.13 Cytoplasmic and nuclear roles of FABP7 and its interaction with AA and DHA 
FABP7 can bind to AA or DHA depending on the relative abundance of each that has entered or 
has been produced in the cell.  FABP7 can shuttle AA to the COX2 pathway.  The COX2 pathway 
leads to the conversion of AA to prostaglandin (PGE2).  PGE2 has many functions including roles in 
inflammation; in this instance PGE2 functions to activate downstream signalling pathways and 
induce migration and proliferation.  FABP7 can also shuttle DHA to the nucleus where DHA is 
transferred to PPAR-γ. DHA and PPAR-γ bind to DNA and inhibit COX2 pathway activation and 
thus PGE2 synthesis leading to down-regulation of pro-migratory signalling. The binding of DHA 
and PPAR-γ and DHA to DNA can also lead to activation of anti-proliferative pathways.  Diagram 
adapted from (Mita et al., 2010). 
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FABP3, also called mammary derived growth inhibitor (MDGI), has high sequence homology with 
FABP7 and has been shown to be down-regulated by IGF-I dose dependently in mutant mice.  
Furthermore it was found that insulin like growth factor-II (IGF-II), a ligand of the IGF axis, 
expression was inversely correlated with FABP3 expression (Huynh & Beamer, 1998).  FABP3, 
similarly to FABP7, is also thought to inhibit cancer cell growth and promote differentiation; one 
study found this by expressing a peptide designed to mimic the effects of FABP3 in breast cancer 
cell lines (Wang et al., 2000).  Nevo et al. (2010) found that one possible reason for the tumour 
suppressing activity of FABP3 is that it regulates integrin activity which in turn has a role in cell 
motility, growth and adhesion.  Considering the sequence homology of FABP3 and FABP7 it may 
be possible that FABP7 also has interactions with integrin, IGF-I and –II and thus the IGF axis.  
This evidence suggests that the role of FABP7 may be different in different cancers and that 
expression may relate to cancer progression and stage.  However, the association of FABP7 and 
prognosis in breast cancer is not understood; learning more about it will add to understanding 
about what drives TNBC.  Equally as important as the function of FABP7 are the mechanisms that 
regulate it. 
 
1.6.1 Methylation and acetylation of FABP7 
Epigenetic changes alter gene expression without affecting the sequence of DNA (Esteller, 2008); 
such changes have been shown to play an important role in gene expression of cancer cells and 
thus cancer development and progression. 
Two examples of epigenetic mechanisms are histone acetylation and DNA methylation.  Two 
families of enzymes regulate histone acetylation, histone acetyl transferases (HATs) and histone 
deacetylases (HDACs).  HATs weaken the interactions between DNA and histones by acetylating 
lysine residues; the weakened interactions cause the chromatin to decondense and allow 
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transcription of genes to occur (Hassig & Schreiber, 1997; Struhl, 1998; Wade et al., 1997).  HDACs 
reverse the acetylation so chromatin condenses and thus gene transcription is prevented (Struhl, 
1998; Wade et al., 1997).  DNA methylation is the addition of a methyl group to CpG regions of 
DNA.  CpG regions are composed of a cytosine base linked to a guanine base by a phosphodiester 
bond.  DNA methyltransferases (DNMT) methylate the cytosine to make 5-methylcytosine; which 
is important in determining whether a gene is expressed (Pradhan & Esteve, 2003).  If methylation 
occurs in the promoter region of a gene then that gene can be silenced because binding of 
transcriptional proteins is impeded (Momparler & Bovenzi, 2000; Worm & Guldberg, 2002).  DNA 
methylation can also silence genes through facilitation of histone deacetylation.  Methyl-CpG 
binding proteins (MeCPs) are recruited to the methylated sites and can bind to DNA and 
chromatin (Nan et al., 1997).  The MeCPs then in turn recruit HDACs that, as described, remove 
acetyl groups and cause chromatin to condense (Nan et al., 1998).  Additionally repression of 
transcription can occur through the binding of HDACs directly to the DNA methyltransferase 
DNMT1 (Fuks et al., 2000).  In cancer these mechanisms can become dysregulated leading to 
hypermethylation or hypoacetylation so a gene is under-expressed or hypomethylation or 
hyperacetylation where a gene is over-expressed (Archer & Hodint, 1999; Grønbaek et al., 2007).  
Epigenetic changes have been studied within different subtypes of breast cancer to try to discover 
the difference in what drives them and to open up new targets for treatment.  Suzuki et al. (2009) 
used immunohistochemistry (IHC) to show decreased histone acetylation in DCIS and invasive 
ductal carcinoma (IDC) compared to normal breast epithelium; they also found that HDAC 
expression was also decreased in tumours compared to normal tissue.  It was suggested that this 
may be due to the relative activity levels of HDACs and HATs. Elsheikh et al. (2009) reported 
similar findings also using IHC.  Differing methylation states have been found between the 
different subtypes of breast cancer; in particular it was noted that luminal B breast cancers have a 
high global methylation frequency compared to other subtypes (Holm et al., 2010).  A recent 
study identified novel genes and their methylation status and found this was associated with 
34 
 
prognostic factors in breast cancer; in particular a gene called RECK was associated with poorer 
prognosis when it was methylated (Hill et al., 2011).  There is some evidence suggesting that 
FABP7 may be epigenetically changed in cancer.  For example differences in FABP7 methylation 
was observed between subsets of chronic lymphocytic leukaemia; FABP7 was listed as a 
methylated gene in the immunoglobulin heavy-chain variable mutated genes type (Kanduri et al., 
2010).  Etcheverry et al. (2010) used techniques to study whole genome methylation and 
identified FABP7 as one of several genes that were hypomethylated in glioblastomas compared to 
the normal brain; this results in over-expression of FABP7 protein in glioblastomas.  As discussed 
FABP3 has a similar structure and function to FABP7 in breast cells.  A study by Huynh et al. (1996) 
demonstrated that FABP3 is hypermethylated and thus silenced in both breast cancer cell lines 
and a selection of patient breast tumours.  It is therefore possible that FABP7 may be 
hypermethylated in some breast cancers.  Currently there is little information regarding changes 
in the acetylation status of FABPs in cancer.  However it has been reported that the expression of 
FABPs can be altered through changes in histone acetylation; trichostatin A (TSA), an HDAC 
inhibitor, was demonstrated to increase A-FABP (FABP4) expression in RAW 264.7 macrophages 
(Coleman et al., 2010).  Treatment with TSA was also enough to negate the inhibitory effect of 
linoleic acid on FABP4 expression (Coleman et al., 2010).  It would be useful and interesting to see 
if FABP7 in breast cancer cell lines is regulated by epigenetic mechanisms.   
 
1.6.2 Fatty acid regulation of FABP7 
There are many other mechanisms other than acetylation and methylation that can alter gene 
expression.  For example, there is an abundance of evidence demonstrating that fatty acids (FAs) 
can alter gene expression.  FAs have important roles in metabolism, cell signalling and 
maintenance of membrane fluidity and permeability; they are vital components of living cells.  As 
reviewed by Duplus et al., (2000), FAs can negatively and positively regulate gene expression; this 
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can be direct, for example, by the binding of FAs to transcription factors, or indirect by the 
regulation of signal transduction pathways (figure 1.14) (Jump, 2004).  Gottlicher et al., (1992) 
were among the first to determine that fatty acids such as linoleic acid and oleate can bind to 
nuclear receptors such as PPARs; in turn affecting gene transcription.  Other transcription factors 
targeted by FAs include hepatic nuclear factor 4 (HNF4), retinoic X receptor (RXR) and sterol 
regulatory element binding proteins (SREBPs) (Jump & Clarke, 1999; Duplus &Forest, 2002; Jump, 
2004; Sampath & Ntambi, 2004;).  FAs not only alter gene expression at a transcriptional level but 
also at a post-transcriptional level; for example through the regulation of mRNA degradation 
(Duplus & Forest, 2002). 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 The mechanisms by which fatty acids can alter gene expression.   
Fatty acids can directly alter gene expression by binding to a transcription factor.  Fatty acids can 
also change gene expression indirectly by modifying membrane composition and cellular 
metabolism; this in turn activates signalling pathways which can regulate the abundance and 
activity of transcription factors.  Ultimately changes in the gene expression affect cellular 
metabolism, growth and differentiation. This diagram is taken from Jump (2004). 
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Lipid binding studies have shown that some FABPs have an affinity for certain FAs; this could help 
explain FABP functions although evidence is conflicting.  For instance Zimmerman et al. (2001) 
noticed that generally FABPs have a higher affinity for unsaturated FAs.  In contrast to this, it was 
confirmed that although FABP7 has a high affinity for unsaturated FAs it actually bound saturated 
FAs with a higher affinity; this was the opposite of what was predicted.  Since FABP7 is found in 
the brain and as the brain requires high levels of unsaturated FAs, it was thought that FABP7 
would have a higher affinity for unsaturated FAs (Richieri et al., 2000).  Differences between 
species origin of FABP and the types of FA they bind have also been found, for example, murine 
FABP7 does not bind to palmitate but human FABP7 binds to palmitate, oleate, docosahexaeonic 
acid and arachidonic acid (Xu et al., 1996; Richieri et al., 2000; Zimmerman et al., 2001). 
FAs alter the expression of FABPs; for example FABP4 levels were altered in RAW264.7 
macrophages by exposing the cells to FAs (Coleman et al., 2010).  Unsaturated FAs such as 
linolenic acid and palmitoleic acid decreased FABP4 mRNA and protein; however the unsaturated 
FA eicosapentaenoic acid significantly decreased FABP4 protein but mRNA levels were not notably 
different from the control (Coleman et al., 2010).  Hyder et al. (2010) found that FABP3 and FABP5 
mRNA and protein increased in rat pancreatic islet cells and NS-1E cells (a rat pancreatic β-cell 
line) by treatment with palmitate and oleate; β-oxidation of these FAs is required for the 
increased expression.  This was elucidated by treating the cells with an inhibitor of carnitine 
palmitoyl transferase 1, an enzyme catalysing the rate limiting step in β-oxidation (Hyder et al., 
2010).  Interestingly the research also found that agonists and antagonists of PPARs altered the 
expression of both FABPs; of note both FABP3 and 5 mRNA were increased by a PPAR-α agonist in 
addition FABP5 mRNA was also increased by a PPAR-γ agonist (Hyder et al., 2010).  This indicates 
that the FAs interact with PPARs to increase FABP expression.  FABP1, also known as liver-FABP, 
was up-regulated at both the mRNA and protein level by oleate in rat hepatoma cells (Meunier-
Durmort et al., 1996).  It was found that mRNA levels increased in a dose dependent manner and 
that the protein increase relied on de novo protein synthesis demonstrated using the protein 
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synthesis inhibitor cycloheximidine (Meunier-Durmort et al., 1996).  Other long chain FAs found to 
increase FABP1 expression in the rat hepatoma cells included palmitate, AA and linoleic acid.  The 
group went on to show the up-regulation of FABP1 mRNA was potentiated by treatment with 9-
cis-retanoic acid (9cis-A) (Poirier et al., 1997). 9cis-RA binds to RXRs and oleate bind to PPARs; it 
was postulated that a heterodimer of RXR and a PPAR bound to a PPAR response element (PPRE) 
in the FABP1 gene initiating transcription (Poirier et al., 1997).  Another instance of FA operating 
with other molecules to alter expression is shown by DHA activating the RXR by acting as a 
transcription factor when bound to FABP7; however this causes the activation of the RXR rather 
than FABP7 but it is plausible that there may be some feedback mechanism involved that in turn 
alters the expression of FABP7 (Liu et al., 2012).  FABP3 has been shown to have similarities in the 
way it acts to FABP7, particularly in breast tissue.  FABP3, also called heart-FABP, expression can 
be increased at the mRNA level in cardiomyocytes by treatment with long chain FAs (Chang et al., 
2001).  FAs including palmitate, oleate and AA increased FABP3 mRNA at least 2 fold after 10 
hours of incubation, it was reported that levels remained high after 24 hours but cell viability 
drastically decreased so incubation remained a maximum of 10 hours (Chang et al., 2001).  
Palmitate produced the greatest increase of mRNA and it was postulated that this was due to 
accumulation of palmitate in the cytoplasm inhibiting fatty acid oxidation(Chang et al., 2001).  
These pieces of evidence demonstrate that the relationships between FAs and FABP gene 
expression are complex; as mentioned previously FA can alter gene expression directly or 
indirectly and pre- or post-transcriptionally.  Any of these processes are possible in the FA 
regulation of FABP expression. 
Considering the evidence that FAs can alter the expression of FABPs and that FABP7 is associated 
with TN breast cancer as well as regulating FA metabolism, it is logical that FAs could alter the 
expression of FABP7 in TN breast cancer. 
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1.7 Insulin-Like Growth Factor Binding Protein 2 
Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) is a member of the Insulin-like growth 
factor family of which there are 6 binding proteins and a type 1 IGF receptor (IGF-IR) that regulate 
the mitogenic and anti-apoptotic effects of two ligands, insulin-like growth factor –I and –II (IGF-I 
and IGF-II).  IGFs, particularly IGF-II, have been found to be essential in foetal growth (Duan, 
2002); links with the growth hormone axis and epidemiological studies have shown that IGFs are 
important in determining height; individuals who are taller are more at risk of developing cancer 
particularly of the breast or prostate (Okasha et al., 2002).  Moreover circulating IGFs have been 
linked to the risk of developing breast cancer; for instance one study found that increased serum 
IGFs were linked to an increased risk of developing breast cancer in premenopausal women but 
not those who were postmenopausal (Hankinson et al., 1998).  Another study had similar findings 
and also noted that low serum IGFBP-3 levels were associated with an increased risk of 
developing breast cancer in premenopausal women (Allen et al., 2005).  Both IGF and IGFBP 
expression fluctuate throughout mammary gland development and lactation; altering the 
expression of members of the IGF axis impacts on mammary gland growth and differentiation 
(Flint et al., 2008).  One study, determining IGFBP-2 expression with IHC, found that the more 
aggressive the breast cancer the higher the IGFBP-2 expression when compared to benign lesions 
(Busund et al., 2005).  IGFBP-2 has also been demonstrated to be over expressed in anti-
oestrogen resistant breast cancer cell lines (Maxwell & van den Berg, 1999; Juncker-Jensen et al., 
2006).  So et al. (2008), demonstrated that IGFBP-2 was not of prognostic value in hormone 
receptor positive breast cancers and that there was no correlation with Her2; moreover in the 
hormone receptor negative cases IGFBP-2 was associated with poorer disease specific survival.  It 
was originally thought that the actions of IGFBP-2 and the other IGFBPs were dependent on IGFs 
but IGF independent actions have been identified.  For instance, some IGFBPs have heparin 
binding sites (Firth & Baxter, 2002).  It has recently been found that IGFBP-2 is a novel regulator of 
the tumour suppressor Phosphatase and Tensin-homolog (PTEN) (section 1.8).  Perks et al., (2007) 
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illustrated that the breast cancer cell line MCF-7 does not respond to high levels of IGF-II as a 
result of PTEN induction and that IGFBP-2 suppresses PTEN when it is not bound to IGF-II as 
shown in figure 1.15.  Alternatively, PTEN may regulate the expression of IGFBP-2 as 
demonstrated by Levitt et al., (2005) in the U251 glioma cell line; inducing PTEN expression 
decreased the expression of IGFBP-2 
 
 
 
 
 
 
 
Figure 1.15 The IGF independent actions of IGFBP-2 on PTEN 
When IGF-II binds to the IGF-I receptor there is a feedback increase in PTEN to prevent excessive 
proliferation.  However, when IGFBP-2 is free from IGF-II it can bind to an Integrin receptor and 
down-regulate PTEN.  Hence when IGFBP-2 is over expressed the feedback increase in PTEN in 
response to IGF-II is blocked.  This diagram is from Perks et al. (2007). 
 
Considering the involvement of IGFBP-2 with metabolic pathways and the interaction with PTEN, 
both IGFBP-2 and PTEN are relevant and important to study in relation to TN breast cancer. 
 
Redacted due to copyright
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1.8 Phosphatase and tensin homolog 
Phosphatase and Tensin-homolog (PTEN) is a tumour suppressor gene found on chromosome 10 
(Di Cristofano & Pandolfi, 2000). Its absence or mutations are implicated in many cancers 
including those of the breast, prostate and lung (Li et al., 1997; Torres et al., 2001). PTEN works by 
dephosphorylating PIP3, a product of the PI3K pathway, to PIP2 so the Akt signalling pathway is no 
longer activated and thus cell growth is inhibited and apoptosis is promoted (Salmena et al., 
2008); figure 1.12 shows how PTEN is involved in aspects of metabolism.  PTEN has also been 
found to have an important role in DNA repair.   PTEN regulates the expression of RAD51; 
mutation or loss of PTEN results in a deficiency to repair DNA DSB through lack of complexing of 
RAD51 with Brca (figure 1.8) (Shen et al., 2007).  In unselected breast cancer cohorts with the 
expected frequency of Her2 and hormone receptor positive cases, PTEN loss appears to be a 
relatively rare event (Mendes-Pereira et al., 2009)  and the frequency of PTEN loss in breast 
cancer varies greatly depending on the study.  One study has reported PTEN loss to be as high as 
48% in a breast cancer cohort not selected on the basis of either hormone receptor or Her 
receptor status (Depowski et al., 2001); although most other studies report a much lower 
incidence in cohorts of sporadic breast cancer; eight percent (Panigrahi et al., 2004), fifteen 
percent (Perren et al., 1999) and twenty-eight percent (Lopez-Knowles et al., 2009). Theses 
disparities most likely reflect differences in the reliability of the antibodies used, the age of the 
formalin fixed blocks, the detection methods and the interpretation of the results, particularly 
with respect to the definition of PTEN loss. Conversely, a recent study by Lopez Knowles et al., 
(2010) would suggest that PTEN loss is a more frequent event in BLBC; with nineteen of twenty-
nine cases showing loss of PTEN.  In agreement with this Marty et al. (2008) found that PTEN loss 
and alterations were more common in BLBC than Her2 positive breast cancer.  PARP inhibitors 
have been demonstrated to be effective in breast cancers with defective DNA repair however the 
trials did not show significance.  It could be argued that future trials may provide more promising 
results if patients within the triple negative category are selected on the basis of assayable 
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defects in homologous repair. Relatively few patients would be selected if they were to be chosen 
purely on the basis of BRCA mutations alone (Young et al., 2009). In addition, Brca analysis 
utilising immunohistochemistry has yet to be fully validated for its efficacy on routinely fixed and 
paraffin processed cases of triple negative breast cancer. However, in identifying markers 
predictive of likely response to PARP inhibitors cell line models have shown that tumour cells with 
PTEN loss are sensitive to PARP inhibition and the platinum salt, cisplatin (Mendes-Pereira et al., 
2009), in a similar fashion to tumour cells carrying BRCA mutations.  The initial studies suggested 
that homozygous PTEN mutations that truncate the open reading frame sensitizes tumour cells to 
PARP inhibitors, in a similar way as cancer cells with BRCA1 and BRCA2 deficiencies (Turner et al., 
2008; Farmer et al., 2005).  In addition reconstitution of the prostate cancer cell line PC3, known 
to be lacking in PTEN expression, with ectopic expression of a catalytically inactive PTEN allele, 
was sufficient to restore resistance to PARP inhibitors.  It is envisaged that the role PTEN plays in 
determining response to PARP inhibitors, is mediated by nuclear activity of the protein and it has 
been proposed that a complete absence of nuclear PTEN expression, determined by 
immunohistochemistry could effectively predict response (Mendes-Pereira et al., 2009).  For 
these reasons PTEN is an interesting and highly relevant marker to investigate in TN breast cancer. 
 
1.9 Understanding biomarkers in populations presenting with aggressive breast cancer 
There is a general lack of standardised comparative studies between the types of breast cancer 
affecting women of European descent and those breast cancers affecting Asian women.  Breast 
cancer in Malaysian women occurs less frequently than in Western women but tends to be of a 
more aggressive subtype and occurs at a younger age. In one study, 58% of patients had hormone 
receptor negative breast cancer (Agarwal et al., 2007), which is particularly aggressive, whilst in 
the West this is only approximately 20-25% (Rhodes et al. 2000).  However one study reported an 
incidence of 17.6% TN breast cancer cases in Malaysia; it was also found that TN breast cancer was 
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associated with higher grade (Tan et al., 2009).  This is in conjunction with other studies and 
makes TN breast cancer in Malaysia important to study.  In the UK 81% of TN breast cancer cases 
occur in patients 50 years old or over whereas in Malaysia less than 50% occur in this age category 
and 60% of patients are premenopausal, whilst in the West the majority of breast cancers occur in 
post menopausal women (Yip et al., 2006; Yip 2009).  There are also differences in the mean age 
of occurrence between the three main ethnic groups in Malaysia; in Malays it is 48.1 years, 
Chinese 51.4 years and Indians 52.3 years (Yip et al., 2006).  There are several theories as to why 
there are differences between UK and Malaysian breast cancer.  One is that populations tend to be 
younger in developing countries, hence why in Malaysia there are a higher proportion of younger 
women with breast cancer than in the UK (Yip et al., 2006).  Another is that until relatively recently 
the lifestyle of Asian women has been  less associated with known risk factors of breast cancer, 
compared to the lifestyle of  Western women. In Asia women generally have less oestrogen 
exposure that women in the UK; they tend to start menstruating later and go through the 
menopause earlier; they tend to bear children younger and breastfeed for longer and the use of 
the contraceptive pill is very low (Agarwal et al., 2007).  Lack of screening programs or reluctance 
to see a doctor due to cultural influences may account for the lower incidence and may also 
explain why Malaysian breast cancer results in higher mortality, as it is detected much later on 
(Agarwal et al., 2007; Yip 2009).  There may also be differences in methodology in the assay and 
interpretation of hormone receptor status and Her2 status in Malaysia when compared to the UK; 
perhaps due to a lack of resources.  Consumption of dairy products is much less in Malaysia than 
in the UK.  High dairy product consumption has been associated with high serum levels of IGF-I 
and IGF-II.  A study by Rinaldi et al., (2005) found that high IGF-I serum levels were associated with 
higher breast cancer risk particularly in younger women.  In Chinese women high IGF-I serum 
levels were also found to be associated with increased breast cancer risk but only in 
premenopausal women (Yu et al., 2002).  The differences between populations may be a result of 
dietary or oestrogen exposure factors or they may even be a result of genetic differences.   
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1.10 Study design 
This study sought to investigate patterns of FABP7 expression in patient samples and cell lines, 
what regulates FABP7 expression in breast cancer cell lines, the effect of FABP7 over-expression 
on breast cancer cells and the patterns of expression of IGFBP-2 and PTEN in patient samples.  
This study design section brings together the various investigations in this thesis and justifies the 
choices of cell lines, cell line treatments and outlines the patient demographics.   Table 1.3 gives 
the details of the breast cell lines used in this work.   
 
 
 
 
 
Table 1.3 The features of the cell lines used in this work 
This table shows the ER, PR and HER2 status of the cell lines used in this work as well as the 
molecular subtype (gene cluster) and the observed doubling time. 
 
1.10.1 Methylation and Acetylation studies 
To understand if epigenetic mechanisms were involved with the regulation of FABP7 expression, 
5-Aza-2′-deoxycytidine a demethylating agent and Trichostatin A an HDAC inhibitor were used to 
treat breast cancer cell lines.  BT-20 and MDA-MB-231 cell lines were selected for these 
treatments because they are of TN and basal-like phenotype (highly important features in the 
scope of this study) (table 1.3) and because work in chapter 3 demonstrated that expression of 
FABP7 mRNA and protein in these cell lines was higher compared to others tested.  The doses of 
AZA and TSA were chosen based on pre-published dose responses (using breast cancer cell lines) 
        
 
Cell Line 
Gene 
Cluster ER PR HER2 
Doubling Time 
(hr) 
 
 
BT-20 Basal A - - - 30 
 
 
HS578T Basal B - - - 76 
 
 
MCF-7 Luminal + + - 22 
 
 
MCF10a Basal B - - - 27 
 
 
MDA-MB-231 Basal B - - - 33 
 
 
MDA-MB-361 Luminal + - + 75 
 
 
MDA-MB-453 Luminal - - - 36 
 
 
SKBR3 Luminal - - + 26 
 
 
T47D Luminal + + - 35 
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by collaborators at the University of Bristol.  The duration of TSA treatment was kept at a 
maximum of 24 hours because preliminary work (not included) showed that extending it caused 
significant cell death.  The maximum AZA treatment duration was 72 hours because beyond this 
preliminary work (not shown) showed extensive cell death.  In addition considering the short half 
life of AZA it is unlikely increasing treatment duration would have impacted on FABP7 expression. 
 
1.10.2 Fatty acid choice and dose justification 
To study changes in FABP7 expression BT-20 and MDA-MB-231 cells were treated with the FAs 
oleate, palmitate, AA and DHA.  The cell lines were selected for the same reasons as in the 
methylation and acetylation studies. The FAs were chosen based on their interaction with FABP7 
and because they cover a range of carbon chain length, saturation and therefore three-
dimensional structure.  This is important when looking for alterations in expression because the 
FA structure can influence the way it interacts with other fats, proteins and even DNA.  Such 
features of each FA are shown in table 1.4 
 
 
 
 
 
 
Table 1.4 Details of the fatty acids used in this work 
This table shows the saturation, carbon chain length and schematic structure of each of the fatty 
acids used in this work. 
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A dose response experiment was carried out for each of the breast cancer cell lines in order to 
choose a dose of FA that did not cause extensive cell death; cell death would result in protein 
degradation and decreases in total protein levels therefore negating any specific effects of the FAs 
in FABP7 expression. 
Palmitate dose ranges of 50µM to 500µM were investigated based on the work by Zeng et al., 
(2010).  MCF-10a, HMT-3522 S1 and MCF-7 breast cancer cell lines were exposed to 100µM, 
200µM and 400µM of palmitate resulting in up to 50% cell death.  The dose range was extended 
in this experiment due to the fact that the cell lines were different and would perhaps respond 
slightly differently.  These doses were further confirmed as appropriate based on the research by 
Hardy et al. (2000); doses of palmitate ranging from 10µM up to 400µM were investigated in 
MDA-MB-231 cells. 
Doses of 50µM to 500µM were also investigated for oleate.  Dose ranges of 100µM to 400µM 
have previously been studied in MCF-7 and MCF-10a (Zeng et al., 2010).  These doses of oleate 
have also been found to increase FABP1 expression in the FAO rat hepatoma cell line (Meunier-
Durmort et al., 1996).  The effect on cell growth of oleate has been studied in MDA-MB-231 cells 
with a dose range of approximately 1.8-8.9µM; however this was over a much longer time period 
than was being investigated in this study. Again the dose range was extended due to the fact that 
MDA-MB-231 and BT-20 cells may respond differently to other breast cancer cell lines.   
For investigating the effect of AA on the breast cancer cell lines a range of 1-50µM was selected.  
Again this was deemed suitable based on information in the literature.  For example 
Razanamahefa et al., (2000) tested doses ranging between approximately 8µM and 33µM, with 
T47D breast cancer cells exposed to AA for up to 3 days.  Smaller doses were investigated by Najid 
et al., (1989) (10pM-10µM) in MCF-7 cells but over a time period of up to 10 days.  Chamras et al., 
(2002) also looked at the effect of AA on MCF-7 cells with doses of 1µM-100µM, however again 
the time points differed from the present study.   The BRIN-BD11 rat islet cells were treated with 
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50, 100 or 150µM of AA for 24 hours (Keane et al., 2011).  These doses were found to alter the 
expression of various genes related to insulin secretion (Keane et al., 2011).  Despite the cells not 
being a breast cell line it was useful to know these doses impact on gene expression. 
A range of 10-200µM of DHA was tested to observe the percentage cell death.  This range was 
chosen based on the research by Blanckaert (2010); MDA-MB-231 cells were treated with either 
20µM or 100µM over 24, 24 and 72 hours; proliferation and apoptosis were studied.  The range 
was extended to account for variability in dosing and assessment methods and for the reason that 
the BT-20 cell line may have responded differently.  This range was further confirmed rational as 
Ding et al., (2004) investigated DHA at doses between 15µM and 300µM in MDA-MB-231 and 
MCF-7 cells; however only at a 72 hour time point. 
Bonferroni’s multiple comparison test was carried out using Graphpad Prism 5 to determine the 
most appropriate dose of each FA to use to investigate the expression of FABP7 in the breast 
cancer cell lines MDA-MB-231 and BT-20 cell lines.  The data in figures 1.16 & 1.17 show the 
percentage cell death and total cell numbers, dead and alive, for MDA-MB-231 and BT-20 cells 
treated with each FA for 24 hours.  
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Figure 1.16 Fatty acid dose responses in MDA-MB-231 cells 
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Figure 1.17 Fatty acid doses responses in BT-20 cells 
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For palmitate a final dose of 50µM was chosen for both cell lines. In the MDA-MB-231 cells there 
was a significant difference in cell death compared to the control at this dose (p=0.05) and it may 
also be growth inhibitory as there were less total cells compared to the control.  However there 
were still a mean of over 85% of cells alive and the actual number of cells alive was considered 
enough to give a good RNA yield; therefore 50µM was deemed a high enough dose to exert an 
effect without causing an undesirable amount of cell death or growth inhibition.  A dose 50µM of 
palmitate was also chosen for BT-20 cells as there was no significant difference in cell death and 
no reduction in total cell numbers compared to the control.  A dose of 100µM palmitate was not 
chosen for BT-20 cells, even though it gave similar average percentage cell death (16.5%) and 
apparent growth inhibition as 50µM of palmitate in MDA-MB-231 cells, as it was considered 
preferential to have as little cell death as possible with a dose high enough to exert an effect.   
 
A dose of 100µM oleate was selected for both cell lines because there was no significant increase 
in percentage cell death compared to the control and the total cell numbers indicated little 
growth inhibition.  Interestingly 50µM oleate significantly decreased cell death (p=0.05) compared 
to the control in MDA-MB-231 cells; there was a trend for 100µM oleate to also decrease cell 
death although this was not statistically significant. There was also a trend for 50µM oleate to 
protect against cell death in the BT-20 cells again this was not statistically significant.  A dose of 
200µM of oleate in both cell lines considerably increased cell death to a mean of 64.1% (p<0.001) 
and 100% (p<0.001) in MDA-MB-231 and BT-20 cells respectively. 
 
For AA treatments 10µM was chosen as a suitable dose for both MDA-MB-231 cells and BT-20 
cells.  In the MDA-MB-231 cell lines this dose caused 10.5% cell death and may have been slightly 
growth inhibitory judging by the total cell numbers.  In the BT-20 cells 10µM of AA caused a mean 
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cell death of 16.9% and again may have been slightly growth inhibitory compared to the total cell 
numbers of the control. Increasing the dose to 20µM increased mean cell death to 14.4% in the 
MDA-MB-231 cells however this was not statistically significant; in the BT-20 cells the increased 
dose significantly increased mean cell death to 23.4% (p<0.001).  A lower dose was not chosen 
because there was no significant difference in mean cell death between the 1µM, 5µM and 10µM 
AA doses.  
DHA dosing was regarded as appropriate at 10µM in both cell lines. There was little if any growth 
inhibition as the total cell numbers were comparable to the controls in both cell lines.  The 
percentage cell death was significant compared to the control at a dose of 10µM (p=0.05); 
however at 20µM there was further increased mean cell death in particular in the BT-20 cell line 
from 16.8% to 32.1% (p<0.001).  
 
1.10.3 FABP7 over-expression studies 
After investigating what regulates FABP7 with AZA, TSA and FA treatments, the effect of FABP7 
over-expression on breast cancer cells was studied.  BT-20 cells were chosen to transiently over-
express FABP7 because they are of TN and basal-like phenotype.  Following transfection with 
either a control or FABP7 vector, BT-20 cells were counted to study proliferation and cell death.  
The cells were also treated with FAs and an apoptosis inducer staurosporine, to investigate 
whether FABP7 protected against cell death.  PCR was used to look for changes in expression of 
genes involved in apoptosis. 
 
1.10.4 Patient demographics 
To investigate the expression of FABP7, IGFBP-2 and PTEN in patient samples a Malaysian TN 
breast cancer cohort was used.  Tissue samples from breast cancer patients reported as being 
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negative for ER, PR and Her2 and diagnosed between 2004 and 2009 at the University of Malaya 
Medical Centre, were selected for  this study.  TN phenotype was confirmed by using 
immunohistochemistry for ER PR and Her2 (section 2.1) and positive cases excluded from further 
analysis.  The age of onset of breast cancer in the patients ranged from 23 to 83 years old with a 
median of 53 years.  The majority of cases (93%) were invasive ductal carcinomas, with the 
remaining being either medullary or metaplastic cancers.  
 
1.11 Overall Aims 
To study the expression of the metabolic biomarkers FABP7, IGFBP-2 and PTEN in clinical cases of 
Malaysian TN breast cancer.  To use appropriate cell lines in order to more fully understand 
whether epigenetic mechanisms and FAs regulate FABP7 expression. To over-express FABP7 in a 
breast cancer cell line to further understand the role of FABP7 in breast cancer. 
 
1.12 Overall Hypotheses 
The expression of the metabolic biomarker FABP7 is associated with patient survival and 
clinicopathological parameters in TN breast cancer. FABP7 in breast cancer cell lines is regulated 
by epigenetic mechanisms and FAs.  Over-expression of FABP7 in cell lines alters cell survival and 
growth.  The metabolic biomarkers IGFBP-2 and PTEN are inversely associated in patient samples 
and are also associated with clinicopathological parameters in TN breast cancer 
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2 General Materials and Methods 
 
2.1 Immunohistochemistry 
All reagents used were from Fisher Scientific (Loughborough, UK) unless otherwise stated. 
 
2.1.1 Tissue section details 
One hundred and twenty-two triple negative breast cancer cases were selected for use in this 
study from the University of Malaya with full ethical approval.  The tissue had been formalin fixed 
and paraffin processed.  Tissue sections 3µm thick were cut using a Leica microtome and then 
floated onto a water bath and picked up onto Tissue-Tek® adhesive slides (ThermoFisher Scientific 
Surrey, UK).  Between 10-20 tissue sections were cut for each case.  To confirm TN phenotype all 
of the cases were IHC stained for ER, PR and Her2; any cases that were positive for the markers 
were excluded from the study. 
 
2.1.2 Buffers 
Sodium citrate buffer (10mM sodium citrate) for antigen retrieval was made by dissolving 29.4g of 
sodium citrate in 10 litres of ddH2O and adding 54mL of HCl.  The pH was adjusted to pH 6.0 by 
adding a few drops of 1M HCl.  After thorough mixing and the desired pH reached the buffer was 
stored at 4oC (Bancroft & Gamble, 2002).  Tris-EDTA buffer (10mM Tris, 1mM EDTA) for antigen 
retrieval was made by dissolving 12g of Tris hydroxymethylamine (Tris and 3.7g of 
ethylenediaminetetraacetic acid (EDTA, di-sodium salt) in 10 litres of ddH2O.  After mixing 
thoroughly the pH was adjusted to pH 9.0 by adding a few drops of 1M HCl.  The buffer was 
stored at 4oC.  Tris buffered saline (TBS) wash buffer (0.5M Tris) was made by dissolving 88g of 
sodium chloride and 6.05g of Tris  in 10 litres of ddH2O and adding 44mL of HCl.  The pH was 
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adjusted to pH 7.4 by adding a few drops of 1M HCl.  After thorough mixing and the desired pH 
reached the buffer was stored at 4oC (Bancroft & Gamble, 2002). 
 
2.1.3 Antigen Retrieval 
Twenty of the tissue sections at a time were loaded into a plastic rack and prepared for antigen 
retrieval by deparaffinising in two baths of Histoclear for five minutes each.  The tissue sections 
were then rehydrated by being taken through two baths of 100% industrial methylated spirits 
(IMS) for five minutes each and then left in a bath of gently running tap water for a few minutes.  
The slides were then treated with 0.3% hydrogen peroxide (H2O2) (30% H2O2 diluted 1:100 with d 
H2O) for five minutes to remove any endogenous peroxidase activity and washed thoroughly in 
dH2O before being placed in a plastic container with 750mL of retrieval buffer (Rhodes et al., 
2010).  A lid was put on the container and then the container placed in a Panasonic NE-664 650W 
microwave for heating to 100oC for 30 minutes on the high setting (Rhodes et al., 2010).  After 30 
minutes the slides were carefully removed and cooled by gently running tap water in to the 
container.  After this stage it was very important not to let the slides dry out at any time as this 
would have resulted in weak, poor quality staining.  The slides were then placed on a staining tray 
and rinsed thoroughly with TBS so they were ready to be stained.  If less than 20 slides were being 
used the rack was filled up with blank slides to ensure even and reproducible heat distribution. 
 
2.1.4 Immunohistochemistry Kits 
The Universal Elite Kit (Vector Laboratories, Peterborough, UK) comprised of blocking serum-
(Normal Horse Serum), secondary antibody, (Biotinylated Universal antibody anti-rabbit/mouse 
IgG, Heavy & Light chain) and Vectastain Elite ABC reagent.  The goat IgG Elite kit (Vector 
Laboratories, Peterborough, UK) comprised of blocking serum, (Normal Rabbit Serum) secondary 
antibody, (Biotinylated Anti-Goat IgG, Heavy & Light chain) and Vectastain Elite ABC reagent.  The 
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Elite ABC kits were chosen because of their increased sensitivity so that smaller amounts of 
protein could be detected and so that a higher dilution of primary antibody could be used and 
thus preventing background staining.  Diaminobenzidine tetrahydrochloride (DAB) substrate-
chromogen system from Dakocytomation (Cambridge, UK) was used for visualisation and made 
according to the instructions and prepared fresh just before use. 
 
2.1.5 Details of primary antibody clones 
The details of the primary antibody clones can be seen in table 2.1.
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Table 2.1 Details of primary antibodies including optimised conditions 
This Table shows the details of the primary antibodies used in immunohistochemistry experiments. It also shows the final 
optimised dilution, antigen retrieval buffer and type of Elite kit used in combination with the particular primary antibody. 
 
 
 
Antibody 
Clone Antigen 
Type of 
Antibody Supplier 
Antigen Retrieval 
Buffer Elite Kit Dilution 
6F11 ER-α 
Monoclonal 
Mouse 
Novacastra Labs  
(Newcastle-upon Tyne, UK) Citrate pH 6.0 Universal 1:100 
SP2 PR (A & B) 
Monoclonal 
Rabbit 
Lab Vision Ltd 
(Runcorn, UK) Citrate pH 6.0 Universal 1:200 
SP3 HER2 
Monoclonal 
Rabbit 
Lab Vision Ltd 
(Runcorn, UK) Citrate pH 6.0 Universal 1:400 
D5/16 B4 CK5/6 
Monoclonal 
Mouse 
Dakocytomation  
(Cambridge, UK) Tris-EDTA pH 9.0 Universal 1:300 
LL002 CK14 
Monoclonal 
Mouse 
Novacastra Labs  
(Newcastle-upon Tyne, UK) Citrate pH 6.0 Universal 1:150 
6H2.1 PTEN 
Monoclonal 
Mouse 
Dakocytomation  
(Cambridge, UK) Tris-EDTA pH 9.0 Universal 1:600 
C18 IGFBP-2 
Polyclonal 
Goat 
Santa Cruz Biotechnology 
(Middlesex, UK) Citrate pH 6.0 Goat IgG 1:700 
 
FABP7 
Polyclonal 
Goat 
R&D systems 
(Abingdon, UK) Citrate pH 6.0 Goat IgG 1:400 
G13 FABP7 
Polyclonal 
Goat 
Santa Cruz Biotechnology  
(Middlesex, UK) Citrate pH 6.0 Goat IgG 1:200 
C20G5 FAS 
Monoclonal 
Rabbit 
New England Biolabs 
(Hertfordhire, UK) Citrate pH 6.0 Universal 1:100 
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2.1.6 Controls 
As whole tissue sections were used rather than tissue microarrays; where possible, normal 
components within the tissue section were used as an internal control.  Omission of the primary 
antibody controls were also carried out to ensure the specificity of the secondary antibody; a 
selection of cases that had previously stained positive for each antibody were incubated overnight 
in TBS rather than primary antibody. 
 
2.1.6.1 Oestrogen receptor, Progesterone receptor and Her2 receptor controls. 
Formalin fixed, paraffin processed cell lines with known expression of each of the receptors were 
used as positive controls as described previously (Rhodes et al., 2010).  Additionally, where 
possible, normal ducts within the tissue section were used as internal controls. 
 
2.1.6.2 IGFBP-2 antibody control 
To test the specificity of the anti-IGFBP-2 antibody an IGFBP-2 blocking peptide (Santa Cruz 
Biotechnology, UK) was used.  The blocking peptide was used at five times the concentration of 
the antibody (Santa Cruz Biotechnology, technical support); for example as the concentration of 
the antibody and blocking peptide were the same, 5µL of blocking peptide, 1µL of antibody in 
500µL of TBS.  The antibody and blocking peptide were incubated together in a tube for two hours 
at room temperature.  Following this, 194µL of TBS was added to achieve the correct dilution of 
primary antibody.  This solution was then used for incubation overnight at 4oC instead; this was 
used on a selection of cases that had previously stained positive using the anti-IGFBP-2 antibody. 
 
2.1.6.3 FABP7 antibody control 
Two FABP7 antibodies were tested, the R&D systems (Abingdon, UK) antibody was chosen as it 
gave less background staining than the Santa Cruz Biotechnology (UK) antibody.  However as both 
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antibodies resulted in very similar staining patterns the Santa Cruz Biotechnology (UK) antibody 
was used to verify the results of the R&D systems (Abingdon, UK) antibody staining as a FABP7 
blocking peptide (Santa Cruz Biotechnology, UK) was available.  This was used as follows; the 
FABP7 blocking peptide was used at five times the concentration of the antibody (Santa Cruz 
Biotechnology, technical support); for example 5µL of blocking peptide, 1µL of antibody in 200µL 
of TBS.  The antibody and blocking peptide were incubated together in a tube for two hours at 
room temperature.  Following this, 194µL of TBS was added to achieve the correct dilution of 
primary antibody.  This solution was then used for overnight incubation at 4oC on a selection of 
cases that had previously stained positive using both FABP7 antibodies.  FABP7 staining of normal 
breast ducts and adipose tissue served as a useful internal positive control (Alshareeda et al., 
2012). 
 
2.1.7 Haematoxylin counterstain  
Haematoxylin was prepared according to Bancroft & Gamble (2002).  Haematoxylin (2.5g) was 
dissolved in 25mL of 100% ethanol and then added to 500mL of warm distilled water with 50g of 
potassium alum added.  The mixture was then bought to the boil quickly and 0.5g of sodium 
iodate was added slowly.  The flask was chilled in an ice bath and once cool 20mL of glacial acetic 
acid was added.  The stain was filtered before use. 
 
2.1.8 Immunohistochemical staining method 
Following antigen retrieval the slides were washed in TBS and then incubated in the blocking 
serum for 20 minutes. Next the sections were incubated with the primary antibody diluted in TBS, 
overnight at 4oC; this incubation was used as it gives lower background staining.  After a thorough 
wash with TBS, incubation with the secondary antibody took place for 30 minutes.  The slides 
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were briefly rinsed with TBS and then incubated with ABC reagent for 30 minutes.  The sections 
were washed in TBS and then distilled water and then DAB solution was left on them for 10 
minutes.  The slides were washed thoroughly in tap water and then counterstained in Harris’s 
Haematoxylin for two minutes.  The sections were differentiated in 1% acid alcohol (1% HCl in 70% 
ethanol) for a few seconds, and then immersed in tap water to allow a colour change for purple to 
blue in alkali conditions (blued in tap water). They were then dehydrated, cleared and mounted in 
distyrene plasticizer and xylene mountant (DPX). 
 
2.1.9 Evaluation of immunohistochemistry results 
Interpretation of the staining for the markers was carried out by 2 individuals to ensure 
reproducibility of the results.  The basal-like phenotype was determined as cytoplasmic positivity 
of CK5/6 and/or CK14 in over 10% of the tumour with appropriate staining in normal glands as a 
positive internal control (Zhang et al., 2010). 
The Allred scoring system was used to assess nuclear ER and PR staining, as outlined in table 2.2.  
Staining of Her2 was assessed with the scoring system in table 2.3 as used in a clinical setting 
(Wolff et al., 2007).  A modified Allred scoring system was used to score the staining for IGFBP-2 
and FABP7 as shown below in table 2.2; except it was cytoplasmic staining rather than nuclear 
staining that was assessed.  Cytoplasmic staining was scored on intensity (score 0-3) and 
proportion (score 0-5); these two scores were added together to given a final score between 2 
and 8 (table 2.2). For the purposes of comparing IGFBP-2 expression, with PTEN loss and other 
clinicopathological variables, a cut-off point score of >5 was used to define IGFBP-2 positivity.  
This cut off was chosen based on the results from So et al. (2008); where intermediate and strong 
staining of IGFBP2 (which equates to an Allred score of >5), was associated with worse breast 
cancer specific survival in hormone receptor negative disease 
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Table 2.2 The Allred scoring system applied to ER, PR, IGFBP-2, FABP7 and FAS staining. 
The proportion score and intensity score were added together to reach an overall score.  In the 
case of IGFBP-2 a cut off point of >5 was used to define positivity; so as a minimum positive cases 
would have strong staining in 1-10% of cells or weak staining in 33-66% of cells. 
 
 
 
 
 
 
 
 
 
 
 
HER2 score Result of IHC stain 
0 No staining 
1+ 
Weak or incomplete membrane staining in 
any amount of tumour cells 
2+ 
Complete membrane staining that is either 
weak or non-uniform in >10% of tumour cells 
3+ 
>30% of tumour cells have intense uniform 
staining 
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Table 2.3 Her2 IHC scoring system 
Incomplete membrane staining is defined as positive staining in areas of the cell membrane i.e. 
the whole cell membrane is not stained positive.  Complete membrane staining is defined by the 
whole cell membrane staining positive.  Please see figure 1.5 for a visual representation of this. 
 
Assessment of PTEN loss; the majority of tumours were of large size and heterogeneous in nature, 
with respect to PTEN expression. Consequently, PTEN expression was considered lost if there was 
complete absence of staining (both cytoplasmic and nuclear) in at least two thirds of the invasive 
tumour compartment, with PTEN staining in the adjacent normal stromal tissue being used as the 
internal positive control. 
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2.2 Cell Culture 
 
2.2.1 Cell Line Details 
The immortalised breast cancer cell lines BT-20, MBA-MB-453, MBA-MB-361, MDA-MB-231 and 
the non-tumourigenic breast cell line MCF10A were obtained from the European Collection of Cell 
Cultures (ECACC; Salisbury, UK).  The immortalised glioma cell line U251 was obtained from the 
Health Protection Agency (Salisbury, UK). 
 
2.2.2 Cell Culture Conditions 
All cell culture media components were purchased from Lonza (Slough, UK), unless otherwise 
specified. Cells were grown according to supplier’s instructions.  Cells were grown in Greiner Bio-
one (Gloucester, UK) filter lid tissue culture flasks or tissue culture plates (size stated as 
appropriate).  Phosphate-buffered saline (PBS) was made by dissolving PBS tablets (Fisher 
Scientific, Loughborough, UK) in ddH2O and then autoclaving.  Costar serological pipettes and 
tissue culture plates were purchased from Fisher Scientific (Loughborough, UK).  A Hettich 
Mikro200 centrifuge was used for pelleting cells. 
 
2.2.3 BT-20 cell line culture 
Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% Foetal Bovine Serum (FBS), 
and 2mM L-glutamine (LG) was used to grow the cells.  The cells were cultured in cell culture 
flasks at 37oC in 5% carbon dioxide in a humidified atmosphere.  BT-20 cells are adherent and so 
upon reaching 80-90% confluence they were washed in cell dissociation buffer (CDB) (Invitrogen; 
Paisley, UK) and then incubated with fresh CDB for 10 minutes at 37oC.  To remove the cells from 
the bottom of the flasks they were incubated for approximately 10 minutes at 37oC in a mixture of 
CDB 0.25% Trypsin/0.53mM EDTA (Sigma-Aldrich, Dorset, UK); however they were observed 
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carefully at intervals to ensure they were not overexposed.  To inactivate the trypsin, growth 
medium was added to the flask; the cell suspension was then transferred to a tube and placed in a 
centrifuge for three minutes at 16100g.  The supernatant was removed and the cell pellet 
resuspended in 10mL of medium and the cells then passed through a needle 10 times using a 
syringe, to separate them.  An aliquot was removed for counting and then the cells were re-
seeded at a density of 0.5 x 106 cells/T75 flask. 
 
2.2.4 MDA-MB-361 cell line culture 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 20% FBS and 2mM LG was used 
to grow the cells.  The cells were cultured in cell culture flasks at 37oC in 5% carbon dioxide in a 
humidified atmosphere.  MDA-MB-361 cells are adherent and on observation tended to grow in 
mounds rather than spread out across the bottom of the flask.  Upon reaching what was 
determined as an appropriate confluency, i.e. when the mounds were large and quite close 
together covering over 60% of the bottom of the flask, the cells were washed twice in sterile 
phosphate-buffered-saline (PBS).  They were then incubated with 0.25% Trypsin/0.53mM EDTA 
(Sigma-Aldrich, Dorset, UK) for approximately 10 minutes at 37oC until the cells became detached 
from the flask.  The cells were then treated as described above ready for counting or reseeding; 
MDA-MB-361 cells were seeded at a density of 0.9 x 106 cells/T75 flask. 
 
2.2.5 MDA-MB-453 and MDA-MB-231 cell line culture 
DMEM supplemented with 10% FBS and 2mM LG was used to grow the cells.  The cells were 
cultured in cell culture flasks at 37oC in 5% carbon dioxide in a humidified atmosphere.  MDA-MB-
453 and MDA-MB-231 cells are adherent and so upon reaching 80-90% confluence they were 
washed twice in sterile PBS.  To remove the cells from the bottom of the flasks they were 
incubated for approximately 10 minutes at 37oC in  0.25% Trypsin/0.53mM EDTA (Sigma-Aldrich, 
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Dorset, UK), until the cells became detached from the flask.  The cells were then treated as 
previously described ready for counting or reseeding; MDA-MB-453 cells and MDA-MB-231 cells 
were seeded at a density of 0.5 x 106 cells/T75 flask. 
 
2.2.6 MCF10A cell line culture 
DMEM:F12 (Invitrogen; Paisley, UK) was supplemented with 5% heat inactivated horse serum, 
2mM LG, and 1% hydrocortisone.  Additionally the medium was supplemented with 143IU of 
Insulin Actrapid (Novo Nordish, Bagsvaerd, Denmark), 0.01% Cholera toxin (List Biologicals, Surrey 
UK) and 0.01% Epidermal Growth Factor.  The cells were cultured with the medium in cell culture 
flasks at 37oC in 5% carbon dioxide in a humidified atmosphere.  MCF10A  cells are adherent and 
so upon reaching 80-90% confluence they were washed in cell dissociation buffer (CDB) 
(Invitrogen; Paisley, UK) and then incubated with fresh CDB for 10 minutes at 37oC.  To remove 
the cells from the bottom of the flasks they were incubated for approximately 10 minutes at 37oC 
in a mixture of CDB and 0.25% Trypsin/0.53mM EDTA (Sigma-Aldrich, Dorset, UK); however they 
were observed carefully at intervals to ensure they were not overexposed.  The cells were then 
treated as described previously ready for counting or reseeding; MCF10A cells were seeded at a 
density of 0.5 x 106 cells/T75 flask. 
 
2.2.7 U251 cell line culture 
EMEM supplemented with 10% FBS, 2mM LG, 1% Non Essential Amino Acids (NEAA) and 1% 
Sodium Pyruvate (NaP) was used to grow the cells.  The cells were cultured in cell culture flasks at 
37oC in 5% carbon dioxide in a humidified atmosphere.  U251 cells are adherent and so upon 
reaching 70-80% confluence they were washed in PBS.  To remove the cells from the bottom of 
the flasks they were incubated for approximately 10 minutes at 37oC in 0.25% Trypsin/0.53mM 
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EDTA (Sigma-Aldrich, Dorset, UK).  However they were observed carefully at intervals to ensure 
they were not overexposed.  To inactivate the trypsin, growth medium was added to the flask; the 
cell suspension was then transferred to a tube and placed in a centrifuge for three minutes at 
16100 g.  The supernatant was removed and the cell pellet resuspended in 10mL of medium and 
the cells then passed through a needle 10 times using a syringe, to separate them.  An aliquot was 
removed for counting and then the cells were re-seeded at a density of 0.5 x 106 cells/T75 flask.   
 
2.3 Cell Treatments 
2.3.1 Growth Media and controls for Cell Line Treatments 
To make serum free medium (SFM) for use in cell line treatment experiments, DMEM:F12 
(Invitrogen; Paisley, UK) was supplemented with 0.02% bovine Serum albumin (BSA) (Sigma-
Aldrich Dorset, UK)  0.12% Sodium Bicarbonate and 2mM LG.  For experiments using fatty acids 
SFM was made omitting the BSA. SFM media was used for cell line treatment experiments so that 
FBS did not negate any effects of the specific treatments. 
Control vessels of the cell lines were set up alongside the cells to be treated but instead of being 
subjected to the treatment the cells in these vessels remained in serum free medium unless 
otherwise stated. 
2.3.2 Trichostatin A  
Trichostatin A (TSA) was purchased from Tocris Bioscience (Bristol, UK) for acetylation of FABP7 
studies; 500µL of DMSO was added to create a 6614.4µM stock solution.  The stock solution was 
aliquoted and stored at -20oC until use.  A 500µM working solution was prepared by taking 5µL of 
6614.4µM stock and adding it to 2992.5µL of SFM.  BT-20 and MDA-MB-231 cells were seeded 
into T25 flasks at 0.5 x 106 cells/ flask, in their respective growth media.  Growth medium was 
replaced 24 hours later with 3mL of SFM.  Following 24 hours in SFM the cells were dosed with 
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either 0.25µM or 0.5µM TSA by adding 7.5µL or 15µL of 500µM working solution respectively to 
the flasks. These doses were chosen based on dose response curves generated from previous 
work by (pre-published Zeng et al, University of Bristol) and because similar doses have been used 
to demonstrate the re-expression of the ER by TSA in breast cancer cell lines (Yang et al., 2000).  
The cells were exposed to TSA for 24 hours and were then subjected to either RNA or protein 
extraction. 
 
2.3.3 5-Aza-2′-deoxycytidine 
5-Aza-2′-deoxycytidine (AZA) (Sigma-Aldrich, Dorset, UK) stock solution, for methylation of FABP7 
studies, was prepared by dissolving 1mg of AZA in 1mL of dH2O to give a 4382µM solution.  This 
solution was then passed through a 0.2µM filter to sterilise it. A 500µM stock was then prepared 
using the 4382µM solution and SFM.  This two-step dilution allowed for appropriate volumes and 
doses to be used to treat the cells.  BT-20 and MDA-MB-231 cells were seeded into T25 flasks at 
0.5 x 106 cells/ flask, in their respective growth media.  Growth medium was replaced 24 hours 
later with 3mL of SFM.  Following 24 hours in SFM the cells were treated with 1µM or 2.5 µM AZA. 
After 24, 48 or 72 hours of exposure the cells were subjected to either protein or RNA extraction.  
These doses of AZA and time points were used as they have been used to demonstrate the re-
expression of the ER in ER negative breast cancer cell lines (Ferguson et al., 1995). 
 
2.3.4 Fatty Acid dose responses in cell lines BT-20 and MDA-MB-231 
For each FA a dose response was carried out to ensure the appropriateness of each dose.  Cells 
were seeded into 6 well plates at a density of 0.15X106/well.  The following day the medium was 
changed to SFM.  After 24 hours in SFM the cells were dosed with 1.5mL of medium containing 
the FA; FA doses were made up as in appendix I.  Serum free growth medium was supplemented 
with Fatty acid free BSA (Sigma-Aldrich, Dorset, UK) so the final concentration used was 0.1%.  
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This ensured that any effect observed would be from the FA of interest rather than from FAs in 
BSA.  The BSA also bound the FA to aid solubilisation and to make the FA available to the cells.  
The various concentrations of fatty acid free BSA as in appendix I were made up in BSA free SFM 
and then sterile filtered.  The final concentration of ethanol was considered negligible at <0.1%.  
The control well received SFM with 0.1% fatty acid free BSA.  The cells were exposed to the FA for 
24 hours and were then counted, as described below, after staining with Trypan blue solution 
(Fisher Scientific, Loughborough, UK).  The following methods for solubilising the FAs palmitate 
and oleate has been previously carried out by collaborators (Zeng et al., 2010), this method was 
also found suitable for AA and DHA. 
 
2.3.5 Palmitate 
A 400mM stock solution of palmitate was prepared by adding 103mg of palmitate to 1mL of 
sterile filtered ethanol and heating until the palmitate was fully dissolved.  The doses tested were 
50µM, 100µM, 200µM, 400µM and 500µM.  Solutions were heated and thoroughly mixed at 
every stage to ensure the palmitate was in solution.  This range of doses was chosen based on 
research findings using palmitate to treat cultured cells (appendix I). 
 
2.3.6 Oleate 
A 400mM stock solution of oleate was prepared by adding 38.1µL of oleate solution to 261.9µL of 
sterile filtered ethanol.  The solution was heated and mixed thoroughly.  The doses tested were 
50µM, 100µM, 200µM, 400µM and 500µM.  Solutions were heated and thoroughly mixed at 
every stage to ensure the oleate was in solution. This range of doses was chosen based on 
research findings using oleate to treat cultured cells (appendix I). 
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2.3.7 Arachidonic acid 
A 40mM stock solution of arachidonic acid (AA) was made by adding 3.84µL of AA to 296.16µL of 
sterile filtered ethanol. The solution was heated and mixed thoroughly.  The doses tested were 
1µM, 5µM, 10µM, 20µM and 50µM.  Solutions were heated and thoroughly mixed at every stage 
to ensure the AA was in solution. This range of doses was chosen based on research findings using 
AA to treat cultured cells (appendix I). 
 
2.3.8 Docosahexaenoic acid 
A 40mM stock solution of docosahexaenoic (DHA) acid was made by adding 2.79µL of DHA to 
297.21µL of sterile filtered ethanol. The solution was heated and mixed thoroughly.  The doses 
tested were 10µM, 20µM, 50µM, 100µM and 200µM.  Solutions were heated and thoroughly 
mixed at every stage to ensure the DHA was in solution. This range of doses was chosen based on 
research findings using DHA to treat cultured cells (appendix I). 
Final conditions used for each FA are stated in the appropriate chapters. 
 
2.3.9 Cell counting using Trypan blue 
Cell counting using Trypan blue was used to ensure cells were seeded at a correct and consistent 
density and to assess the impact on cell death of treatments used.  Trypan blue counting has been 
found to give results consistent with other methods to assess cell viability such as flow cytometry 
(Gill et al., 1997) and PARP cleavage by western blotting (Thomas et al., 2010).  Cells were 
removed from the culture vessel using trypsin and then pelleted as previously described.  Cells 
were then fully re-suspended in a known volume of growth medium to allow calculation of total 
cells per culture vessel.  Cell suspension (30µL) was mixed with 30µL of Trypan blue solution and 
then added to a chamber of a Neubauer haemocytometer.  Live and dead cells were counted 
separately in both chambers of the haemocytometer to take into account the dilution factor of 
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the Trypan blue; live cells were bright whilst dead cells were dark blue upon observation down 
the microscope.  Total cells, alive and dead, were then calculated using the following equation: 
Total number of cells (dead and/or alive) = (cells counted x 104) x volume of cell suspension in mL 
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2.4 Protein extraction 
2.4.1 Lysis Buffer 
Lysis buffer was made using the components in table 2.4; they were from Sigma-Aldrich (Dorset, 
UK) unless otherwise stated. 
 
 
 
 
 
Table 2.4 Lysis buffer composition 
To make the 100x sodium orthovanadate solution 36.8mg of sodium orthovanadate was dissolved 
in 20mL dH20.  The solution was adjusted to pH10 so it turned yellow.  It was then boiled until it 
became clear. The substances above in the table were then added to dH2O to make up 1L of 
solution.  The lysis buffer was stored at 4oC; when required for use 10µL each of protease inhibitor 
cocktail and phosphatase inhibitor cocktail 2 was added to every 1mL of lysis buffer to inhibit 
protein degradation and loss of phospho groups.  Both cocktails are commercially available from 
Sigma-Aldrich (Dorset, UK) 
 
2.4.2 Cell Lysate Preparation 
Cells were either lysed directly in the culture vessels after washing twice with PBS or removed 
from the bottom of the culture vessel by trypsinisation and pelleted by centrifuging at 16100g for 
three minutes.  Depending on the size and number of cells in the pellet or culture vessel, between 
20-500µL of lysis buffer, with 10µL phosphatase and protease inhibitor cocktails per 1mL of lysis 
buffer (Sigma-Aldrich, Dorset, UK), was added and gently mixed.  This was incubated for 30 
minutes at 4ᴼC with gentle agitation.  The lysate was then collected, clarified by centrifugation for 
  To make 1L of lysis buffer 
 
 
Quanitity (g) 
Final 
Concentration 
 Tris HCL 1.576 10mM 
 Sodium Chloride 2.92 50mM 
 EDTA 1.86 5mM 
 Sodium Pyrophosphate 6.66 15mM 
 Sodium Fluoride 2.1 50mM 
 Sodium Orthovanadate 10mls of 100x solution 100µM 
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15 minutes at 4ᴼC (18900g) and the supernatant collected.  The resulting pellet was discarded and 
the lysate supernatant was then stored at -20oC until required for use. 
 
2.4.3 Protein quantification of cell lysates 
The Pierce BCA protein assay kit (Fisher Scientific Loughborough, UK) was used according to the 
kit instructions.  The kit comprised of two solutions that were mixed just before use in a 1:50 ratio 
to make the working solution.  Briefly 5µL of protein standards of known concentration ranging 
between 5-250µg/µL and 5µL of samples were incubated in individual wells of a 96 well plate with 
200µL of working solution from the kit for 30 minutes.  Protein standards and all samples were 
measured in duplicate. Samples were tested neat and at 1:5 and 1:10 dilutions to ensure a result 
that would be within the range of the standards.  After incubation the plate was put onto a 
Labsystems Multiskan Plus plate to be read at a wavelength of 540nm.  The plate reader was 
connected to a computer with Genesis plate reader software that then read the light absorbance 
of the samples in the wells and calculated the concentration using a standard curve generated 
from the protein standards. 
The pierce 660nm protein assay kit (Fisher Scientific Loughborough, UK) was used according to 
manufacturer’s instructions for samples lysed in x2 Laemmli buffer.  Briefly 10µL of protein 
standards of known concentration ranging between 5-250µg/µL and 10µL of samples were 
incubated in individual wells of a 96 well plate with 150µL of working solution from the kit for 5 
minutes.  Samples were diluted and analyzed as above except read at a wavelength of 660nm. 
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2.5 Western Blotting 
All reagents were purchased from Fisher Scientific (Loughborough, UK) unless otherwise stated.  
Any modifications to this method are stated in the relevant chapters. 
 
2.5.1 Buffers and Solutions 
A 10x running buffer stock was made by dissolving 30.3g of Tris, 144g of glycine and 10g of 
sodium dodecyl sulphate (SDS) in 1 litre of ddH2O.  When required for use the 10x running buffer 
was diluted 1:10 in ddH2O to the volume required to make 1x running buffer. 
A 10x transfer buffer stock was made by dissolving 30.3g of Tris and 144g of glycine in 1 litre of 
ddH2O.  When required for use the 10x transfer buffer was diluted by taking 100mL of it and 
adding 200mL of methanol and 700mL ddH2O to make 1x transfer buffer.  
A 10x washing buffer stock (TBS-T 1% Tween 20) was made by dissolving 24.2g of Tris (tris 
hydroxymethylamine), 80g of sodium chloride and 10mL of Tween 20 in 1L of ddH2O.  When 
required for use the 10x washing buffer was diluted 1:10 in ddH2O to the volume required to 
make 1x washing buffer. 
Ammonium persulphate solution (APS)was made by dissolving 25mg of ammonium persulphate in 
100mLs of ddH2O.  Tris 1.5M pH8.8 was made by dissolving 27g of Tris in 150mL of ddH2O and 
2mLs of concentrated HCl.  Tris 0.5M pH6.8 was made by dissolving 3g of Tris in 50mL ofddH2O, 
the correct pH was reached by adding 1M HCl drop-wise.  SDS (10%) was made by dissolving 10g 
of SDS is 100mL of ddH2O. 
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2.5.2 Acrylamide gel electrophoresis 
Gels were cast using BioRad (Hertfordshire, UK) glass cassettes and casting stands.  The resolving 
gel contained 12% acrylamide (37.1:1 acrylamide:bisacrylamide) in 1.5M pH 8.8 Tris buffer with 
0.12% SDS, 0.12% APS and 0.012% TEMED.  The stacking portion of the gel served to “condense” 
the proteins before entering the resolving portion of the gel; it comprised of 4% acrylamide 
(37.1:1 acrylamide:bisacrylamide) in 0.5M Tris buffer pH6.8 with 0.1% SDS, 0.1% APS and 0.015% 
TEMED..  The stacking portion was poured on top of the resolving portion after it had set. 
Laemmli sample buffer x2 concentration (Sigma-Aldrich, Dorset, UK), comprising of 4% SDS, 20% 
glycerol, 10% 2-mercaptoethanol and 0.004% bromophenol blue in 0.125M Tris buffer pH6.8, was 
added to samples that had been aliquoted out so they would each have the same amount of total 
protein per tube (the amount of protein used in each experiment is stated in the relevant 
sections).  Samples were heated at 100oC for five minutes on a heat block.  Novex Sharp pre-
stained ladder (Invitrogen; Paisley, UK) was used to ensure protein separation and identify the 
proteins of interest by size.  The gel was loaded and the BioRad tetra tank (Hertfordshire, UK) was 
filled with running buffer.  The gel underwent electrophoresis at 100V until the dye had run out of 
the stacking portion into the resolving portion; the voltage was then set to 120V and until the dye 
front reached the end of the gel unless otherwise stated. 
 
2.5.3 FABP7 positive control 
The FABP7 recombinant peptide (Abcam, Cambridge, UK) was loaded onto the gel for use as a 
positive control during optimisation.  The peptide was diluted 1:50 with PBS and then 15µL loaded 
into the well.  U251 cell line lysates were used as a positive control at 30µg/well unless otherwise 
stated. 
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2.5.4 Protein Transfer 
Hybond-P polyvinyl difluoride (PDVF) membrane (Fisher Scientific Loughborough, UK) was 
activated in methanol for five minutes then wetted in transfer buffer and sandwiched in a 
cassette with the gel and pre-wetted filter paper and pads.  To ensure good contact between the 
gel and membrane any bubbles were rolled out.  The cassette sandwich was placed in a transfer 
tank filled with transfer buffer and a cool pack.  Transfer took place for one hour at 100V. 
 
2.5.5 Primary and secondary antibodies for protein detection. 
Following protein transfer the membrane was blocked in the 5% milk powder (Tesco supermarket, 
UK) in TBS-T for one hour at room temperature.  The membrane was then incubated with primary 
antibody; details of the dilutions and diluents for each primary antibody can be seen in table 2.5.  
Incubation took place overnight at room temperature. The following morning the membrane was 
washed in TBS-T three times for 15 minutes each wash; next it was incubated in secondary 
antibody for one hour at room temperature; secondary antibody details are in table 2.5. When 
probing for more than one protein on the same membrane, the membrane was cut in an 
appropriate place according to the sizes of the proteins of interest and the protein ladder 
position. 
 
 
 
Table 2.5 Primary and Secondary antibody details 
This table shows the details of the primary antibodies, corresponding secondary antibodies and 
the optimal conditions for protein detecting following western blotting.  All secondary antibodies 
were horseradish peroxidase labelled.  All antibodies were diluted in 5% Milk powder in TBS-T. 
 
Antigen 
Primary Antibody Species, 
Clone & Supplier 
Primary Antibody 
Diluent 
Primary Antibody 
Dilution 
Secondary Antibody 
Clone & Supplier 
Secondary 
Antibody Diluent 
Seconday Antibody 
Dilution 
FABP7 
Goat, R&D Systems 
(Abingdon, UK) 5% Milk in TBS-T 1:500 
anti-goat, Sigma-Aldrich 
(Dorset, UK) 5% Milk in TBS-T 1:2000 
FABP7 
G13,Goat,  Santa Cruz 
Biotechnology (Middlesex, UK) 5% Milk in TBS-T 1:400 
anti-goat, Sigma-Aldrich 
(Dorset, UK) 5% Milk in TBS-T 1:1500 
β-actin 
AC-40, Mouse, Sigma-Aldrich 
(Dorset, UK) 5% Milk in TBS-T 1:10,000 
anti-mouse, Sigma-
Aldrich (Dorset, UK) 5% Milk in TBS-T 1:5000 
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2.5.6 Membrane Imaging 
Following secondary antibody incubation the membrane was washed again in three changes of 
TBS-T for 15 minutes each wash.  A SuperSignal West Femto Chemiluminescent Substrate kit from 
Fisher Scientific (Loughborough, UK) was used according to the instructions for visualisation, 
briefly the two reagents in the kit were mixed in equal volumes to give a working solution.  The 
membrane was incubated with the working solution for five minutes.  The membrane was then 
imaged using a ChemiDocIt system (UVP, Cambridge, UK) connected to a computer with 
VisionWorksLS software.   
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2.6 RNA extraction 
Two methods of RNA extraction were used depending on the experiment.  The ISOLATE RNA Mini 
Kit (Bioline, London UK) was used due to the ease of use in high-throughput conditions such as in 
the cell line experiments using AZA, TSA and FAs.  The TRI-reagent (Sigma-Aldrich, Dorset, UK) was 
used in experiments when there were less samples to prepare and high yield was required; for 
instance, in transfection experiments.  The particular method used is stated in the relevant 
chapters. 
 
2.6.1 RNA extraction using a kit 
RNA extraction took place using an ISOLATE RNA Mini Kit (Bioline, London UK); it was used 
according to kit instructions.  The kit was used to help remove genomic DNA (gDNA) and to 
prevent RNA degradation as the solutions contained inhibitors of RNAses.  Briefly growth medium 
was fully aspirated and cells were then incubated with kit lysis buffer for three minutes.  A cell 
scraper was used to homogenise the cells with the lysis buffer.  The homogenate was then 
transferred to a spin column in a collection tube.  It then underwent a series of spins and washes 
according to the instructions so the RNA bound to the spin column without any contaminants. 
Finally RNase-free water was incubated in the spin column for one minute and then the column 
was spun to elute the RNA.  The RNA was then stored at -80oC until required for use. 
 
2.6.2 RNA extraction using TRI reagent 
RNA extraction took place with TRI reagent according to manufacturer’s guidelines.  TRI reagent 
prevented RNA degradation and gave high yield of RNA even with samples with low numbers of 
cells.  Growth medium was removed and an appropriate volume of TRI reagent was added 
depending on the culture vessel size (1mL per 10cm2 culture dish area).  The TRI-reagent was 
76 
 
passed through a pipette several times to homogenize the sample and then left to incubate at 
room temperature for five minutes.  The homogenised sample was then transferred to a 1.5mL 
micro-centrifuge tube for processing.  Next 200µL (per 1mL of TRI reagent) of chloroform was 
added to the tube, shaken vigorously and then incubated for 15 minutes at room temperature.  
The tube was then spun for 15 minutes at 4oC, 16100g.  The colourless aqueous phase was 
transferred to a fresh tube and 500µL of isopropanol (per 1mL of TRI reagent) was added; the 
tube was vortexed for a few seconds and then allowed to incubate for 10 minutes at room 
temperature.  To pellet the RNA the tube was spun at 16100 g at 4oC for 8 minutes; the 
supernatant was then discarded and 1mL (per 1mL of TRI reagent) of 75% ethanol was added to 
the pellet to wash it.  The tube was then spun for five minutes at 11200g; the ethanol was 
removed and the RNA pellet air dried.  The RNA was dissolved in nuclease free water by vortexing.  
The RNA was then stored at -80oC until required for use. 
DNase I Amplification Grade treatment kit was purchased from Sigma-Aldrich (Dorset, UK) and 
used to treat the Tri-Reagent extracted RNA samples to remove genomic DNA.  For each sample 
1µL of DNase buffer and 1U (1µL) of DNase was added to 2µg of RNA in a volume of 8µL.  The 
mixture was incubated at room temperature for 15 minutes.  EDTA stop buffer (1µL) was then 
added and the mixture incubated at 70oC for 10 minutes; following this the mixture was then 
cooled on ice.  The RNA was then re-quantified to ensure the concentrations of the samples were 
unchanged from the quantity prior to DNase treatment. 
 
. 
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2.6.3 RNA extraction from formalin fixed paraffin embedded tissue 
To help determine whether FABP7 protein levels, as determined by IHC, correlated with mRNA 
expression, RNA was extracted from formalin fixed paraffin embedded (FFPE) tissue; this was 
done using an RNeasy FFPE kit (Qiagen, Crawley, UK).  Three 10µM thick tissue sections were 
placed in microcentrifuge tubes and deparaffinized by adding 1mL of histoclear.  The tubes were 
then vortexed for 10 seconds and incubated at 56oC for three minutes; then they were 
centrifuged at 9450g for two minutes to pellet the tissue.  The histoclear wash was repeated a 
further two times.  The histoclear supernatant was discarded and to remove any residual 
histoclear the tissue was washed in 1mL of ethanol by vortexing and then centrifuging at 9500g 
for two minutes.  This was also repeated another two times.  As much of the ethanol was 
removed as possible without disturbing the pellet; the pellet was then air dried until any 
remaining ethanol had evaporated.  Next 240µL of Buffer PKD was added and mixed by vortexing; 
it was then spun for one minute at 5600g; 10µL of proteinase K was added to the lower clear 
phase and mixed with pipetting.  The kit instructed to incubate at 56oC for 15 minutes, however, a 
considerably higher RNA yield, with no change in quality, was obtained by incubating overnight at 
56oC.  The following morning the tubes were incubated at 80oC for 15 minutes; it was important 
that the tubes were placed on the heating block for incubation only when the temperature had 
reached 80oC and were not allowed to gradually warm up.  The lower clear phase was transferred 
to a new tube and chilled on ice for three minutes and then centrifuged for 15 minutes at 10200g.  
The samples were then DNase treated by adding 25µL of DNase Booster Buffer and 10µL of DNase 
I stock solution and mixed by inversion.  The tubes were pulsed in a centrifuge to collect liquid on 
the sides of the tubes.  The tubes were incubated with the DNase treatment at room temperature 
for 15 minutes.  To adjust the binding conditions 500µL of Buffer RBC was added and mixed and 
then 1.2mL of ethanol added; 700µL of the sample was transferred to an RNeasy MiniElute spin 
column in a 2mL collection tube.  The spin column was centrifuged for 15 seconds at 5600g.  The 
flow through was discarded and then more sample was added to the columns and the steps 
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repeated until the entire sample had passed though the column.  A volume of 500µL of RPE buffer 
was added to the column and spun for 15 seconds 5600g.; this was repeated except with a spin of 
two minutes.  The column was transferred to a new collection tube and centrifuged at full speed 
for five minutes; this ensured there was no ethanol carried over during RNA elution.  Finally the 
column was transferred to a new tube and the RNA eluted with 20µL of nuclease free water by 
incubation for one minute followed by centrifugation at 9500g for one minute.  The RNA was then 
ready for downstream assays. 
 
2.6.4 RNA quantification 
The Nanodrop 1000 spectrophotometer (ThermoFisher Scientific Surrey, UK) pedestals were 
thoroughly cleaned and then distilled water was used to blank the machine.  RNA (1.5µL) was 
loaded onto the pedestal of the Nanodrop.  The Nanodrop then gave an absorbance reading 
which was converted to an amount of RNA within the Nanodrop software V3.7.1 of the connected 
computer.  Each sample was measured in duplicate and the pedestals wiped thoroughly between 
each sample.  The Nanodrop also gave a 260/280 ratio and a 260/230 ratio.  The 260/280 ratio 
was preferably between 1.76 and 2.1; anything below meant there was significant protein 
contamination and anything above indicated there was RNA degradation.  The 260/230 ratio 
ideally was around 1.8, anything significantly below this indicated that was contamination from 
substances such as ethanol, phenols, carbohydrates or salts.  Once quantified the RNA could be 
used for downstream assays. 
 
2.6.5 RNA Integrity 
The RNA integrity was tested using agarose gel electrophoresis.  A 50x stock solution of Tris-
acetate-EDTA (TAE) was prepared and comprised of 20M Tris-acetate and 0.05M EDTA solution 
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pH8..  The 50x TAE buffer was diluted 1:50 with ddH2O prior to use. A gel was prepared by heating 
1% agarose in 1x TAE buffer (0.4M Tris-acetate, 0.001M EDTA) in a microwave until boiling. 
Ethidium Bromide solution was added and the mixture swirled to give a final concentration of 
50µg/mL.  It was then poured into a gel tray with combs to form the wells and allowed to set.  
Each RNA sample (5µL) was added to 15µL of nuclease free H2O and 5µL of Crystal 5x DNA loading 
buffer (Bioline, London UK).  Each sample was then loaded into the wells of the gel and the gel 
underwent electrophoresis at 80V for 20 minutes in TAE buffer.  The gel was imaged using a 
MiniBis UV illuminometer (DNR Bio-Imaging Systems, Stretton Scientific, Derbyshire, UK).  The 
RNA integrity was considered acceptable if there were 2 bands on the gel corresponding to the 
18S and 28S ribosomal RNAs and if the 28S band was more intense than the 18S band. 
 
2.7 Complementary DNA synthesis 
The resulting RNA was then used for downstream synthesis of DNA to analyse expression of 
mRNA. 
2.7.1 Reverse Transcription polymerase chain reaction (PCR) 
1µg of RNA was used for conversion to cDNA.  The cDNA synthesis was carried out using the 
GoScriptTM Reverse Transcription system (Promega, Southampton, UK). DNase treated RNA (1µg 
in a volume of 5.5µL) was added to 10µL of nuclease free H2O and 1µL/0.5µg of Random Primer 
for each sample.  The samples were then heated to 70 oC for five minutes and then chilled on ice 
for at least five minutes.  A reverse transcriptase containing mixture was prepared for n+2 
samples to allow for pipetting error.   The reaction mixture per sample comprised of 4.0µL 
GoScriptTM 5x Reaction Buffer, 4.4mM MgCl2, 0.5mM of each dNTP/2mM of PCR nucleotide mix, 
20U recombinant RNasin® ribonuclease inhibitor and 1.0µL of GoScriptTM Reverse Transcriptase. 
This mixture was then added to each sample (9.82µL). 
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A minus reverse transcriptase control (-RT) was used as a negative control.  The RNA underwent 
the same treatment with the same reagents except the GoScriptTM Reverse Transcriptase was 
replaced with nuclease free water.  It was used as a means of determining whether there was any 
DNA contamination.  A no-template (NT) negative control was also used to ensure there was no 
DNA contamination from other sources; instead of any RNA being used the sample comprised of 
10µL of nuclease free water and was treated as reverse transcriptase positive samples.  The 
samples were then incubated as follows in table 2.6 using a PTC-200 DNA engine gradient cycler. 
 
 
 
Table 2.6 Reverse Transcription conditions 
This table shows the temperature and duration conditions for reverse transcription PCR. 
 
2.7.2 Primers 
Primers were designed using Primer Express Version 2.0 (Applied Biosystems, UK); details of the 
primer sets used are in table 2.7 and table 2.8.  Primers were ideally required to have a %GC 
content between 40 and 60% and each primer of a primer set was to have a similar if not identical 
melting temperature.  Primers were also designed to span exon boundaries or to lie either side of 
an intron; gDNA contains both introns and exons so designing primers in this way ensured that 
gDNA was not amplified or the gDNA amplified product was much larger.  The β–actin primers 
were designed by Dr Liku Tereza, who kindly shared the primer sequences for this work.  The 
primers for BCL-X, Caspase 9 and survivin splice variants were kind gifts from Dr Rachel Hagen.  
Primers were ordered from Eurofins MWG operon (London, UK).  They were reconstituted 
according to manufacturer’s instructions and then diluted, to give a 5µM working stock, with 
nuclease free water ready for use and then were aliquoted and stored at -20oC.   
Step Temperature (°C) Time (minutes) 
 Anneal 25 5 
 Extend 42 60 
 Inactivate 70 15 
 Chill 4 hold 
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Table 2.7 Standard PCR primer details 
This table shows the details of the primers used in standard PCR experiments.  The survivin primer 
sets generated three different products the names and size (bp) are stated.  Caspase 9 and BCL-X 
primer sets gave two products each.  Β-actin was used as a reference gene. 
              
Gene 
NCBI Accession 
Number 
Splice Variant 
Product Size 
(bp) 
  Primer Sequence 5' to 3' 
Tm (Melting 
Temperature oC) 
Survivin NM_001168 Full Length 450 Forward GCTCCGGCCAGAGGCCT 65.5 
  
EX3 330 Reverse GCATGGGTGCCCCGACG 65.5 
  
2B 520 
   Caspase 9 NM_001229.3 9A 270 Forward GCTCTTCCTTTGTTCATC 57.9 
  
9B 740 Reverse CATCTGGCTCGGGGTTA 63.7 
BCL-X NM_138578.1 BCL-XS 160 Forward CATGGCAGCAGTGAAGC 59.4 
  
BCL-XL 350 Reverse GCATTGTTCCCGTAGAGA 59.8 
β-actin NM_00101.3 
 
70 Forward CCTGGCACCCAGCACAAT 59 
        Reverse GCCGATCCACACGGAGTACT 60 
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Table 2.8 qPCR Primer details 
This table details the primer sets used in qPCR experiments.  The product sizes for each primer set 
are stated for validation purposes i.e. to test the primers the qPCR products were subjected to 
agarose gel electrophoresis. 
 
2.7.3 Standard PCR 
To ascertain which cell lines expressed FABP7 mRNA standard PCR was carried out using GoTaq® 
Hot Start Polymerase system (Promega, Southampton, UK).  This was used according to 
manufacturer’s instructions.  The reaction mix per sample comprised of  5µL 5x Green 
GoTaq®Flexi Buffer, 1.5mM MgCl2, 0.48mM of dNTP PCR nucleotide mix, 0.5µM each of forward 
and reverse gene specific primers, 0.1µL of GoTaq® Hot Start Polymerase and 2.5µL of each 
sample made up to a final volume of 25µL with nuclease free water.   The PCR reaction mixtures 
were incubated in a PTC-200 DNA engine gradient cycler as in table 2.9. 
            
Gene 
NCBI Accession 
Number 
Product  
Size (bp) Primer Sequence 5' to 3' 
Tm (Melting 
Temperature oC) 
FABP7 NM_001446.3 70 Forward GGCTTTCTGTGCTACCGGA 59 
   
Reverse CACGCCTAGAGCCTTCATGT 59 
β-actin NM_00101.3 70 Forward CCTGGCACCCAGCACAAT 59 
   
Reverse GCCGATCCACACGGAGTACT 60 
Survivin FL NM_001168.2 433 Forward GAGCTGCAGGTTCCTTATC 59 
   
Reverse ACAGCATCGAGCCAAGTCAT 64.8 
Survivin EX3 NM_001012270.1 240 Forward GGCGGCATGGGTGCCCCGACGTT 61 
   
Reverse TGGTTTCCTTTGCATGGGG 63.2 
Survivin 2B NM_001012271.1 266 Forward GGCGGCATGGGTGCCCCGACGTT 61 
   
Reverse GTGCTGGTATTACAGGCGTAAG 62.4 
Caspase 9A NM_001229.3 184 Forward AGTGGACATTGGTTCTGGAG 61.6 
   
Reverse CTTCTCACAGTCGATGTTGG 61 
Caspase 9B NM_001229.3 127 Forward TGGTGATGTCGAGCAGAAA 64.1 
   
Reverse CTGGTCGAAGGTCCTCAAAC 63.8 
ER NM_000125.3 71 Forward TCTTGGACAGGAACCAGGGA 60.1 
      Reverse TGATGTAGCCAGCAGCATGT 59.75 
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Table 2.9 Standard PCR cycling conditions 
This table shows the temperatire and duration conditions for each stage of the standard PCR.  
Thirty-four cycles of denaturing, annealing and extension took place. 
 
2.7.4 Tris-acetate-EDTA (TAE) Buffer 
A 50x stock solution was prepared by dissolving 121g of Tris in 240mL of ddH2O.  Acetic acid 
(28.6mL)and 50mL of 0.5M EDTA solution pH8 was added.  Finally ddH2O was added to make up a 
final volume of 500mL.  The 50x TAE buffer was diluted 1:50 with ddH2O prior to use. 
 
2.7.5 Agarose gel electrophoresis 
A 2.5% agarose gel was made as described in section 2.6.5 for running the PCR products on.  Each 
sample was loaded into wells (10µL) and the gel underwent electrophoresis at 100V for 30 
minutes in TAE buffer.  The gel was imaged using a MiniBis UV illuminometer (DNR BioImagaing 
Systems, Stretton Scientific, Derbyshire, UK).   
 
2.7.6 Semi-Quantitative Real Time PCR 
A GoTaq® Real-Time PCR system was used (Promega, Southampton, UK). A master mix was made 
for n+5 reactions to allow for pipetting error.  The master mix per reaction comprised of 8µL of 
  Temperature (°C) Time (mins)   
 
 
95 2 
  Denature 95 1 
  Anneal 59 1 34 cycles 
 Extension 72 1 
  
 
72 5 
    4 Hold   
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GoTaq® qPCR Master Mix, 200nM each of the gene specific forward and reverse primers and 
0.16µL of CRX reference dye made up to a volume of 14.6µL with nuclease free water. 
A standard curve was generated by pooling cDNA from each sample together and then serial 
diluting it as follows: 1:2, 1:5, 1:10, 1:20, 1:40, 1:80 and 1:160.  Neat to 1:40 were used as 
standards for FABP7 and 1:5 to 1:160 were used for the reference gene β-actin. 14µL of the PCR 
mix was added to wells of a 96 well PCR plate along with 2µL of standard or 2µL of sample, 
including –RT and NT samples.  Standards were plated in duplicate and samples were plated in 
triplicate.  The plate was then spun to ensure all the mix and cDNA was at the bottom of the well 
and then was placed on a 7300 Applied Biosystems PCR machine connected to 7300 software. 
Cycling then took place as in table 2.10.  In addition, to check the specificity of the primers, 
dissociation curves were generated by adding the dissociation curve setting to the end of the 
qPCR cycle (95oC for 15 seconds, 60oC for 1 min, 95oC for 15 seconds and 60oC for 15 seconds), 
specific primers produced one clean peak, non-specific amplification or primer-dimers were seen 
as two or more peaks.  Additionally the products were run on an agarose gel as described in 
section 2.7.3 to check product was of expected size and only one product was present for each 
sample.  FABP7 primers were validated against mRNA from U251 cells known to express FABP7.  
However, U251 mRNA was not included in qPCR experiments as a positive control because it 
would have prevented any FABP7 signal from the breast cell line samples from being detected. 
 
 
 
Table 2.10 qPCR cycling conditions 
This table show the cycling conditions for semi-quantitative PCR. 
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2.7.7 Analysis of qPCR results 
Results were analysed using the relative standard curve method.  The cycle threshold (Ct) values, 
generated from the qPCR run, were exported into Microsoft Excel; the Ct values from the set of 
serially diluted standards were used to plot a standard curve with the equation y=mx+c; 
acceptable correlation efficiency (R2 Value) of the data set was set at R2>0.98.  In addition the 
efficiency was checked by looking at the m value of the standard curve; primers generating m 
values of 3.2 - 3.6 were determined to be efficient for qPCR (E values = 110%-90%).  The Ct values 
of the samples were then converted using values from the graph equation y=mx+c, as follows: Log 
Value of Ct was derived from the following equation: Log Value of Ct =((Ct-c)/m) where c and m 
are from the graph equation generated from the serially diluted standards.  These values were 
then antilogged (10^x). This was done for the Ct Values of both the gene of interest and the 
chosen reference gene, β-actin.  Gene of interest expression values were then normalised to β-
actin values so that the relative expression of the gene of interest in each sample could be 
compared and if required fold change in mRNA calculated.  
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2.8 Transfection of BT-20 cells 
To study the role of FABP7 in TN and BLBC, the breast cancer cell line BT-20 was transiently 
transfected with a plasmid containing the FABP7 gene. 
2.8.1 The pCMV-SPORT6 containing FABP7 
The pCMV-SPORT6 vector containing the full length cDNA clone FABP7 (accession number 
NM_001446.3) was purchased from Thermo-scientific (Surrey, UK); it was in the form of a ready 
to use glycerol stock of transformed bacteria.  A map of the vector can be seen in figure 2.1; the 
FABP7 gene was inserted between the NotI and SalI restriction sites. 
 
 
 
 
 
 
 
 
 
Figure 2.1 A schematic map of the pCMV-SPORT6 vector 
The vector contains the FABP7 gene (1004bp; accession number NM_001446.3) between the 5’ 
SalI and 3’ NotI restriction sites.  The complete plasmid size is 5400bp.  The insert was removed 
using SalI and XhoI restriction enzymes creating a fragment of length of around 1000bp with the 
remaining vector fragment of 4353bp.  
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The glycerol stock was used to inoculate a Lysogeny broth (LB) agar plate (ddH20, containing 10g/L 
of tryptone, 5g/L of yeast extract, 5g/L of NaCl and 15g of agar autoclaved, poured into sterile 
dishes and the allowed to set).  Due to the ampicillin resistance gene on the plasmid, 100µg/mL 
ampicillin (Sigma-Aldrich) was added to the agar whilst still molten, to prevent contaminants, or 
untransformed E.coli, from growing.  The agar plate was incubated overnight at 37oC; the 
following day a single colony was selected to inoculate 5mL of LB (no agar) also containing 
100µg/mL ampicillin.  The broth was incubated overnight on a shaker at 200rpm. at 37oC. 
 
2.8.2 Plasmid purification 
The overnight cultures to generate plasmid were purified using the PureYield Plasmid Miniprep 
System (Promega, Southampton, UK); it was used according to manufacturer’s instructions.  3mL 
of culture was spun to pellet the cells; the culture media supernatant was removed and then the 
cells re-suspended 600µL of nuclease free water.  The resuspension was then subjected to 
plasmid purification. 
 
2.8.3 Generation of a control pCMV-SPORT6 vector  
To generate a control pCMV-SPORT6 vector, 1µg of purified plasmid, containing the FABP7 gene, 
was digested using the restriction enzymes SalI and XhoI (Promega, Southampton, UK).  XhoI was 
used instead of NotI as it has compatible ends with SalI and is only a few base pairs away; no 
important plasmid features were lost.  Restriction digest took place at 4oC overnight; the digest 
contained 16.3µL of ddH2O. 2µL of restriction enzyme 10X buffer, 0.2µL BSA (1mg/mL), 1µg of 
DNA and  0.5µL restriction enzyme (10u/µL),  (Promega, Southampton, UK) giving a final volume 
of 20µL. 
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The following morning 5µL of DNA loading buffer was added and the restriction digest was run on 
a 1% TAE buffer agarose gel at 100V for 30 minutes.  Two bands were seen; a smaller band of 
around size 900-1000bp and a larger the size of around 4000-4500bp; these bands were the 
predicted size for the FABP7 gene and the plasmid backbone respectively.  The larger 4000-
4500bp band, containing the plasmid backbone, was extracted from the gel and purified using the 
wizard SV gel prep kit according to manufacturer’s instructions.  The purified DNA was then 
religated with T4 DNA ligase (Promega, Southampton, UK) due to the compatible ends.  0.5µg of 
DNA was incubated overnight with T4 ligase and its respective buffer, at 4°C.  The control pCMV-
SPORT6 plasmid was transformed into JM109 competent cells (Promega Southampton, UK) by 
heat shock.  Bacterial cells were cultured in super optimal broth with catabolite repression (SOC) 
medium (supplied with JM109 cells) overnight on a shaker at 200rpm at 37oC.  The culture broth 
was then streaked and incubated on an LB plate with ampicillin as previously described.  This 
ensured selection of only transformed JM109 bacterial cells.  A single colony was then selected for 
growth in LB broth and then the control plasmid was then purified as described above. 
 
2.8.4 Glycerol stock generation 
Glycerol stocks of cultured bacteria; both the FABP7 and JM109 cells; were made by mixing 900µL 
of culture with 100µL of glycerol to give a 10% glycerol solution.  The stocks were kept at -80°C 
until required for use.  Further validation of plasmids took place as in chapter 5. 
 
2.8.5 Transfection procedure optimisation 
The day before transfection, cells were seeded as previously described into 6 well plates at a 
density of 0.5x106 cell per well with complete growth medium.  The following morning cells were 
serum starved in Optimem growth medium (Invitrogen, Paisley, UK) for two hours.  During this 
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time the transfection solutions were prepared.  Fugene HD (Promega, Southampton, UK) 
transfection reagent was allowed to warm up to room temperature. 0.5µg, 1µg, 2µg and 3µg of 
purified GFP plasmid (a kind gift from the University of Bristol) were tested with a 1:2 and 1:3 
volume of Fugene HD.  For example 0.5 µg was tested with 1µL or 1.5µL of Fugene HD per well.  In 
line with this a plasmid alone well and a Fugene HD alone well were set up and treated the same 
as the other wells for use as a control to assess any effect of the 2 components in isolation.  The 
plasmid was added to 100µL (volume per well) of Optimem and vortexed.  An appropriate volume 
of Fugene HD (depending on the amount of plasmid and ratio tested) was then added to the tube 
without it being allowed to touch the sides.  The transfection solution was then left to incubate 
for 15 minutes at room temperature.  After this time, the solution was added drop-wise to the 
cells. After four hours the culture medium with transfection reagent was removed and replaced 
with complete growth medium.  Forty-eight hours later, to allow maximal protein production, the 
amount of fluorescence from the GFP produced was assessed by flow cytometry (Accuri C6 flow 
cytometer, BD Biosciences, Oxford, UK).  This gave an indication of the optimal conditions.  
Toxicity of the transfection was noted by observing the cells under a microscope.  Cells were 
removed from the wells with 0.25% Trypsin/0.53mM EDTA (Sigma-Aldrich, Dorset, UK) and the 
resuspended in 500µL of PBS to prevent phenol red interference.  The reading was gated to 
included live cells and exclude debris; the FL1 channel was used to measure the percentage of 
cells fluorescing and judge the transfection efficiency.  Propidium iodide (PI) staining was then 
used to judge the toxicity of the transfection conditions in addition to microscopic evaluation.  PI 
solution was prepared by dissolving 10µg of PI per 1mL of PBS; the solution was stored at 4oC in 
the dark.  After fluorescence reading with the FL1 channel, 5µL of PI was added to the cell 
suspension and mixed by pipetting.  The sample was passed through the flow cytometer and the 
level of PI staining was assessed using the FL2 channel. The final conditions chosen were 2µg of 
plasmid with a 1:3 ratio of FugeneHD per well of a 6 well tissue culture plate. 
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2.9 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay 
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay is a quantitative 
colourimetric assay that is used to observe cell viability and cytotoxicity.  It does this by assessing 
mitochondrial metabolic activity.  Twenty-four hours post transfection; BT-20 cells were seeded at 
a density of 6,000 cells per well of a 96 well plate.  Six wells were seeded per condition; i.e. 6 wells 
of control plasmid transfection and 6 wells of FABP7 plasmid transfection.  The following morning 
cells had 10µL of MTT (concentration 5mg/mL; Sigma Aldrich, Dorset, UK) added and incubated at 
37°C in the dark for three hours.  Medium was then removed and 25µL of Sorensons glycine 
buffer (0.1M glycine, 0.1M NaCl, adjusted to pH 10.5) was added to increase sensitivity; 200µL of 
DMSO was added and the plate incubated on a shaker for 10 minutes before reading at 570nm on 
a plate reader. 
 
2.10 Oil red O staining 
Oil red O is a fat soluble dye used to demonstrate triglycerides usually in frozen tissue sections.  
This adapted method was used to study whether there was any difference in fat accumulation in 
transfected BT-20 breast cancer cells.  Cells were treated with FAs (section 2.3 onwards), the final 
doses for the FAs were chosen as follows palmitate 50µM, oleate 100µM, AA 10µM and DHA 
10µM; these doses were chosen based on dose response results (section 1.10).  Twenty-four 
hours later the cells were washed twice with PBS and then incubated in 10% formalin (10mL of 
formaldehyde with 90mL PBS) for 10 minutes.  After 10 minutes the formalin was replaced with 
fresh solution and then incubated for one hour at room temperature.  The cells were washed 
twice with ddH2O and then with 60% isopropanol for five minutes.  The isopropanol was removed 
and the cells allowed to dry completely.  During this time the Oil red O working solution was made 
by mixing 6mL of stock Oil red O solution (0.35g Oil red O (Sigma-Aldrich, Dorset, UK) in 100mL 
isopropanol and filtered)) with 4mL of ddH2O and letting the mixture stand for 20 minutes before 
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filtering. The working solution was added to the dry cells and incubated for 10 minutes.  Following 
this the stain was removed and the cells washed four times with ddH2O.  The cells were then 
ready for imaging under an inverted microscope. 
 
2.11 Statistical Analysis 
The statistical software packages SPSS IBM statistics (version 20) and GraphPad Prism 5 were used 
for statistical analysis.  The types of statistical test used for each experiment are detailed in the 
relevant results chapter sections. 
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3 FABP7 in triple negative breast cancer 
 
3.1 Introduction 
Triple negative (TN) breast cancers are defined by their lack of expression of the oestrogen 
receptors (ER) and progesterone receptors (PR) and human epidermal growth factor receptor 2 
(Her2) and account for 10-24% of all breast cancers (Reis-Filho & Tutt, 2008; Tan et al., 2009; Viale 
et al., 2009). Notably, TN breast cancers share many overlapping characteristics with basal-like 
breast cancers (BLBC), in that the majority of TN breast cancers have elevated expression of high 
molecular weight cytokeratins and both have similar gene expression signatures (Dent et al., 
2007; Kreike et al., 2007; Rakha et al., 2007a; Tan et al., 2008; Cheang et al., 2008).  TN tumours 
are predominantly high grade and aggressive cancers with poor prognosis and unlike hormone 
receptor and Her2 positive breast carcinomas, there are no targeted therapeutic regimes that 
have been shown to significantly improve survival (Carey et al., 2010).  The treatment of these 
tumours is therefore challenging and biomarker studies are required to better characterise these 
tumours with the aim of identifying improved therapeutic interventions.  One biomarker that has 
been investigated to a limited extent and that is up-regulated in BLBC is FABP7.  FABP7 is one of 9 
FABPs that have roles in FA metabolism and transport.  Studies have given conflicting evidence as 
to the role of FABP7 in breast cancer (Zhang et al., 2010; Tang et al., 2010); studies looking at 
FABP7 in other cancers such as melanoma and in gliomas have been more consistent in 
demonstrating that it is associated with poor prognosis (Liang et al., 2006; Slipicevic et al., 2008; 
Goto et al., 2010).   
A Malaysian TN breast cancer cohort was investigated for FABP7 expression using 
Immunohistochemistry (IHC).  Assessment of FABP7 expression in clinical samples will investigate 
further its important in BLBC/TN breast cancer and will provide evidence as to whether FABP7 is 
93 
 
associated with good or poor prognosis.  FAS is an enzyme that is responsible for the conversion 
of malonylCoA to palmitate (figure 1.12); FAS is up-regulated in many cancers including those of 
the breast (Alo' et al., 1996; Shurbaji et al., 1996; Rashid et al., 1997; Kuhajda, 2000).  It was 
hypothesised that FAS expression may correlate with FABP7 expression due to the evidence of the 
interaction of FABP7 with palmitate.  
 Breast cancer cell lines are invaluable in fully examining functional roles that FABP7 may be 
playing in breast cancer pathology. However interestingly despite other studies demonstrating 
expression of FABP7 in clinical cases of breast cancer, it has proven difficult to detect FABP7 in in 
vitro breast cancer cell lines. One study knocked down FABP7 in MDA-MB-435 cells, using these 
cells as a breast cancer model (Liu et al., 2012), however there is dispute as to whether the MDA-
MD-435 cell line is of breast or melanoma origin (Rae et al., 2007; Lacroix, 2009).  Consequently 
the aim of the current study was to develop a reproducible method that can be used to detect 
FABP7 protein in breast cancer cell lines lysates.  This method, alongside the investigation of 
FABP7 mRNA and protein expression in patient samples and cell lines, will aid in the future 
investigation of FABP7 in breast cancer. 
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3.2 Aims and hypothesis 
3.2.1 Aims 
i) To quantify FABP7 mRNA and protein in breast cell lines in order to choose an appropriate 
model for further investigation. 
ii) To assess FABP7 IHC staining in a cohort of Malaysian TN breast cancer cases and look at 
associations with basal-like phenotype and clinicopathological features. 
 
3.2.2 Hypothesis 
i) FABP7 expression is associated with the basal-like phenotype, FAS expression and 
clinicopathological features and is therefore of prognostic value in TN breast cancer. 
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3.3 Materials and Methods 
3.3.1 Cell lines used 
The breast cancer cell lines used were BT-20, MDA-MB-231, MDA-MB-453, MDA-MB-361, MCF-7, 
T47D, SKBR3 and HS578T; the normal breast cell line MCF10A was also used (ATCC, UK).  The 
glioma cell line U251 (ATCC, UK) was also used for this work.  Cell lines were grown according to 
the supplier’s instructions either as detailed previously in section 2.2 or cultured by collaborators 
at the University of Bristol, before lysis. 
 
3.3.2 Positive controls for western blotting 
The glioma cell line U251 was cultured for use as a FABP7 positive control as studies have 
confirmed it expresses FABP7 mRNA and protein at high levels (Mita et al., 2010). A full length 
recombinant FABP7 peptide (Abcam, Cambridge, UK), was also used as positive control for the 
detection of FABP7 protein. 
 
3.3.3 Antibody optimisation for western blotting 
A goat polyclonal anti-FABP7 antibody (R&D Systems, USA) and the G-13 anti-FABP7 antibody 
(Santa Cruz Biotechnology, UK) were compared.  The primary antibodies were tested at dilutions 
between 1:200 and 1:1000, with antibody binding carried out overnight.  The positive control full 
length FABP7 peptide (Abcam, UK) and the FABP7 positive glioma cell line U251 were included. 
The anti-goat secondary antibody (Sigma-Aldrich, UK) was tested at dilutions between 1:1000 and 
1:2000 with antibody binding being carried out for one hour at room temperature. 
 
96 
 
3.3.4 Blocking reagent and antibody diluent optimisation for western blotting 
The effect of blocking concentration was assessed by utilising two concentrations of blocking 
reagent, with blocking carried out for 1hr.  5% BSA-TBS-T and 3% BSA-TBS-T were utilised for both 
the initial blocking step and as the antibody diluent. 
 
3.3.5 Transfer time for western blotting 
The effect of transfer time on efficiency of protein detection was assessed by transferring for one 
hour or 1.5 hours at 100V onto Hybond-P PVDF (GE Healthcare Life Sciences, USA) membrane 
using the Mini Trans-Blot apparatus (Bio-Rad, UK) according to manufacturer’s instructions for 
wet blotting.  
 
3.3.6 Protein loading for acrylamide gel electrophoresis 
The threshold of FABP7 detection, by western blotting, in breast cancer cell lines was investigated 
by loading increasing amounts of total protein (50µg-100µg). In addition reducing versus non-
reducing protein loading conditions were investigated. Non-reducing buffer comprised of ddH20 
(37ml), 0.5M Tris-HCl (10ml), Glycerol (8ml), 10% SDS (16ml) and 0.05% Bromophenol Blue (5ml). 
 
3.3.7 Cell lysis optimisation for protein extraction 
Protein lysates were prepared in a number of ways to investigate the effect on FABP7 protein 
detection; 10µL each of phosphatase inhibitor II and protease inhibitor cocktails (Sigma-Aldrich, 
Dorset, UK) were added per 1mL of each lysis buffer.  Standard cell lysis was carried out using lysis 
buffer prepared in house (section 2.4); briefly cells were washed twice with PBS and then lysis 
buffer applied directly to the culture vessel.  This was incubated for 30 minutes at 4ᴼC with gentle 
agitation.  The lysate was then collected, clarified by centrifugation for 15 minutes at 4ᴼC (11200 
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g) and the supernatant collected.  Prior to gel loading, samples were quantified, reduced and 
denatured by heating at 99oC for 5 minutes with an equal volume of Laemmli x2 concentrate 
sample buffer (Sigma-Aldrich, UK).  
RIPA buffer lysis was compared as it has been found to be more appropriate for extracting nuclear 
proteins.  Briefly cells were washed twice with PBS and then lysis buffer applied directly to the 
culture vessel.  This was incubated for 30 minutes at 4ᴼC with gentle agitation.  The lysate was 
then collected, clarified by centrifugation for 15 minutes at 4ᴼC (11200 g) and the supernatant 
collected.   
The final alternative method of lysis investigated was using Laemmli x2 concentrate sample buffer 
(sample buffer) (Sigma-Aldrich, UK).  One study found that Laemmli sample buffer lysis gave 
better protein yields from tissues that had been formalin fixed and paraffin embedded (Nirmalan 
et al., 2009). Direct lysis provided the benefit of more concentrated lysate production, thus 
enabling larger amounts of total protein to be loaded per well, which in turn would increase the 
ability to detect proteins of low abundance.  Briefly cells were washed twice in PBS and then lysed 
directly in the culture vessel by addition of sample buffer.  The flask was incubated at 4oC for 30 
minutes with gentle agitation, followed by collection and sonication in a water bath for 15 
minutes to ensure shearing of DNA, thereby reducing the viscosity of the samples.  Prior to gel 
loading, samples lysed in in-house lysis buffer or RIPA buffer, were heated at 99oC for 5 minutes 
with an equal volume of sample buffer.  Samples lysed in sample buffer were heated at 99oC for 5 
minutes and loaded immediately to further minimise viscosity issues and aid loading. 
 
3.3.8 Protein Quantification 
The amount of total protein present in the cell lysates was determined using a BCA protein assay 
(Pierce, USA), except for samples lysed directly in Laemmli sample buffer, where the 660nm 
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protein assay kit (Pierce, USA) was used both according to manufacturer’s instructions (section 
2.5).  
 
3.3.9 Acrylamide gel electrophoresis optimisation 
Optimisation of electrophoresis was achieved by comparison of protein separation on 12% gels 
prepared in house (section 2.5) and pre-cast Mini PROTEAN TGX 4-20% gradient gels (Bio-Rad, 
UK). Electrophoresis was carried out using the Mini-PROTEAN Tetra system (Bio-Rad, UK). 
 
3.3.10 Protein Visualisation 
Proteins were visualised using SuperSignal West Femto Chemiluminescent Substrate kit (Pierce, 
USA) and imaged using a ChemiDocIt system and VisionWorksLS software (UVP, UK), with β-Actin 
used as a control for loading.  The membrane was cut as described in section 2.5.5 before probing 
with primary antibodies.  In addition positive controls were sometimes cut from the same 
membrane for imaging separately to prevent any interference with protein detection in the breast 
samples. 
Protein was semi-quantified using densitometry by measuring band intensity in ImageJ.  Briefly 
the region of interest tool was selected and exactly the same size box was drawn around each 
band; the program then generated arbitrary numbers based on the intensity of each band. Β-actin 
was checked to ensure even sample loading 
 
3.3.11 RNA extraction and PCR 
For this work the Bioline kit was used to extract RNA as in section 2.6.1; reverse transcription and 
qPCR then took place as in 2.7.1.  For this work 20 cases had tissue blocks available; tissue curls 
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were taken from all 20 to investigate the relationship between FABP7 expression detected by IHC 
and FABP7 mRNA levels in corresponding samples.  RNA extraction from the tissue took place as 
in section 2.6.3.  
 
3.3.12 Clinical cases of breast cancer and immunohistochemistry 
Tissue samples from breast cancer patients reported as being negative for ER, PR and Her2 and 
diagnosed between 2004 and 2009 at the University of Malaya Medical Centre, were used in this 
study.  All tissues had been fixed in 10% neutral buffered formalin between six and 72 hours, and 
processed to paraffin wax blocks, from which sections were cut at 3µm thickness on a rotary 
microtome and mounted onto Tissue Tek Plus glass slides to ensure maximum adhesion. 
The TN phenotype was confirmed by using IHC for ER PR and Her2 (section 2.1) and positive cases 
excluded from further analysis.  FABP7, cytokeratins 5/6 and cytokeratin 14 were tested for by 
IHC as described in section 2.1.  A total of 101 were cases identified as having adequate invasive 
tumour tissue for evaluation and were negative after ER, PR and Her2 testing. 
 
3.3.13 Assessment of immunohistochemistry 
Staining was assessed as described in section 2.1.9.  Cases that were not possible to interpret or 
did not have sufficient positive control staining were omitted from analysis. 
 
3.3.14 Assessment of Tumour Grade and Stage 
Grading was according to the modified Bloom and Richardson criteria (Elston & Ellis, 1991).  All 
slides were reviewed and re-graded for this study by clinical pathologists from the Department of 
Pathology, University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.  Clinical data 
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on patient age, ethnicity and stage, were extracted from the UMMC database for this series of 
cases. 
 
3.3.15 Statistical analysis 
Continuous variables (age) were described using medians and compared using the Mann-Whitney 
U test, while categorical variables (ethnicity, stage, grade, FABP7 score, CK5/6 expression and 
CK14 expression) were expressed as proportions and compared using either Chi square test or 
Fisher’s Exact test.  A Kaplan Meier survival analysis took place on survival data from UMMC. 
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3.4 Results 
3.4.1 Antibody selection, optimisation and assessment of specificity 
At the time of this study there were limited available antibodies for FABP7 that were validated for 
western blotting.  Two commercially available anti-FABP7 primary antibodies were tested; the 
goat anti-FABP7 antibody (R&D systems) and the goat anti-FABP7 antibody, clone G13 (Santa Cruz 
Biotechnology). The antibody diluent was 5% milk powder in TBS-T unless otherwise stated. The 
R&D systems primary antibody and HRP labelled anti-goat secondary antibody (Sigma-Aldrich) 
dilutions were tested in a variety of combinations on blots of 20ng and 50ng of FABP7 full length 
peptide and 30µg lysate from U251 cells.  The secondary antibody dilution, 1:1000, led to the 
development of background as in figure 3.1 A and C.  The primary antibody dilution 1:800 did not 
have sufficient sensitivity for the detection of the 20ng of peptide (figure 3.1 C and D).  The 
combination of 1:500 primary antibody with 1:2000 secondary antibody gave the sharpest, bands 
whilst achieving the best threshold of detection (figure 3.1 B). As a result this combination was 
selected to facilitate further optimisation. 
 
 
102 
 
 
Figure 3.1 The optimisation of primary and secondary antibody dilution 
The FABP7 peptide and U251 lysate were separated by SDS-PAGE and then blotted on to PVDF 
membrane.  The membrane was cut in to 4 pieces and each piece incubated in a different 
combination of primary and secondary antibody dilution. A) primary 1:500, secondary 1:1500. B) 
primary 1:500, secondary 1:2000. C) primary 1:800, secondary 1:1500. D) primary 1:800, 
secondary 1:2000.  The final combination chosen was B as it gave the least background and 
greatest sensitivity. 
 
For comparison of the two available antibodies the dilution of the G13 anti-FABP7 antibody was 
optimised and results compared.  The G13 antibody was tested at dilutions 1:200 (Figure 3.2B), 
1:500 (Figure 3.2C) and 1:1000 (Figure 3.2D) on 30µg of protein lysate from U251 cells. The 
secondary antibody was used at a dilution of 1:2000.    The G13 antibody consistently produced 
higher background and was less sensitive than the R & D antibody (figure 3.2A). However both 
antibodies identified single molecular weight products at the expected molecular weight.  
Although the R&D antibody outperformed its counterpart it was essential to ensure specificity. 
This was achieved using the commercially available blocking peptide for Santa Cruz.   
20ng   50ng      U25120ng   50ng      U251
A
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B
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15kDa
20kDa
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 Briefly the FABP7 blocking peptide was used at five times the concentration of the FABP7 & 
antibody from Santa Cruz, as recommended in the manufacturer’s instructions. The antibody and 
blocking peptide were incubated together for two hours at room temperature.  Following 
incubation the antibody-blocking peptide solution was added to the diluent (5% milk powder in 
TBS-T) to achieve the desired 1:200 dilution of G13 primary antibody. This blot was analysed 
alongside the R&D FABP7 antibody as a method control (Figure 3.2 A). 
 
 
 
 
 
 
 
 
 
Figure 3.2 Comparison of two different FABP7 antibodies 
The sensitivity and specificity of the SC FABP7 antibody was investigated by testing a variety of 
dilutions: B) 1:200, C) 1:500 and D) 1:1000, against the optimised R&D antibody shown in A.  The 
bands were not as clearly defined and there was more background with the SC antibody. 
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104 
 
3.4.2 Optimisation of Blocking Agent 
Blocking reagent can influence the sensitivity and linear dynamic range of any given protein 
detected in a western blot protocol. These effects depend on the unique specific antigen-antibody 
pairing characteristics and thus need to be evaluated on an individual basis.  To test whether the 
choice of blocking reagent significantly affected the detection of FABP7, membranes with FABP7 
recombinant peptide and U251 lysate were blocked in either 5% milk (figure 3.3A) powder or 3% 
BSA (Figure 3.3B). The BSA led to increased background.  Since the milk powder blocking agent 
provided the highest signal-to noise ratio, 5% milk powder in TBS-T was used for all subsequent 
experiments. 
 
Figure 3.3 The optimisation of blocking reagent 
FABP7 full length recombinant peptide and a U251 protein lysate were loaded in replicate form 
onto the gel and separated and blotted as described previously.  The resulting membrane was 
divided for uniformity of samples and blocked in A) 5% milk or B) 3% BSA respectively.  The 
primary and secondary antibodies were diluted in their respective blocking solutions.   The highest 
signal-to-noise ratio was achieved using milk. 
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3.4.3 Comparison of reducing and non-reducing conditions in protein preparation 
Antibody-epitope binding is greatly affected by the conformational structure of the protein of 
interest.  For instance epitopes may be lost or gained if the protein is reduced or denatured when 
disulphide bonds are broken and the protein “linearized”.  There was no information on the R&D 
antibody data sheet about the conditions to which the protein lysates should be subjected.  For 
these reasons reducing and non-reducing conditions during protein lysate preparation were 
tested to investigate whether FABP7 protein detection was improved using either condition.  Non-
reducing buffer comprised of ddH20 (37mL), 0.5M Tris-HCl (10mL), Glycerol (8mL), 10% SDS 
(16mL) and 0.05% Bromophenol Blue (5mL).  As expected non-reducing conditions (figure 3.4) 
resulted in the detected protein band, running at a higher molecular weight than predicted 
according to the manufacturer’s data. However only one band was still detected and this was not 
deemed to be the result of dimerization or aggregation based on molecular weight analysis.  
There was also no change in band intensity as a result of non-reducing conditions showing that 
the R&D anti-FABP7 antibody epitopes were unchanged. This demonstrates that the protein 
lysates should be subjected to reducing conditions in order to linearize them so they separate to 
the predicted size during gel electrophoresis.  In addition it is possible that proteins aggregated 
and were less able to migrate through the gel. Studies have consistently shown that the reducing 
conditions affect protein migration profiles; non-reducing conditions lead to the protein being 
detected at a higher than predicted molecular weight (Routledge et al., 1987) and illustrated the 
importance in choice of reducing condition when looking at dimers, monomers or aggregates of 
protein since dimers or multimers would be lost in reducing conditions (MacPhee, 2010; Lui et al., 
2006).  For these reasons reducing conditions were used in subsequent protein lysate 
preparation.  
 
 
106 
 
 
 
 
 
 
Figure 3.4 The optimisation of blocking reagent and sample reducing conditions 
FABP7 full length recombinant peptide and a U251 protein lysate were subjected to reducing or 
non-reducing conditions and then SDS-PAGE and western blotting took place as described 
previously.  The non-reducing conditions lead to the detected protein band running at a higher 
molecular weight than predicted. 
 
 
3.4.4 Detection of FABP7 protein in breast cell-line lysates 
With the main elements of the protocol optimised, a western blot was carried out with these 
optimised conditions on a panel of breast cell-line proteins lysates.  The optimised conditions 
were as follows:  Transfer 1 hour, blocking reagent and antibody diluents 5% milk, primary 
antibody R&D 1:500 and secondary antibody 1:2000.  Β-actin was used as a loading control.  The 
resulting blot is shown in figure 3.6.  Breast cell-line lysates were loaded initially at 50µg but 
FABP7 protein was not detected (results not shown).  The amount of protein was increased to 
100µg (figure 3.6). FABP7 was detected in 30µg of U251 lysate and the 50ng of FABP7 
recombinant peptide was successfully detected, however FABP7 was not detected in the breast 
cell-lines under these conditions. 
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Figure 3.5 The detection of FABP7 in breast cancer protein lysates with conditions so far 
Breast cell lines were lysed in standard lysis buffer and 100µg of each lysate prepared and 
subjected to western blotting as already described.  The positive controls, recombinant FABP7 
peptide (50ng) and U251 protein lysate were successfully detected and the loading control β-actin 
was even throughout the breast cell lines.  FABP7 protein was not detected in the breast cancer 
cell lines. 
 
3.4.5 Cell lysis optimisation 
It was surprising, given the evidence that FABP7 protein is detected in breast cancer tissues using 
immunohistochemistry, that there was no FABP7 detected in any of the breast cell lines tested. A 
number of hypotheses for this were considered including the possibility of FABP7 being present in 
very low abundance or problems resulting from incomplete lysis and or solubilisation of cellular 
proteins.  In order to ensure that the latter scenario was not hindering detection of FABP7 a 
variety of different protein extraction methods were evaluated using the positive control cell line 
U251.  The subsequent U251 lysates were then quantified as described previously and seperated 
on a 12% acrlaymide gel.  Transfer time, blocking and antibody dilutions were as before.  The 
U251 cells lysed in sample buffer resulted in the strongest FABP7 band (figure 3.7).   
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Figure 3.6 Lysis buffer optimisation 
U251 cells were lysed in either standard lysis buffer, RIPA buffer or sample buffer and the 
subjected to SDS-PAGE on either 12% gel. Blotting and antibody incubations took places as 
previously optimised.  The sample buffer gave the strongest band out of the lysis buffers tested. 
 
 
3.4.6 Acrylamide gel electrophoresis optimisation 
To investigate whether the type of gel used further improved detection of FABP7 a separation 
comparison was made using 12% gels prepared in house and pre-cast Mini PROTEAN TGX 4-20% 
gradient gels (Bio-Rad, UK). Gradient gels provided the benefit of increasing percentage up to 20% 
acrylamide, which would subsequently provide improved band sharpness for proteins such as 
FABP7 which have a very low molecular weight.  Although sample buffer had consistently enabled 
the best signal detection, it was hypothesised that there may be a difference in protein migration 
between the gels depending on the lysis buffer used and consequently all lysis buffers were 
evaluated.  The results are in figure 3.7; the gradient gel resulted in the strongest bands for all 
lysis buffers used.  Following these results the breast cell lines were lysed in sample buffer and 
then subjected to electrophoresis on a gradient gel. 
 
Lysis           RIPA             Sample
buffer        buffer buffer
15kDa
20kDa
U251 lysate
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Figure 3.7 The differences in lysis buffer and choice of acrylamide gel. 
U251 cells were lysed in either standard lysis buffer, RIPA buffer or sample buffer and the 
subjected to SDS-PAGE on either A) an in house 12% gel or B) a precast 4-20% gradient gel.  
Blotting and antibody incubations took places as previously optimised.  The Sample buffer gave 
the strongest band out of the lysis buffers tested.  The gradient gel lead to higher intensity bands 
overall than the 12% gel. 
 
3.4.7 FABP7 protein and mRNA expression in a panel of breast cancer cell lines 
A western blot, with the optimised conditions using sample buffer (x2 Laemmli sample buffer) for 
lysis and a gradient gel, was carried out with the available breast cancer cell lines (Figure 3.8 A).  
BT-20 cells expressed the most FABP7 protein whilst MCF10A and HS587T cells expressed the 
least.  In addition, BT-20 cells also had the highest expression of FABP7 mRNA expression in the 
cell lines tested (Figure 3.9).  MDA-MB-453 and MCF10A cells had the lowest mRNA expression. 
 
 
 
A B
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Lysis           RIPA             Sample
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Figure 3.8 FABP7 protein expression in a panel of breast cancer cell lines 
A: The resulting membrane image of FABP7 detection in breast cancer cell lines.  The positive 
U251 control was imaged separately.  B: The relative band intensity of the protein bands in A.  
This was interpreted using Image J software.  BT-20 cells expressed the most protein in the panel.  
MCF10A and HS578T expressed the least.  The results shown are representative of 3 independent 
experiments with the relative band intensities representing only the membrane in A. 
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Figure 3.9 FABP7 mRNA expression in a panel of breast cancer cell lines 
RNA was extracted from the breast cells and subjected to reverse transcription and then qPCR 
with β-actin as a reference gene.  BT-20 cells had the highest relative expression of FABP7 mRNA 
followed by SKBR3 and MDA-MB-361 cells.  MDA-MB-453 and MCF10A cell had the lowest 
expression of FABP7 mRNA.  Results shown represent the mean of 3 independent experiments 
carried out in triplicate ±SEM. 
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3.4.8 FABP7 expression in patient samples 
FABP7 staining was localised to the cytoplasm and nucleus of cancer cells with some cases and 
areas of tumours exhibiting areas of only cytoplasmic staining (figure 3.10).  Staining intensity 
ranged from weak to intense (figure 3.11) and normal breast ducts and adipose tissue served as 
internal positive controls (figure 3.12).  Of the cases available, 99 were assessable for FABP7.  
Twenty cases (20.2%) had complete absence of FABP7 staining; 38.3% of cases had intermediate-
weak staining (score of 2-6) and 41.1% of cases exhibited strong staining (a score of 7 or 8) (table 
3.1). 
 
 
 
 
 
 
Table 3.1 Frequencies of FABP7 expression in a TN breast cancer cohort 
Immunohistochemistry for FABP7 was carried out on TN breast cancer cases.  There were 20.2% 
of cases that had complete absence of FABP7 staining.  Intermediate-weak staining (score of 2-6) 
was present in 38.3%; the remaining cases (41.1%) had strong FABP7 staining (score of 7-8) 
 
 
 Frequency 
Valid 
Percent 
FABP7 
score 
0 20 20.2 
2 1 1.0 
3 4 4.0 
4 11 11.1 
5 13 13.1 
6 9 9.1 
7 11 11.1 
8 30 30.3 
  Total 99 100.0 
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Figure 3.10 Patterns of FABP7 IHC staining in a triple negative, invasive breast ductal carcinoma 
(IDC) case.
Top: x10 “patchwork” pattern of FABP7 staining, areas of weak to strong staining of the IDC ◀ 
compared to negative staining of surrounding stromal tissue . Bottom:  The same case at x40, 
showing cells with nuclear and cytoplasmic localisation ◀ and cytoplasmic only localisation of 
FABP7 . 
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Figure 3.11 FABP7 IHC staining intensities in 3 triple negative IDC cases 
Top left: x40 Weak FABP7 staining localised to both the nucleus ● and 
cytoplasm ◀ of cells in the IDC. Top right: x40 Intermediate-weak FABP7 
staining, predominantly cytoplasmic ● but some nuclear localisation ◀.  
Bottom: x20 Strong FABP7 staining of the IDC ◀ compared to negative staining 
of the surrounding stromal tissue ●. 
115 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 FABP7 IHC staining in normal ducts and adipose tissue 
X40 Staining of FABP7 with IHC in normal ducts ● and adipose tissue ◀ served as internal positive 
controls. 
 
 
3.4.9 Use of a FABP7 blocking peptide eliminated positive staining 
A second FABP7 antibody (clone G13, Santa Cruz Biotechnology, UK) was used to validate the 
specificity of the staining due to the availability of a blocking peptide.  The results are in figure 
3.13.  A strong FABP7 positive case was selected from the cases stained with the R&D antibody 
and staining repeated with the anti-FABP7 clone G13 antibody.   The addition of the blocking 
peptide with the anti-FABP7 clone G13 antibody (section 2.1.6.3) eliminated the staining.
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Figure 3.13 The use of a FABP7 blocking peptide 
The FABP7 antibody (clone G13) with the availability of a blocking peptide 
was used validate the specificity of the staining.  Top Left:  x20 A FABP7 
positive TN IDC breast cancer case stained for using the R&D FABP7 antibody.  
Top Right: x20 The same IDC TN breast cancer case stained with the G13 
Santa Cruz FABP7 antibody.  Bottom: x20 The addition of the FABP7 blocking 
peptide; staining was eliminated. 
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3.4.10 FABP7 mRNA in patient samples is correlated with IHC protein expression 
RNA was extracted from breast cancer tissue curls and the corresponding slides were stained for 
FABP7 with IHC.  Figure 3.14 shows the FABP7 IHC Allred scores and FABP7 qPCR results from 
FFPE tissue and the correlation of FABP7 protein and mRNA expression in FFPE patient samples.  
Case 14 had the highest amount of FABP7 mRNA and an Allred score of 7; cases 19 and 20 had 
barely detectable levels of FABP7 mRNA and Allred scores of 0 and 2 respectively.  The expression 
of FABP7 mRNA and the Allred score were significantly associated with a p value of 0.0004 with 
Spearman’s correlation. 
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Figure 3.14 FABP7 mRNA and protein expression in patient samples 
RNA was extracted from the 20 available tissue curls and the corresponding sections were stained 
using IHC for FABP7.  The Allred scores are in A; the strongest staining case was 15.  The relative 
FABP7 mRNA expression is in B, case 15 had the second highest expression, case 14 the highest.  
C) The correlation of the FABP7 scores and the relative FABP7 mRNA expression.  The FABP7 
mRNA results and FABP7 IHC scores were significantly correlated (p=0.0004, Spearman’s 
correlation). 
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3.4.11 FABP7 expression and clinicopathological features 
Ethnicity, lymph node involvement, grade (there were no grade 1 cases) and lymphovascular 
invasion were not associated with FABP7 expression.  Stage was associated with FABP7 
expression; cases that were FABP7 positive tended to be of a lower stage (p=0.039). Both basal 
cytokeratins CK14 and CK5/6 positivity were associated with FABP7 positivity (p=0.048 and 
p=0.031 respectively) (figure 3.15) (table 3.2). 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 FABP7 positivity is associated with CK5/6 and CK14 positivity 
Top Left: x40 A FABP7 positive IDC breast cancer case; Top Right: x40 The same breast cancer case 
stained positively with CK5/6.  Bottom Left: x40 A different FABP7 positive IDC case; Bottom Right: 
x40 The same case stained positively for CK14. 
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Table 3.2 Factors associated with FABP7 expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
  FABP7 Score  
P for X2 
test  Overall 0 2 3 4 5 6 7 8 
No. of patients 99          
Ethnicity, N (%)          0.939 
Chinese 59 (60.6) 12 (60) 1 (100) 4 (100) 7 (63.4) 7 (53.8) 4 (44.4) 7 (63.6) 17 (56.7)  
Malay 21 (21.2) 4 (20) 0 0  1 (9.1) 5 (34.5) 1 (11.1) 2 (18.2) 8 (26.7)  
Indian 15 (15.2) 3 (15) 0 0 2 (12.2) 1 (7.7) 3 (33.3) 2 (18.2) 4 (13.3)  
Others 4 (3.0) 1 (5) 0 0 1 (9.1) 0 1 (11.1) 0 1 (3.3)  
Lymph node involved, N (%)          0.612 
Yes 41 (42.3) 12 (60) 0 2 (50) 4 (36.4) 6 (50) 3 (33.3) 3 (27.3) 11 (37.9)   
No 56 (57.7) 8 (40) 1 (100) 2 (50) 7 (63.4) 6 (50) 6 (66.7) 8 (72.7) 18 (62.1)  
Unknown 2          
Stage, N,(%)          0.039a 
Early (Stage 1-2) 66(66.7) 11 (55) 1 (100) 3 (75) 6 (54.5) 5 (38.5) 9 (100) 10 (90.9) 21 (70)  
Late (Stage 3-4) 33(33.3) 9 (45) 0 1 (25) 5 (45.5) 8 (61.5) 0 1 (9.1) 9 (30)  
Grade d, N (%)          0.382 
Grade 2 17 (17.7) 4 (20) 1 (100) 1 (25) 2 (18.2) 2 (15.4) 0 1 (9.1) 6 (21.4)  
Grade 3 79 (82.3) 16 (80) 0 3 (75) 9 (81.8) 11 (84.6) 8 (100) 10 (90.9) 22 (78.6)  
Unknown 3           
Lymphovascular invasion, N 
(%) 
         0.686 
Present 33 (37.5) 8 (44.4) 1 (100) 2 (66.7) 3 (30) 5 (41.7) 3 (42.9) 4 (15.4) 7 (21.4)  
Absent 
Unknown 
55 (62.5) 
11 
10 (55.6) 0 1 (33.3) 7 (70) 7 (58.3) 4 (57.1) 7 (84.6) 19 (78.6)  
CK14 status, N (%)          0.048a 
Negative 41 (54%) 17 (85) 0 3 (75) 5 (45.5) 6 (50) 2 (22.2) 5 (45.5) 16 (59.3)  
Positive 54 (46%) 3 (15) 1 (100) 1 (25) 6 (54.5) 6 (50) 7 (77.8) 6 (54.5) 11 (40.7)  
Unknown 4          
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Table 3.2 continued 
 
 
 
 
 
 
a) Statistically significant d) there were no cases that were grade 1. 
 
 
CK 5/6 status, N (%)          0.031a 
Negative 24 (29.1) 8 (47.1) 2 (66.7) 3 (100) 1 (9.1) 2 (16.7) 1 (11.1) 3 (30) 6  
Positive 63 (70.9) 9 (52.9) 1 (33.3) 0 10 (90.9) 10 (83.3) 8 (88.9) 7 (70) 18  
Unknown 12          
CK14 and CK5/6 status, N 
(%) 
         0.008a 
Negative 55 (65.5) 16 (94.1) 0 3 (100) 6 (54.5) 6 (54.5) 2 (22.2) 6 (60) 16 (72.7)  
Postive 29 (34.5) 1 (5.9) 1 (100) 0 5 (45.5) 5 (45.5) 7 (77.8) 4 (40) 6 (27.3)  
Unknown 15          
CK14 or CK5/6 status, N (%)          0.061 
Negative 36 (36.7) 10 (50) 0 3 (75) 1 (9.1) 3 (23.1) 1 (11.1) 4 (36.4) 14 (48.3)  
Positive 62 (63.3) 10 (50) 1 (100) 1 (25) 10 (90.9) 10 (76.9) 8 (88.9) 7 (63.6) 15 (51.7)  
Unknown 1          
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3.4.12 FABP7 expression is not related to tumour size or patient age 
A Mann-Whitney U test was carried out to look for significance between FABP7 expression and 
tumour size and patient age.  The median age for FABP7 negative cases (those with a score of 6 or 
less) was 52; the median age for FABP7 positive cases (a score of 7 or 8) was 55; this difference 
was not statistically significant (p=0.724) (table 3.3).  The median tumour sizes were 3.5 and 
3.3cm for FABP7 negative and positive cases respectively (p=0.236) (table 3.3). 
 
 
 
Table 3.3 The association of FABP7 expression and patient age and tumour size 
This table shows the association of FABP7 expression with patient age and tumour size.  The 
statistical software used for this analysis automatically converted from chi-squared test to Fisher’s 
exact test for numbers lower than five. 
 
3.4.13 FABP7 expression is associated with FAS expression 
It was hypothesised that FABP7 expression is associated with FAS expression due to the 
involvement of FAS in the production of FAs.  FAS and FABP7 were stained using IHC and assessed 
using a modified Allred score; FAS and FABP7 score cross tabulation is in table 3.4.  FABP7 was 
positively associated with FAS expression (p=0.004) (photomicrograph figure 3.16) 
  Overall 
FABP7 
negative 
FABP7 
positive 
P for X2 
test 
Age (median, 
years) 53 52 55 0.724 
Tumor size 
(median, cm) 3 3.5 3 0.236 
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Table 3.4 FABP7 and FAS staining are positively associated 
This table shows the cross-tabulation of FABP7 scores with FAS scores. FABP7 expression was 
positively associated with FAS expression (p=0.004) 
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Figure 3.16 The association of FABP7 and FAS 
IHC staining of a TN breast IDC case.  Top: x40 Strong positive FABP7 staining localised to both the 
nucleus and cytoplasm of cells.  Bottom: x40 Positive FAS staining in the same IDC case; FAS 
staining was localised to the cytoplasm of cells. 
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3.4.14 FABP7 expression is associated with improved patient survival 
FABP7 staining was grouped into cases that were negative, weak to intermediate (scores 2 to 6) 
and strong (scores 7 and 8).  A Kaplan-Meier survival graph and analysis were carried out.  The 
graph in figure 3.17 shows that cases with strong FABP7 expression have a better survival than 
cases that were weak-intermediate and negative; the FABP7 negative cases had the poorest 
survival.  The 3 year relative survival rate (RSR) for FABP7 negative cases was 74.4% (95%CI 55-
93.8%); for intermediate-weak cases the RSR was 72.9% (95%CI 57.4-88.5%) and for FABP7 
positive cases it was 81.9% (95%CI 65.8-98.1%) However the relationship between FABP7 and 
survival was not significant (p=0.291). 
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Figure 3.17 FABP7 and patient survival 
FABP7 IHC expression was grouped into negative, weak-intermediate and strong staining and then 
a Kaplan Meier survival analysis was carried out.  Results show that strong positive FABP7 had the 
best overall survival and FABP7 absent cases the poorest relative survival. 
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3.5 Discussion 
3.5.1 Western blot optimisation 
This chapter addresses the importance of optimising a western blot protocol in order to 
successfully detect a protein of interest, in this case FABP7.  If it were not for the evidence 
illustrating that FABP7 is present in human breast cancer tissues, the assumption could have been 
made from the original western blots that FABP7 protein is not present in breast cancer cell lines 
thus impacting future work.  There are many variables that have been taken in to account and 
optimised.   
The first and most critical step in producing samples for SDS PAGE analysis and subsequent 
Western blotting is the selection of a suitable lysis buffer. This should always be a considered 
decision, assessing the benefits of each buffer and the nature of the protein of interest. Only 
through careful consideration can we ensure that proteins are effectively released but also 
solubilised. Once the lysis step is fully optimised several other stages need to be carefully 
assessed. The results showed for FABP7 that there was negligible difference in the intensity of 
bands generated from the lysis buffer and RIPA buffer; however the sample buffer lysis protocol 
resulted in a much stronger band for the same amount of total protein loaded.  One reason could 
be that sample buffer lysis protocol results in a higher yield of FABP7 protein from all cellular 
fractions. 
The choice of antibody should be made ideally based on quality, which can be determined by 
reviewing reference sources. However in many instances the choice of commercially available 
antibodies can be limited and in such circumstances comparison between competitors should be 
considered to ensure selection of the best antibody for the task. One should consider the 
differences between polyclonal and monoclonal antibodies and any advantages they confer. For 
example monoclonal antibodies recognise only one epitope and consequently produce lower 
background. However polyclonal antibodies recognise multiple epitopes within the protein of 
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interest which means although they may produce more noise they may also facilitate better 
detection of low abundant or difficult to detect proteins.  In this study both of the antibodies 
employed were polyclonal and we illustrated that the R&D antibody proved to be superior to the 
SC anti-FABP7 primary antibody which produced more noise and therefore poorer band 
detection. This could have in part been explained by the difference in clonality between the 
antibodies. However it is also worthwhile noting that the availability of the blocking antigen is also 
an extremely useful tool in ensuring that any results produced are accurate and specific, hence 
our inclusion of the data produced using the Santa Cruz antibody. This becomes increasingly 
important in situations where multiple bands are detected within a given sample to ensure that 
the correct band or bands of interest are selected for analysis. In our study although only one 
band was detected in each sample the blocking peptide provided reassurance of specificity which 
was important due to the difficulties experienced with detecting the protein in samples of 
interest. The use of the SC antibody with the corresponding blocking peptide enabled us to 
determine whether the bands detected were indeed specific.  The bands were eliminated with 
the addition of the blocking peptide indicating that the antibody is specific and the bands 
detected are FABP7 protein.  
Other points to consider include the choice of blocking reagent. In our study this proved to be 
essential since BSA blocking led to a decreased signal-to-noise ratio, making visualisation of any 
bands difficult. It is also important to ensure that the blocking reagent does not adversely affect 
the linear dynamic range where absolute quantification is required.  The selection of reducing 
versus non-reducing conditions must also be considered carefully in order to ensure that antibody 
epitopes are present and correct thereby ensuring optimal detection. The results showed that 
reducing conditions were optimal since the threshold of detection was unchanged by the 
presence of the reducing agent and the migration profile was more favourable.     
129 
 
The final consideration should be given to the percentage and type of gel utilised. Selection of the 
correct percentage of acrylamide is essential in obtaining the best migration profile and 
subsequently the highest quality Western blot. Proteins of interest must be considered alongside 
any proteins used as a loading control to ensure that the gel selected is complimentary to both 
and in many situations a gradient gel provides the ideal solution. It is also worth considering the 
benefits of consistency and reproducibility provided by commercially available pre-cast gels. 
These results demonstrated that the use of gradient gels facilitated the detection of bands that 
were much stronger overall than the 12% in-house gel, most likely the result of improved protein 
migration and separation. 
 
3.5.2 FABP7 expression in breast cancer cell lines 
This is the first study to detect FABP7 protein in a panel of commonly used breast cancer cell lines; 
without the optimisation of each step it would not have been possible.  This probably accounts for 
the paucity of studies using breast cell lines for investigating FABP7 and those that have, have 
transfected the protein into the cell lines.  BT-20 cells expressed the most protein followed by 
MDA-MB-231 and T47D cells that had comparable protein expression.  MCF-10a and HS578T cells 
had the lowest amount of FABP7 protein as assessed by band densitometry.  BT-20 and MDA-MB-
231 cells are TN and of basal-like phenotype so it is logical to expect that these cells would have 
the highest expression considering the association of FABP7 with BLBC.  As would be expected BT-
20 cells also expressed the most FABP7 mRNA however FABP7 mRNA levels in MDA-MB-231 cells 
were considerably lower.  Protein and mRNA do not necessarily correlate and it is possible that 
there is a high turnover of FABP7 mRNA in MDA-MB-231 cells or that there is more RNA 
degradation in these cells.  The same may be true of the reverse; SKBR3 cells have comparably 
high FABP7 mRNA expression but lower protein expression, FABP7 protein degradation could be a 
factor.  Overall FABP7 protein and mRNA expression is low in the breast cell lines, particularly 
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compared to expression in U251 cells and it is therefore debatable whether knock-down 
experiments would notably alter FABP7 protein or mRNA expression in breast cell lines.  There is 
ample evidence, including the present study, documenting FABP7 expression in TNBC particularly 
in patient samples (Zhang et al., 2010; Tang et al., 2010).  There are several putative reasons for 
the low abundance of FABP7 in cell lines; one is that there is an absence of biological factors that 
would be in the tumour microenvironment in vivo that are vital for expression to occur.  For 
instance a 3D environment may be needed.  Studies have shown that surrounding stromal tissue 
is important when considering gene expression and tumour development and progression; a 
limitation is that the cell-line models in the present study do not have such composition and 
perhaps this why expression levels of FABP7 differ from those reported in patient samples (Finak 
et al., 2008).  Other factors to consider are vascularisation, hypoxia and macromolecules such as 
fatty acids that a tumour may or may not be exposed to in vivo compared to in vitro cell lines.  
However despite such limitations it is still necessary to quantify FABP7 in breast cancer cells lines 
in order to choose an appropriate model for further investigation. 
 
3.5.3 FABP7 mRNA and protein correlation in patient samples 
To further validate the antibody used in the present study and understand FABP7 expression RNA 
was extracted from 20 FFPE patient samples and FABP7 mRNA quantified with qPCR.  The qPCR 
results were compared to the IHC expression assessed with a modified Allred score.  There was a 
significant association between the FABP7 IHC score and mRNA expression.  This helps to 
demonstrate that the antibody used in IHC is sensitive and specific, as high mRNA levels do 
equate to high protein expression.  It is useful to know that FABP7 mRNA and protein are 
associated as it helps provide possible explanations as to why protein expression in the breast cell 
lines is low; it is likely that there are factors preventing FABP7 mRNA expression or its stability in 
the breast cancer cell lines rather than an issue with mRNA to protein translation or protein 
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stability.  Ascertaining the mechanisms involved in FABP7 mRNA expression would be beneficial in 
understanding why FABP7 is in low abundance in cell lines and allow appropriate cell line models 
to be selected for further investigation of FABP7. 
 
3.5.4 FABP7 is expressed in patient samples 
To further investigate the importance of FABP7 in breast cancer it was decided to look at 
expression levels in a cohort of Malaysian TN breast cancer cases to see if lFABP7 expression 
patterns followed those in western cohort studies (Zhang et al., 2010; Tang et al., 2010; 
Alshareeda et al., 2012).  FABP7 expression was then compared to clinicopathological features.  
FABP7 staining was predominantly cytoplasmic with some nuclear staining also present in positive 
cases; this staining pattern is in agreement with other studies (Zhang et al., 2010; Tang et al., 
2010; Alshareeda et al., 2012).  In the present study around 80% of cases had some level of FABP7 
staining; using a score of 7 or 8 over 40% of cases were strongly positive.  This is higher than the 
reported percentage positivity of 15.6% in an unselected breast cancer cohort (Zhang et al., 
2010).  When looking BLBC within their cohort 38.4% were FABP7 positive; this is comparable to 
the present study (Zhang et al., 2010).  This could be a reflection of the majority of cases being of 
basal-like phenotype in the present study.  The staining in patient samples was validated by use of 
a blocking peptide; staining was eliminated indicating specificity for FABP7.  The presence of 
FABP7 in patient samples further confirms its relevance in breast cancer particularly in those of 
TN phenotype.   
 
3.5.5 FABP7 is associated with tumour stage and basal-like phenotype. 
FABP7 IHC scores were compared to patient features such as stage, patient age and grade and to 
the staining of CK5/6 and CK14.  Interestingly FABP7 positivity was associated with a lower stage; 
132 
 
this could indicate that its presence is of favourable prognosis and is therefore consistent with the 
work by Zhang et al (2010).  There were no grade 1 cases in the present study so a relationship 
between FABP7 and grade would not have been possible to elucidate, although Zhang’s cohort 
was unselected, larger and consisted of grade 1 tumours, a relationship of grade with FABP7 was 
not present.  This is in contrast to Tang et al. (2010) who found FABP7 positive breast cancer cases 
were more likely to be of a higher grade, as did another study looking at FABP7 in astrocytomas; 
nuclear FABP7 positivity was associated with higher grade.  Ethnicity and patient age were not 
factors associated with FABP7 status.  Neither was lymph-node involvement; this is contrast to 
findings showing that lymph-node involvement was lower in FABP7 positive cases (Zhang et al., 
2010).  Reasons for the difference in significant findings could be due to the size of the cohort or 
the use of cut of points and staining interpretation.  As expected, FABP7 was significantly 
associated with CK5/6 and CK14 expression; this in conjunction with other molecular and 
immunohistochemical studies demonstrating the relationship between FABP7 and BLBC (Zhang et 
al., 2010; Tang et al., 2010). 
 
3.5.6 FABP7 and FAS expression are significantly associated 
FAS is responsible for the conversion of malonyl CoA to palmitate which can then be altered to 
synthesize other FAs.  It was hypothesised that high expression of FAS may confer positivity of 
FABP7 to enable the transportation and solubilisation of increased palmitate and FA production.  
The present study found that FABP7 scores were significantly positively correlated with FAS IHC 
scores.  In contrast one study used IHC to show that liver FABP was commonly over-expressed in 
gastric cancers however its over-expression was not associated with over-expression FAS 
(Hashimoto et al., 2004).  Cell line models are required to explore the relationship further and to 
ascertain whether the expression of the markers are directly related or which marker is 
responsible for the over-expression of the other and if palmitate is involved. 
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3.5.7 FABP7 expression is associated with increased survival 
Cases were grouped into those that were completely negative for FABP7, weak to intermediate 
(scores 2-6) and strong positive cases (scores 7&8); the data were then analysed with Kaplan 
Meier survival analysis.  Although not significant there was a trend that strong positive cases had 
the best overall survival probability followed by weak-intermediate FABP7 cases and completely 
negative cases having the poorest survival probability.  A larger cohort and longer follow-up time 
period may be beneficial in further understanding the relationship between FABP7 and survival.  
The findings of the present study are in conjunction with results from Zhang et al. (2010) though 
in contrast to another study using a breast cancer cohort and studies looking at glioma and 
melanoma where FABP7 positivity conferred poorer survival (Kaloshi et al., 2007; Tang et al., 
2010; Goto et al., 2010).  The increased survival probability with FABP7 expression in the present 
study ties in with the association of FABP7 with lower stage.  A limitation of the study by Tang et 
al. (2010) was that there were only a small number of TN cases on the cohort; the association of 
FABP7 with poor survival could be a reflection of TN cancers having poor survival rates compared 
to other breast cancer subtypes.  A recent study looked at the cellular localisation of FABP7; 
nuclear localisation was associated with high tumour grade and stage and interestingly in BLBCs 
nuclear FABP7 had improved prognosis and less chance of reoccurrence than cases with 
cytoplasmic staining alone (Alshareeda et al., 2012).  Upon observation the majority of positive 
cases in the present study had a combination of nuclear and cytoplasmic FABP7 localisation; 
nuclear staining alone was not observed by itself perhaps providing a reason as to why significant 
improved prognosis was seen in this TN/BLBC cohort.  This is in contrast to a study on FABP7 in 
gliomas; nuclear FABP7 was associated with EGFR expression and in turn this was an indicator of 
poor prognosis (Liang et al., 2006).  It is possible that the relative abundance of FA and the 
localisation of FABP7 within cells influence tumour phenotype; as suggested by Mita et al. (2010) 
the relative abundance of AA and DHA can influence which pathways are activated.  For example 
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FABP7 is hypothesised to shuttle DHA to the nucleus to activate PPAR-γ and result in down 
regulation of pro-migratory genes or it shuttles AA to cytoplasmic pathways such as COX2 to 
initiate pro-migratory pathway activation (Mita et al., 2010).  It is possible that there are other 
pathways in breast cancer that are activated and perhaps different FAs are present thus 
explaining the different associations of nuclear and cytoplasmic FABP7 and how it may influence 
tumour phenotype and patient outcome.  This evidence suggests that cellular localisation of 
FABP7 and interaction with FAs are important in patient survival and tumour progression and thus 
FABP7 expression warrants further investigation. 
 
Very little FABP7 mRNA and protein was detected in any of the breast cancer cell lines tested 
though FABP7 mRNA and protein was present in 20 samples selected for mRNA analysis.  In 
addition the majority of patient samples expressed FABP7 at the protein level detected by IHC.  
One reason that FABP7 is in low abundance in the cells lines tested could be that FABP7 is 
hypermethylated or hypoacetylated or that a factor is missing in vitro that is required for FABP7 
expression, such as certain FAs.   
 
3.6 Conclusions  
FABP7 protein and mRNA can be detected in breast cell lines; BT-20 breast cell lines expressed the 
highest amount of both FABP7 protein and mRNA of the cell lines tested.  FABP7 expression in 
patient samples is associated with lower stage and the basal-like phenotype as assessed by 
cytokeratins 5/6 and 14 expression.  FABP7 expression is associated with improved patient 
survival though the trend was not significant. 
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4 What regulates FABP7 expression in triple 
negative breast cancer cell lines? 
 
4.1 Introduction 
Evidence suggests the mRNA expression of various FABPs is altered by methylation and 
acetylation of the DNA.  For example differences in FABP7 methylation was observed between 
subsets of chronic lymphocytic leukaemia (CLL); FABP7 was listed as a methylated gene in the 
immunoglobulin heavy-chain variable mutated genes type of CLL (Kanduri et al., 2010).  FABP7 
has been investigated as one of several genes that were hypomethylated in glioblastomas 
compared to the normal brain; this results in over-expression of FABP7 in glioblastomas 
(Etcheverry et al., 2010).  FABP3, also known as MDGI, has been found to be similar to FABP7 with 
respect its effects in breast cancer cell lines.  A study by Huynh et al. (1996) demonstrated that 
FABP3 is hypermethylated and thus silenced in both breast cancer cell lines and a selection of 
patient breast tumours.  It is postulated that FABP7 may be hypermethylated in a similar fashion 
in breast cancers.  Currently there is little information regarding changes in the acetylation status 
of FABPs in cancer.  However it has been reported that the expression of FABPs can be altered 
through changes in histone acetylation.  Trichostatin A (TSA), an HDAC inhibitor, was 
demonstrated to increase FABP4 expression in RAW 264.7 macrophages (Coleman et al., 2010).  
Treatment with TSA was also enough to negate the inhibitory effect of linoleic acid on FABP4 
expression (Coleman et al., 2010).  Drugs, such as 5-Aza-2′-deoxycytidine (AZA), a DNA 
demethylating agent, and TSA, can be used to investigate global changes in epigenetic states and 
moreover used to explore whether FABP7 in TN breast cancer cell lines is regulated by epigenetic 
mechanisms. 
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Fatty acids (FA) can alter gene expression (section 1.6.2) through direct or indirect mechanisms or 
transcriptional or posttranscriptional action.  In particular they alter the expression or FABPs.  It 
was found that FABP4 levels could be altered in RAW264.7 macrophages by exposing the cells to 
FAs (Coleman et al., 2010).  Unsaturated FAs such as linolenic acid and palmitoleic acid decreased 
FABP4 mRNA and protein; however the unsaturated FA eicosapentaenoic acid significantly 
decreased FABP4 protein but mRNA levels were not different from the control (Coleman et al., 
2010).  FABP3 and FABP5 mRNA and protein have been found to be increased in rat pancreatic 
islet cells and NS-1E cells (a rat pancreatic β-cell line) by treatment with palmitate and oleate 
(Hyder et al., 2010).  FABP1, also known as Liver-FABP, can be up-regulated at both the mRNA and 
protein level by oleate in rat hepatoma cells (Meunier-Durmort et al., 1996).  Other long chain FAs 
that increased FABP1 expression in rat hepatoma cells included palmitate, arachidonic acid (AA) 
and linoleic acid.  FAs can work in conjunction with other molecules to alter expression; 
docosahexaenoic acid (DHA) activates the retinoid X receptor (RXR) by acting as a transcription 
factor when bound to FABP7; however this causes the activation of RXR rather than FABP7 itself 
but it is plausible that there may be a feedback mechanism involved that in turn alters the 
expression of FABP7 (Liu et al., 2012).  FABP3 has been shown to have similarities to FABP7, 
particularly in regards to the effects of FABP3 expression in breast tissue; FAs including palmitate, 
oleate and AA increased FABP3 mRNA at least two fold (Chang et al., 2001).  The relationship 
between FABP gene expression and FA is complex.  FABP7 binds to palmitate, oleate, DHA and AA 
and evidence suggests that these FAs alter FABP gene expression; MDA-MB-231 and BT-20 cells 
were exposed to FAs in order to investigate changes in FABP7 expression.  
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4.2 Aims and hypothesis 
4.2.1 Aims 
i) To investigate whether FABP7 expression is changed by AZA and TSA in TN breast cancer 
cell lines. 
ii) To investigate whether the FAs, oleate, palmitate, AA and DHA alter expression of FABP7 
in TN breast cancer cell lines. 
iii) To investigate whether any of the compounds have synergistic or combined effects on 
FABP7 expression when used together. 
 
4.2.2 Hypothesis 
i) FABP7 expression in TN breast cancer cell lines is affected by methylation and acetylation 
and the availability of FAs. 
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4.3 Materials and Methods 
4.3.1 Cell culture and dosing experiments 
Cells were seeded at a density of 0.8x106 per T25 flask.  For the AZA, TSA and FA experiments they 
were treated as described in section 2.3.  The final doses for the FAs were chosen as follows 
palmitate 50µM, oleate 100µM, AA 10µM and DHA 10µM; these doses were chosen based on 
dose response results (section 1.10).  The doses of AZA and TSA were chosen based on results 
from collaborators at the University of Bristol who were looking at changes in gene expression in 
the same breast cancer cell lines.  In addition to this BT-20 cells were treated with AZA and TSA 
combined; cells were exposed to 2.5µM AZA for 48 hours when 0.5µM TSA was added, the cells 
were then harvested after 24 hours TSA exposure and therefore 72 hours of AZA exposure.  To 
test the combined effects of AZA and FAs BT-20 cells were exposed to 2.5µM AZA for 48 hours; 
after this time the growth medium was changed to contain either one of the FAs, at this time a 
second dose of 2.5µM AZA was also given.  AZA alone and fatty acid alone controls were set up 
for this experiment.   
 
4.3.2 RNA extraction and PCR 
For these experiments cells were subjected to RNA extraction using the Bioline kit (section 2.6.1).  
RNA was converted to cDNA (section 2.7.1) and then FABP7 and ER mRNA was quantified using 
qPCR (section 2.7.4).  Β-actin was used as a reference gene. 
 
4.3.3 Protein extraction and western blotting 
The combinations of AZA and FA treatment that gave the largest increase in FABP7 mRNA were 
repeated to extract protein for western blotting.  This time point was not increased to allow for 
protein production because preliminary work at increased time points showed cell death 
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increased and FABP7 protein levels were unchanged.  Protein extraction took place with Laemmli 
x2 sample buffer (section 3.4.4); the lysates were then subjected to western blotting using a 
gradient gel (section 3.3.5). 
 
4.3.4 Statistical analysis 
Analysis was carried out on the results of 3 independent experiments that had been carried out in 
triplicate unless otherwise stated.  The statistical package Graphpad Prism 5 was used to produce 
graphs and produce statistics for these experiments.  Whenever there was more than one 
comparison against the control a one-way ANOVA with a Bonferroni post-hoc test was used to 
highlight differences; a students paired t-test was then carried out to confirm significant 
differences.  Data are presented as mean ± standard error of the mean (SEM). 
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4.4 Results 
 
4.4.1 AZA and TSA increase ER mRNA expression in BT-20 and MDA-MB-231 cells 
Expression of oestrogen receptor (ER) mRNA was measured (from the same RNA extractions used 
to measure FABP7 expression) after treatment with 0.5µM TSA for 24 hours and 2.5µM AZA for 
72 hours.  This was as a control to demonstrate that the AZA and TSA were causing changes in 
gene expression; ER in the same breast cancer cell lines has been found to be re-expressed after 
treatment with these drugs.  The results are in figure 4.1; TSA increased ER mRNA by 6.1 fold (A: 
MDA-MB-231 cells p=0.0025) and 8.1 fold (B: BT-20 cells p=0.0001).  AZA also significantly 
increased ER mRNA in both cell lines, 32.4 fold (A: MDA-MB-231 cells p=0.0001) and 33.5 fold (B: 
BT-20 cells p=0.0001). 
 
4.4.2 AZA but not TSA increases FABP7 mRNA in MDA-MB-231 cells 
MDA-MB-231 cells were first treated with 1µM AZA for up to 72 hours or 0.25µM or 0.5 µM TSA 
for 24 hours.  As shown in figure 4.2, FABP7 mRNA was increased after 48 (C) and 72 (D) hours by 
1.53 and 1.45 fold respectively however the increase was only statistically significant after 48 
hours (p=0.0311).  There were no significant changes in FABP7 mRNA due to treatment with TSA 
(A) or AZA for 24 hours (B).  Next a higher dose of AZA was used to treat the MDA-MB-231 cells 
and FABP7 expression measured after 48 and 72 hours as no increase was noted at 24 hours.  
Although this time 1µM AZA resulted in a 1.53 fold increase in FABP7 mRNA, it was not 
statistically significant.  As in figure 4.3 a 2.5µM dose of AZA gave a significant increase at both 48 
(A) and 72 (B) hours, 1.56 (p=0.0073) and 2.11 (p=0.0167) respectively.  There was not any 
observable change in cell death as a result of AZA or TSA treatment.  
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Figure 4.1 Fold change in ER mRNA after treatment with TSA or AZA 
MDA-MB-231 and BT-20 cells were treated with 0.5µM TSA for 24 hours and 2.5µM AZA for 72 
hours.  Results are expressed as fold change relative to ER mRNA in untreated cells in SFM alone. 
A) Fold change in ER mRNA in MDA-MB-231 cells: TSA increased ER mRNA 6.1 fold** (p=0.0025); 
AZA increased ER mRNA 32.4 fold*** (p=0.0001). B) Fold change in ER mRNA in BT-20 cells:  TSA 
increased ER mRNA 8.1 fold*** (p=0.0001); AZA increased ER mRNA 33.5 fold*** (p=0.0001).  
Data represent the mean of 3 independent experiments carried out in triplicate ±SEM. 
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Figure 4.2 Fold change of FABP7 mRNA in MDA-MB-231 cells treated with AZA or TSA 
Results are expressed as fold change relative to FABP7 mRNA in cells in SFM alone.  A) Fold 
change in FABP7 mRNA after 0.25µM (0.81 fold change) and 0.5µM (1.00 fold change) TSA 
treatment for 24 hours.  B) Fold change in FABP7 mRNA after 24 hours 1µM AZA treatment (1.02 
fold change).  C) Fold change in FABP7 mRNA after 48 hours 1µM AZA treatment *(1.53 fold 
change p=0.0311).  D) Fold change in FABP7 mRNA after 72 hours 1µM AZA treatment (1.44 fold 
change) Data represent the mean of 3 independent experiments carried out in triplicate ±SEM. 
.
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Figure 4.3 Fold Change of FABP7 mRNA in MDA-MB-231 cells treated with 2 different doses of 
AZA 
Results shown are expressed as fold change relative to FABP7 mRNA in cells in SFM alone.  A) Fold 
change in FABP7 mRNA after 48 hours 1µM (1.53 fold change) or 2.5µM **(1.56 fold change 
p=0.0073) AZA treatment.  B) Fold change in FABP7 mRNA after 72 hours 1µM (0.96 fold change) 
or 2.5µM *(fold change of 2.11 p=0.0167) AZA treatment.  Data represent the mean of 3 
independent experiments carried out in triplicate ±SEM. 
 
4.4.3 FABP7 mRNA expression changes in BT-20 cells after treatment with TSA or AZA 
BT-20 cells were treated with 0.25µM and 0.5µM TSA for 24 hours and 1µM or 2.5µM AZA for 24, 
48 and 72 hours (figure 4.4).  A dose of 0.5µM TSA (A) gave a 1.6 fold increase in FABP7 mRNA 
although this was not statistically significant.  A significant increase in FABP7 mRNA with AZA 
treatment was only present after 72 hours exposure (D), 1µM gave a 1.83 fold increase (p= 
0.0212); 2.5µM gave the largest fold increase of 2.19 (p=0.0001). There was not any observable 
change in cell death as a result of AZA or TSA treatment. 
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Figure 4.4 Fold change of FABP7 mRNA in BT-20 cells treated with TSA or AZA 
Results are shown as fold change in FABP7 mRNA relative to FABP7 mRNA in BT-20 cells in SFM 
alone.  A) Fold change in FABP7 after TSA treatment for 24 hours, 0.25µM gave a 0.76 fold change 
and 0.5µM gave a 1.6 fold increase.  B) Fold change in FABP7 mRNA after 24 hours 1µM AZA (1.17 
fold change) or 2.5µM (1.40 fold change) AZA treatment.  C) Fold change in FABP7 mRNA after 48 
hours 1µM (1.19 fold change) or 2.5µM (1.57 fold increase) AZA treatment. D) Fold change in 
FABP7 mRNA after 72 hours AZA 1µM *(1.83 fold increase p=0.212) or 2.5µM ***(2.19 fold 
increase p=0.0001) AZA treatment. Data represent the mean of 3 independent experiments 
carried out in triplicate ±SEM. 
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4.4.4 AZA and TSA combined increase FABP7 mRNA expression 
Since the biggest increase in FABP7 mRNA was noted in the BT-20 cell line after 72 hours and as it 
appeared that dose of 0.5µM TSA could increase FABP7 mRNA; BT-20 cells were treated with both 
2.5µM AZA for 72 hours and 0.5µM TSA for the final 24 hours.  Figure 4.5 shows that a 2.73 fold 
increase in FABP7 mRNA resulted (p=0.0001) compared to TSA (1.4 fold) and AZA alone (1.9 fold 
p=0.0125). 
 
 
 
 
 
 
 
 
 
Figure 4.5 Fold change in FABP7 mRNA in BT-20 cells after treatment with TSA and AZA together 
Results are shown as fold change in FABP7 mRNA relative to FABP7 mRNA in BT-20 cells in SFM 
alone.  BT-20 cells were treated with 2.5µM AZA for 72 hours, 0.5µM TSA was added for the final 
24 hours.  There was 2.73*** fold increase in FABP7 mRNA (p=0.0001) relative to cells in SFM 
alone and compared to TSA (1.4 fold) and AZA alone **(1.9 fold p=0.0125). Data represent the 
mean of 3 independent experiments carried out in triplicate ±SEM. 
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4.4.5 Fatty acid treatment and FABP7 mRNA expression in MDA-MB-231 cells 
MDA-MB-231 cells were treated with doses of oleate palmitate, AA and DHA.  Figure 4.6 shows 
FABP7 mRNA expression after 24 hours (A) and 48 hours (B).  The only statistically significant 
change was with 10µM AA for 24 hours and this was a fold decrease of 0.47 (p=0.0152).  The 
same trend was present at 48 hours. 
 
 
 
 
 
 
 
 
 
Figure 4.6 Fold change in FABP7 in MDA-MB-231 cells after treatment with fatty acids 
Results are presented as fold change in FABP7 mRNA relative to FABP7 mRNA in cells in SFM  
Resulting fold changes at 24 hours are illustrated in A and are as follows: oleate 0.81, palmitate 
0.63, AA 0.47 *(p=0.0152) and DHA 0.77.  Fold changes at 48 hours are shown in B and are as 
follows: oleate 0.87, palmitate 0.87, AA 0.63 and DHA 0.96. Data represent the mean of 3 
independent experiments carried out in triplicate ±SEM. 
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4.4.6 Fatty acids alter expression of FABP7 mRNA in BT-20 cells 
BT-20 cells were treated with oleate, palmitate, AA or DHA; results are in figure 4.7 for 24 hours 
(A) and 48 hours (B).  After 24 hours exposure of oleate there was a small but significant increase 
in FABP7 mRNA by 1.2 fold (p=0.0291), however after 48 hours oleate treatment led to a 
reduction in FABP7 mRNA by 0.69 fold (p=0.0151).  DHA increased FABP7 mRNA by 1.31 fold 
(p=0.0413) after 24 hours but no significant changes were present at 48 hours.  Palmitate also 
increased FABP7 mRNA but significant increases were not present until after 48 hours (1.38 fold 
p=0.0350).   
 
 
 
 
 
 
 
Figure 4.7 Fold change in FABP7 in BT-20 cells after treatment with fatty acids 
Results are shown as fold change in FABP7 mRNA relative to FABP7 mRNA in BT-20 cells in SFM 
alone  BT-20 cells were treated with either oleate, palmitate, AA or DHA.  Results are presented as 
fold change in FABP7 mRNA relative to FABP7 mRNA in cells in FA free BSA.  Resulting fold 
changes at 24 hours are illustrated in A and are as follows: oleate 1.28*(p=0.0291), palmitate 
1.18, AA 1.12 and DHA 1.31 *(p=0.0413).  Fold changes at 48 hours are shown in B and are as 
follows: oleate 0.69 *(p=0.0151), palmitate 1.38 *(p=0.0350), AA 0.98 and DHA 1.18. Data 
represent the mean of 3 independent experiments carried out in triplicate ±SEM. 
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4.4.7 AZA and combined FA treatment alter the expression of FABP7 mRNA in BT-20 cells 
BT-20 cells were treated with 2.5µM AZA for 48 hours and then treated with each of the FAs for a 
further 24 hours with a second dose of AZA.  The second dose of 2.5µM AZA gave the highest fold 
increase than previous AZA alone treatments (140 fold (p=0.0005).  AZA and palmitate together 
gave the biggest fold increase of 249 (p=0.0005).  Oleate, AA and DHA with AZA gave bigger fold 
changes than alone but were less than the fold increase of AZA alone; 65.5, 95 and 35 
respectively.  The results of this experiment are show in figure 4.8. 
 
4.4.8 AZA combined with palmitate treatment increases FABP7 protein in BT-20 cells 
Next the expression of FABP7 protein was assessed in response to AZA and palmitate treatment 
as this combination had increased FABP7 mRNA expression the most compared to other AZA and 
FA combinations (figure 4.9).  The relative band intensities indicate that combined treatment of 
BT-20 cells with AZA and palmitate gave the largest increase in FABP7 protein expression. 
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Figure 4.8 The expression of FABP7 mRNA in BT-20 cells treated with FAs and AZA combined 
Results shown are fold change in FABP7 mRNA expression relative to FABP7 mRNA in BT-20 cell in 
SFM alone.  The fold changes for the FA alone treatments were in line with those seen in figure 
4.6.  Two doses of AZA gave a fold increase of 140 ***(p=0.0005).  The fold changes for the AZA 
and each of the following FAs were: oleate 65.5 **(p=0.0040), palmitate 249 ***(p=0.0005), AA 
95 **(p=0.0038) and DHA 35 **(p=0.0013). Data represent the mean of 3 independent 
experiments carried out in triplicate ±SEM. 
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Figure 4.9 Western blot showing FABP7 protein in untreated cells, palmitate and AZA alone and 
combined treated cells 
BT-20 cells were treated with AZA, palmitate and both combined, and then lysed in sample buffer and 
a western blot performed.  A) The cell line U251 was used as a positive control for FABP7 and imaged 
separately; Β-actin was used as a loading control.  B) The relative intensities of each band were 
analysed by ROI manager in Image J.  AZA and palmitate combined gave the highest band intensity 
followed by AZA alone; this indicates that there is more FABP7 protein present. This figure represents 
one repeat of three. 
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4.5 Discussion 
As epigenetic mechanisms and FAs have been shown to regulate FABPs, MDA-MB-231 and BT-20 
cells were treated with AZA, TSA and FAs to determine whether FABP7 is regulated by such 
mechanisms in breast cancer cell lines  
 
4.5.1 ER mRNA expression is increased in BT-20 and MDA-MB-231 cells with AZA and TSA 
To demonstrate that TSA and AZA could alter gene expression, PCR was carried out to look for ER 
re-expression as ER has been shown to be methylated and affected by acetylation in these cell 
lines (Ferguson et al., 1997; Yang et al., 2000; Yang et al., 2001). ER mRNA increased significantly 
with AZA treatment up to 32 and 33 fold in MDA-MB-231 and BT-20 cells respectively.  ER was 
increased by TSA to 6.1 fold in MDA-MB-231 cells and to 8.1 fold in BT-20 cells.  The increases in 
ER expression in both cell lines with both treatments were similar to the fold changes reported by 
Yang et al. (2001) They treated MDA-MB-231 and MDA-MB-453 cells with 2.5µM AZA for up to 96 
hours; this resulted in a 31 fold increase in ER mRNA in MDA-MB-231 cells and a 36 fold increase 
in the MDA-MB-453 cells. 
 
4.5.2 AZA significantly increases FABP7 mRNA expression 
The increases with the highest doses of AZA at 72hours in both cell lines were significant though 
not as high as expected.  If FABP7 is methylated in the cell lines used in the current study then the 
fold increases would have been more marked perhaps similar to the level of ER mRNA increases.  
Longer time points and higher doses could have been investigated further though the half-life of 
AZA is relatively short and higher doses are likely to have resulted in toxicity based on pre-
published experiments by collaborators at the University of Bristol using AZA and TSA on breast 
cell lines.  The time points used would have been sufficient to take into account cell turnover and 
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the half life of the drug so duration was not increased further.  The FABP7 promoter was analysed 
for CpG islands (using bioinformatics.org) and none were found; this is in agreement with Goto et 
al., (2010); however the experiments were still required as methylation could occur at regions 
other than the promoter, at histones or at regions other than CpG islands such as so called “weak 
CpG regions” (Meissner et al., 2008). One study found that AZA causes re-expression of genes 
though demethylation of histones in particular H3 residues (Wozniak et al.,  2007).  An alternative 
is that the increases in FABP7 mRNA were a secondary effect of AZA treatment; for example 
global expression of genes was studied after treatment of cells with AZA. It was found that 116 
genes were up-regulated by around four fold by such treatment but methylation of DNA was not 
connected; suggestions for this included demethylation of histones, increased RNA stability and 
changes in regulatory genes to give a knock on increase of the particular genes of interest (Shi et 
al., 2003).  The signal transducer and activator of transcription (STAT) transcription factors have 
been shown to be up-regulated in response to AZA treatment; there are CpG islands that could 
have been methylated or alternatively the increase could have been a result of demethylation of 
an upstream regulator of STATs (Karpf et al., 1999).  Interestingly STAT3 is a potential 
transcription factor of FABP7, the FABP7 promoter has three STAT3 binding sites; (identified in 
genecards) moreover STAT3 is important in mammary gland development and breast cancer cell 
proliferation; breast tumours that expressed both activated STAT5 and STAT3 were more 
differentiated than those with activated STAT3 alone (Walker et al., 2009).  STAT3 has also been 
found to be methylated at histones (Yang et al., 2010).  For these reasons it is probable that 
FABP7 is indirectly increased by AZA treatment, perhaps  by a transcription factor such as STAT3 
that is methylated at either CpG islands or at histones; other transcription factors identified in 
genecards include nuclear factor-I (NF-I) and ETS related gene-4 (ERG-4) and could equally altered 
by epigenetic mechanisms to increase FABP7 mRNA.   
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4.5.3 TSA treatment did not increase FABP7 mRNA expression 
Treatment with TSA did not significantly increase FABP7 mRNA with either dose in both cell lines.  
As with treatment with AZA, the effects may be indirect, treatment only occurred for 24 hours so 
indirect increases in FABP7 mRNA may not have had chance to occur.  STAT3 is hyperacetylated in 
many breast tumours and as a result is over-expressed; inhibiting HDACs with TSA increased 
methylation of tumour suppressor genes, such as p53, through STAT3 interacting with DNMT1 
(Lee et al., 2012).  This shows that transcription factors and substances such as TSA can have 
opposing effects on epigenetic alterations of gene expression at the same time.  It is possible that 
such mechanisms maybe involved in the expression of FABP7.  A study by Van Lint et al. (1996) 
demonstrated that of 340 genes tested only the expression of 8 genes were changed in response 
to treatment with TSA or another HDAC inhibitor trapoxin.  Considering that hyperacetylation of 
histones is global it was surprising that the expression of so few genes was altered; they 
considered that the action of HDAC inhibitors may be more specific and that some histones are 
more sensitive to hyperacetylation than others, possibly due to differences in the 
microenvironment (Van Lint et al., 1996).  This could be a reason as to why FABP7 mRNA 
expression was not altered significantly by TSA treatment.  Another important point was that 
changes in gene expression may be secondary to HDAC inhibitor treatment i.e. that change in 
expression is a result of the change in expression of another gene that is directly affected by TSA 
(Van Lint et al., 1996). In light of this it is unlikely that the FABP7 gene is altered directly by 
acetylation.  Increasing the dose or duration of TSA would have had significant cytotoxic effects 
on the breast cell lines so it is not feasible with the current method to study longer term effects of 
TSA on FABP7 expression. 
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4.5.4 Combined AZA and TSA treatment resulted in an increase in FABP7 mRNA expression 
that was higher than that induced by either drug alone. 
Synergism is defined as the working together of two ‘things’ to produce an effect that is greater 
than the sum of their individual effects.  Using AZA and TSA together further increased FABP7 
mRNA in BT-20 cells, than either used alone; it is likely that this is the result of the two substances 
combined rather than them having a synergistic action.  For example the ER was expressed in 
breast cell lines to a level of around 400 fold after treatment with AZA and TSA together, each on 
their own gave a 30-40 and five fold increase respectively (Yang et al., 2001).   
 
4.5.5 FA treatment altered expression of FABP7 mRNA 
It was decided to investigate whether FAs could regulate FABP7 expression; each FA was chosen 
due to their association with FABP7 and the evidence that they regulate other FABPs; the FAs also 
covered a range of chain lengths and saturation differences.  Differences in chain length and three 
dimensional structure of the FAs as a result of saturation differences could inhibit or promote 
binding of transcription factors or co-factors.  The FA treatments resulted in different changes in 
FABP7 mRNA expression between the cell lines.  Reasons for this are that BT-20 cells have more 
FABP7 mRNA than MDA-MB-231 cells to begin with and that signalling pathways may be activated 
at a different level in each cell line by the FA.  The only statistically significant change in FABP7 
mRNA in the MDA-MB-231 cells was after 24 hours of treatment with 10µM AA resulting in a 
decrease of 0.47 fold.  Palmitate also decreased FABP7 mRNA at the same time point but this was 
not significant.  Interestingly AA has been well documented to decrease gene expression.  For 
example 3T3-L1 pre-adipocyte cells were treated with AA and then GLUT4 mRNA analysed; not 
only did the amount GLUT4 mRNA transcription decrease over time but so did the stability of the 
mRNA leading to near total protein reduction (Tebbey et al., 1994); little work has been done 
since looking at FAs and mRNA expression.  In addition to this AA decreased the enzymatic activity 
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of stearoyl-CoA desaturase and its mRNA expression (Sessler & Ntambi, 1998).  These two studies 
looked at mRNA expression and stability of GLUT4 or stearoyl-CoA desaturase at time points from 
30 minutes to 48 hours post FA treatment.  The genes were decreased at different time points 
(Tebbey et al., 1994; Sessler & Ntambi, 1998).  In the current study if FABP7 mRNA expression was 
measured at time points before 24 hours then perhaps a gradual reduction in expression could be 
seen followed by an increase in FABP7 mRNA between 24 and 48 hours where FABP7 mRNA 
expression was comparable to the control.  After 48 hours palmitate increased FABP7 mRNA by 
1.38 fold in BT-20 cells, the opposite of what was noted in MDA-MB-231 cells.  This increase of 
FABP7 mRNA in BT-20 cells with palmitate is in conjunction with another study; it was noted that 
of the FAs tested palmitate produced the greatest increase of mRNA of FABP3 and it was 
postulated that this was due to accumulation of palmitate in the cytoplasm inhibiting fatty acid 
oxidation (Chang et al., 2001).  This does not explain why palmitate resulted in opposing effects 
on FABP7 mRNA expression in each cell line; however, palmitate has been shown to both increase 
and decrease gene expression.  For instance, in rat islet cells it can inhibit preproinsulin levels 
through its conversion to ceremide (Kelpe et al., 2003).  In contrast to this palmitate induces 
interleukin-6 mRNA expression and NF-κB activation in skeletal muscle cells (Weigert et al., 2004).  
The opposing effects of palmitate could be explained by different pathways being active in each of 
the tissue types and in the present study, the breast cell lines.  The difference in effect could be 
due to how much FABP7 mRNA is present basally or how much palmitate accumulates in the cells.  
What is intriguing is that oleate treatment in BT-20 cells initially increased FABP7 mRNA relative 
to untreated cells at 24 hours and then levels dropped significantly after 48 hours.  One potential 
reason for this is the mRNA being translated into protein and subsequently degrading beyond 24 
hours.  Considering the 48 hour time point on its own it is clear that oleate and palmitate have 
opposing effects on FABP7 mRNA expression; such opposing effects of these 2 FAs have been 
documented in other studies.  Oleate has been demonstrated to activate PI3K and in turn 
proliferation whereas palmitate has the opposite effect in MDA-MB-231 cells (Hardy et al., 2000); 
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this investigation also found that oleate blocks the effects of palmitate.  Another study looked at 
gene transcription after oleate or palmitate treatment in HepG2 cells; palmitate up-regulated 724 
genes and suppressed 1035 and oleate induced 1669 and down-regulated 1535 genes; of these 
genes there were only 417 genes that were up-regulated and 452 down-regulated by both oleate 
and palmitate (Das et al., 2001).  However this does not explain why oleate initially increased 
FABP7 mRNA, one possible reason is that the BT-20 cells are adapting to the oleate treatment; 
they respond by initially increasing production of FABP7 but then a feedback mechanism may be 
activated leading to a reduction in FABP7 production.  This increase by oleate treatment is in 
conjunction with FABP1 being up-regulated at both the mRNA and protein level by oleate in rat 
hepatoma cells (Meunier-Durmort et al., 1996); very little work has been done since looking at 
changes in FABP expression as a result of exposure to FAs.  The other significant change in FABP7 
mRNA in BT-20 cells was with DHA after 24 hours resulting in an increase in FABP7 mRNA.  Of 
note is that DHA activates the RXR by acting as a transcription factor when bound to FABP7; 
however this causes the activation of the receptor rather than FABP7 itself but it is plausible that 
there may be some feedback mechanism involved that in turn alters the expression of FABP7 (Liu 
et al., 2012).  This is also indicative that FAs can have secondary effects resulting in changes in 
FABP7 mRNA.  For instance, FAs could activate or increase expression of transcriptions factors or 
deactivate and prevent expression of inhibitors of FABP7 expression.  Another possibility is that 
transcription factors could be recruited to the promoter site FABP7 as a result of FA treatment; as 
palmitate treatment has been found to increase binding of various transcription factors to the 
Glucose 6-phophatase gene promoter (Xu et al., 2007). 
 
4.5.6 Combinations of AZA and FA increase FABP7 mRNA in BT-20 cells 
A combination of AZA and the FAs were used to treat BT-20 cells to investigate whether there was 
any synergistic action as FAs and AZA altered FABP7 mRNA expression individually.  The second 
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dose of AZA considerably increased FABP7 mRNA compared to the first experiments with AZA 
alone, this gives further indication that the action is indirect; a second dose would ensure many 
pathways upstream of FABP7 would be highly activated within a shorter time compared to one 
dose of AZA, resulting in further up-regulation of FABP7 within the 72 hour time point.  Moreover, 
treatment with AZA and palmitate resulted in the highest observed fold increase of FABP7 mRNA 
in the present study, significantly more than AZA alone and palmitate alone fold changes 
combined together.  As discussed there is evidence that palmitate increases binding of 
transcription factors to promoter regions; it is possible that AZA results in demethylation of genes 
that regulate FABP7 and transcription of those genes is increased with palmitate treatment.  An 
alternative is that palmitate may alter mRNA stability or activity of transcription factors.  
Intriguingly, oleate, AA and DHA treatment with AZA significantly reduced the expression of 
FABP7 mRNA than the 2 doses of AZA alone.  Oleate decreasing FABP7 mRNA after AZA treatment 
is in agreement with previous results showing oleate decreases FABP7 mRNA when used 
individually to treat BT-20 cells; this could be reflective of oleate and palmitate having opposite 
effects.  There was no significant change with AA treatment alone and only a small significant 
increase with DHA alone as seen in the previous experiment at 24 hours.  One reason DHA may 
decrease FABP7 mRNA after AZA treatment, relative to two doses of AZA alone, is because there 
was very little FABP7 mRNA present basally for AA and DHA to alter expression.  The increase in 
FABP7 mRNA expression as a result of AZA could have allowed the actions of AA and DHA to be 
more marked. 
 
4.5.7 AZA and palmitate increase FABP7 protein expression in BT-20 cells 
To ascertain whether there were changes in protein expression following on from the AZA and FA 
treatment, a western blot was carried out on lysates from AZA alone and palmitate combined 
with AZA treated BT-20 cells, as these treatments resulted in the greatest fold increases in FABP7 
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mRNA.  Band densitometry normalised to β-actin was carried out as it was hard to see subtle 
changes in relative amount of FABP7 protein by eye.  There was an increase in protein by AZA 
alone and AZA and palmitate treatment combined in conjunction with the increase in FABP7 
mRNA.  It is surprising that there was not a greater increase in protein considering the fold 
changes in FABP7 mRNA.  There were a number of potential reasons for this; mRNA expression 
does not always link to protein expression and this could be due to protein or mRNA degradation 
or a delay in protein being produced.  It would be hard to postulate whether the increase in 
FABP7 mRNA is enough to physiologically affect the cells and in addition the effects of AZA, TSA 
and FAs are not specific to FABP7. 
 
 
4.6 Conclusions  
It is unlikely that FABP7 is directly regulated by methylation and acetylation; changes in FABP7 
mRNA are likely to reflect alterations in genes upstream of FABP7.  Treatment of TN breast cell 
lines BT-20 and MDA-MB-231 with FAs resulted in small increases and decreases in FABP7 mRNA; 
this could be a result of direct or indirect mechanisms.  Palmitate and AZA synergistically 
increased FABP7 mRNA and protein levels.   
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5 FABP7 over-expression in the triple negative 
breast cancer cell line BT-20 
 
5.1 Introduction 
To assess the functional relevance of FABP7 in breast cancer pathology, FABP7 was transiently 
over-expressed in BT-20 cells. The effects of FABP7 over-expression on cell growth and viability 
was investigated.  In addition to this expression of pro/anti apoptotic genes (bcl-X, caspase 9 and 
survivin) were assessed in order to investigate the influence of FABP7 expression on cell survival.  
Bcl-x is related to the bcl-2 gene and functions as an independent, dominant regulator of 
apoptosis and two distinct splice variants have been identified (Boise et al., 1993); bcl-xL, the 
larger variant and bcl-xS, the smaller variant.  Blc-xL is an anti-apoptotic splice variant whilst bcl-xS 
is pro-apoptotic (Mercatante et al., 2001).  In the prostate cancer cell line PC3 apoptosis can be 
induced by shifting splicing from bcl-xL to bcl-xS, however reducing bcl-xL levels but keeping bcl-xS 
levels constant was less efficient at inducing apoptosis.  In addition increasing bcl-xS in the breast 
cancer cell line MCF-7 reduced survival but not to the same extent as in PC3 cells (Mercatante et 
al., 2001).  Changes in bcl-x splicing have also been found to alter tumour growth in xenografts 
(Bauman et al., 2010).  As bcl-x protein has been reported to be over-expressed in around 40% of 
invasive breast cancers (Olopade et al., 1997), changes in splicing were investigated in relation to 
FABP7 over-expression.   
Caspase 9 is an initiator of apoptosis; there are also 2 splice isoforms,  caspase 9A, longer and pro- 
apoptotic and caspase 9B, shorter and anti-apoptotic (Srinivasula et al., 1999; Massiello & 
Chalfant, 2006).  One study found that down-regulating the splice factor SRp30a decreased 
caspase 9A and increased caspase 9B (Massiello & Chalfant, 2006).  Another regulator of caspase 
9 splicing is hnRNPL, down-regulating it was found to decrease the caspase 9A:9B ratio and in turn 
decrease tumourigenicity (Goehe et al., 2010).  Studying changes in the ratio of caspase 9 splice 
160 
 
isoforms in relation to FABP7 transfection gives information on the apoptotic state that cells are 
in.  Survivin is an inhibitor of apoptosis protein (IAP) with 2 splice isoforms, survivin ΔEx3 and 
survivin 2B.  Survivin ΔEx3 exhibits anti-apoptotic properties similar to that of full length survivin 
whereas survivin 2B has a portion of intron 2 retained and has reduced anti-apoptotic abilities 
(Mahotka et al., 1999; Badran et al., 2004).  It has been suggested that survivin 2B is a natural 
antagonist to survivin ΔEx3 and full length survivin and its expression may be favourable with its 
anti-tumourigenic properties (Li, 2005).  Moreover full length survivin protein expression was 
found to be expressed in around 70% of breast cancers; when combined with the apoptotic index 
of the tumour the results suggested that inhibition of apoptosis by survivin is a poor prognostic 
factor (Tanaka et al., 2000).   
Bcl-x, caspase 9 and survivin and their splice isoforms were relevant because they give 
information on both the pro- and anti-apoptotic features of the cells and therefore provide 
further in vitro evidence as to the likely effect of FABP7 expression in breast cancer cells.  In 
addition this study examined whether FABP7 over-expression in BT-20 cell line conferred 
resistance or sensitivity to cell death by various insults.  For example staurosporine (STRP) is a 
bacterial alkaloid that inhibits a range of protein kinases; STRP induces apoptosis but the 
pathways through which it does this are not fully understood, it is thought that there are several 
mechanisms by which STRP may exert its action (Weil et al., 1996; Yoo et al., 2012).  STRP has 
been successfully used in other studies to treat BT-20 cells and evaluate sensitivity to cell death 
after other treatments.  For example STRP induced cell death was reduced by treatment of cells 
with IGF-I (Davison et al., 2011); STRP was also used to demonstrate that a tyrosine kinase, FAK, 
prevented cell death by binding to a death domain of receptor interacting protein (RIP).  STRP 
induced apoptosis caused degradation of FAK that was RIP dependent as STRP caused a higher 
amount of apoptosis in RIP positive cells than negative (Kurenova et al., 2004).  Due to the 
apoptotic properties of STRP, it was chosen to treat BT-20 cells post over-expression of FABP7.  As 
well as this it was informative to know whether over-expression of FABP7 altered percentage cell 
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death with treatment of FAs; as FABP7 binds oleate, palmitate, AA and DHA; it was hypothesised 
that FABP7 transfected BT-20 cells would respond differently to treatment with these FAs, either 
shuttling fats to increase death or act as a sink and stopping signalling induced by fats to prevent 
death.  Oil red O staining was used in addition to counting cells to look for changes in FA 
accumulation.  These investigations may give an indication of the role of FABP7 in breast cancer 
cell lines and their survival and growth 
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5.2 Aims and hypotheses 
5.2.1 Aims 
i) To investigate whether FABP7 expression influences cell death 
ii) To investigate whether FABP7 affects FA accumulation in BT-20 cells. 
 
5.2.2 Hypotheses 
i) FABP7 will alter sensitivity to cell death by treatment with FAs and STRP 
ii) FABP7 will alter the expression of bcl-x, caspase 9 and survivin and their splice isoforms. 
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5.3 Materials and Methods 
5.3.1 Tissue culture and dosing experiments 
BT-20 cells were seeded at a density of 0.5x106 per well of a 6 well plate.  Cells were transfected 
as described in section 2.8.  Non-transfected cells, FugeneHD alone treated and control vector 
transfection cells were used as controls in these investigations.  To study cell death and growth, 
cells were transfected as detailed previously and then trypsinized and counted following trypan 
blue staining (section 2.3.9) after 24, 48 and 72 hours.  In addition to this, 24 hours post 
transfection cells, were trypsinized and seeded at 6000 cells per well of a 96 well plate.  The 
following morning cells were subjected to an MTT assay within the 48 hour time period, to assess 
cell viability as described in 2.9.  For the FA and cell death experiments transfected BT-20 cells 
were treated as described in section 2.3 with 2 doses of each FA chosen on the results of the dose 
response in section 1.10 and also on the results of work carried out by Liu et al. (2012).  The doses 
for the FAs were as follows; palmitate 50µM and 200µM, oleate 50µM and 100µM, AA 10µM and 
50µM and DHA 10µM and 50µM.  FAs were given 24 hours post transfection and incubated with 
the cells for a further 24 hours.  For the STRP experiments, cells were transfected and then 
medium changed to SFM 45 hours post transfection; this time point was chosen because the STRP 
treatment totalled 3 hours meaning that cells were treated and collected within 48 hours post 
transfection.  After one hour 1µM of STRP was spiked into the medium; two hours later the dead 
cells were collected and the live trypsinized and re-suspended together for counting (section 
2.3.9).  The dose and time of STRP incubation were chosen based on previous optimisation work; 
cells were treated with doses of STRP ranging between 0.25µM and 2µM for between one and 
three hours.  
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5.3.2 Sequencing of FABP7 pCMV.SPORT6 vector 
The plasmid was sent according to instructions using pre-paid barcodes to Eurofins MWG Operon 
DNA sequencing service.  It was sequenced in both directions using T7 and SP6 primers.  This 
verified that the plasmid contained the correct and complete FABP7 gene. 
The results of the sequencing were then aligned with the FABP7 sequence (accession 
NM_001446.3).  The alignment was done using EMBL-EBI ClustalW2 online program 
 
5.3.3 Generation of an empty pCMV.SPORT6 vector was generated for use as a control 
The following procedure is outlined in detail in section 2.8.  To generate the empty vector the 
FABP7 pCMV.SPORT6 vector was subjected to a double restriction enzyme digest.   The larger 
band of the double digest was extracted and purified and then religated.  The religation product 
was transformed into competent JM109 cells which were then cultured and subjected to plasmid 
prep as described.  To verify that it was an empty pCMV.SPORT6 vector that had been cultured it 
was subjected to a single and double digest alongside the FABP7 containing vector with SMAI and 
HINDIII.   
 
5.3.4 RNA extraction, PCR and gel densitometry 
The TRI reagent method as detailed in section 2.6.2 was utilised for RNA extraction, as this 
method gave higher yield. For initial experiments RNA was collected 24, 48 and 72 hours post 
transfection.  Reverse transcription, standard and qPCR took place as in section 2.7.  The standard 
PCR products were imaged and semi-quantified using densitometry by measuring band intensity 
in ImageJ.  Briefly, the region of interest tool was selected and exactly the same size box was 
drawn around each band; the program then generated arbitrary numbers based on the intensity 
of each band. Β-actin was checked to ensure even sample loading.  The ratios of the bands were 
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calculated for each sample again to ensure loading was equal and to visualize changes in 
apoptotic potential.  All results for the mRNA expression of bcl-x, survivin and caspase, are 
presented so the larger the expression or ratio on the graph the lower the apoptotic 
potential/higher anti-apoptotic potential gene expression.  qPCR was used to identify the time 
point with the biggest increase in FABP7 mRNA and to confirm results from the standard PCR 
densitometry.  Again the ratio of the splice variant expression was calculated to see differences in 
pro- or anti-apoptotic properties. 
 
5.3.5 Western Blotting 
Protein extraction and western blotting was carried out as detailed in section 2.5.  Protein lysates 
were made 24, 48 and 72 hours post transfection to identify suitable time points for further work. 
 
5.3.6 Statistical Analysis 
All statistics were carried out on the results of 3 independent experiments that had been carried 
out in triplicate unless otherwise stated.  The statistical package Graphpad Prism 5 was used to 
produce graphs and carry out statistical analyses for these experiments.  Whenever there was 
more than one comparison against the control a one-way ANOVA with a Bonferroni post-hoc test 
was used to highlight differences; a students paired t-test was then carried out to confirm 
significant differences.  Data are presented as mean ± standard error of the mean (SEM). 
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5.4 Results 
5.4.1 T7 primer vector sequencing 
GTACGCGTAGCTTGGGCCCCTCGAGGGATACTCTAGAGCGGCCGCCCTTTTTTTTTTTTTTTCACGTGTAAG
ATTTTTATTCAAATTTGATTTACATTCCAAAAGAAATTATAAAATGTATTCACTTGTTTATAAAAAAAAGGGG
GGGGGGACAAAACTTTAATTCAAATTATAAAACATGATAAATTTTCAGATTAAAATTGGGCAAGTTGCTTG
GAGTAACAAGTTTTTAAATCACCATTTTCCACCTCCACACCAAGGATAACCTTCTAATTAATGATCAGCCATG
TTGTAATAGGATAGCACTGAGACTTGAGGAAACAGAAAAACTGAAGAGCTCTTCCAAGCCCCGACCAGGA
ACATTTTTATGCCTTCTCATAGTGGCGAACAGCAACCACATCACCAAAAGTAAGGGTCATAACCATTTTGCC
ATCCTTAATTTCTCTTACAAAATTTGTTTCTTTGCCATCCCATTTCTGTATGTGAACAAGTTTGTCTCCATCCA
GGCTAACAACAGACTTACAGTTTCTATCATCTGCAGTGGTTTCATCAAACTCTTCTCCCAGCTGGAAACTAA
TCTCCGTGTTCTTGAATGTGCTGAGAGTCCTGATGACCACTTTGTCTCCTTCTTGACTGATAATTACCGTTGG
TTTGGTCACATTTCCCACCTGCCTAGTGGCAAAGCCCACGCCTAGAGCCTTCATGTACTCATCAAAGTTCTG
ACTGTTGGTCAGCTTCCAGGTAGCACAGAAAGCCTCCACCATCCTTGCCCTTTCCCCTCTTTAGAGACAGGA
GCGGGGATCTTCTGGTCTAATTGCCACTGCAGCTCAGAAGACCCTTTACACCTCAGCAAGCAGCTCCTGCCT
TCTTATTTGGAAAGAGGGTGGGCAAAAATCCAGTGATTTAAATTGCAAACACACCCCTCCAGTGTCCCTCTT
TCCAAGAGCTGCGGACGCGTGG 
 
5.4.2 SP6 vector sequencing  
GCAGGCTGGTACCGGTCCGGATTCCCGGGATATCGTCGACCCACGCGTCCGCAGCCTCTTGGAAAGAGGG
ACACTGGAGGGGTGTGTTTGCAATTTAAATCACTGGATTTTTGCCCACCCTCTTTCCAAATAAGAAGGCAG
GAGCTGCTTGCTGAGGTGTAAAGGGTCTTCTGAGCTGCAGTGGCAATTAGACCAGAAGATCCCCGCTCCTG
TCTCTAAAGAGGGGAAAGGGCAAGGATGGTGGAGGCTTTCTGTGCTACCTGGAAGCTGACCAACAGTCAG
AACTTTGATGAGTACATGAAGGCTCTAGGCGTGGGCTTTGCCACTAGGCAGGTGGGAAATGTGACCAAAC
CAACGGTAATTATCAGTCAAGAAGGAGACAAAGTGGTCATCAGGACTCTCAGCACATTCAAGAACACGGA
GATTAGTTTCCAGCTGGGAGAAGAGTTTGATGAAACCACTGCAGATGATAGAAACTGTAAGTCTGTTGTTA
GCCTGGATGGAGACAAACTTGTTCACATACAGAAATGGGATGGCAAAGAAACAAATTTTGTAAGAGAAAT
TAAGGATGGCAAAATGGTTATGACCCTTACTTTTGGTGATGTGGTTGCTGTTCGCCACTATGAGAAGGCAT
AAAAATGTTCCTGGTCGGGGCTTGGAAGAGCTCTTCAGTTTTTCTGTTTCCTCAAGTCTCAGTGCTATCCTAT
TACAACATGGCTGATCATTAATTAGAAG 
 
5.4.3 FABP7 mRNA sequence 
CAGCCTCTTGGAAAGAGGGACACTGGAGGGGTGTGTTTGCAATTTAAATCACTGGATTTTTGCCCACCCTC
TTTCCAAATAAGAAGGCAGGAGCTGCTTGCTGAGGTGTAAAGGGTCTTCTGAGCTGCAGTGGCAATTAGA
CCAGAAGATCCCCGCTCCTGTCTCTAAAGAGGGGAAAGGGCAAGGATGGTGGAGGCTTTCTGTGCTACCT
GGAAGCTGACCAACAGTCAGAACTTTGATGAGTACATGAAGGCTCTAGGCGTGGGCTTTGCCACTAGGCA
GGTGGGAAATGTGACCAAACCAACGGTAATTATCAGTCAAGAAGGAGACAAAGTGGTCATCAGGACTCTC
AGCACATTCAAGAACACGGAGATTAGTTTCCAGCTGGGAGAAGAGTTTGATGAAACCACTGCAGATGATA
GAAACTGTAAGTCTGTTGTTAGCCTGGATGGAGACAAACTTGTTCACATACAGAAATGGGATGGCAAAGA
AACAAATTTTGTAAGAGAAATTAAGGATGGCAAAATGGTTATGACCCTTACTTTTGGTGATGTGGTTGCTG
TTCGCCACTATGAGAAGGCATAAAAATGTTCCTGGTCGGGGCTTGGAAGAGCTCTTCAGTTTTTCTGTTTCC
TCAAGTCTCAGTGCTATCCTATTACAACATGGCTGATCATTAATTAGAAGGTTATCCTTGGTGTGGAGGTGG
AAAATGGTGATTTAAAAACTTGTTACTCCAAGCAACTTGCCCAATTTTAATCTGAAAATTTATCATGTTTTAT
AATTTGAATTAAAGTTTTGTCCCCCCCCCCCTTTTTTTTATAAACAAGTGAATACATTTTATAATTTCTTTTGG
AATGTAAATCAAATTTGAATAAAAATCTTACACGTG 
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5.4.4 Validation of vectors for transfection 
Figure 5.1 shows the products after agarose gel electrophoresis.  The undigested vector ran at 
approximately 3.8kB, the single digest with SalI product over 5kB and there were 2 products of 
the double digest with SalI and XholI one at about 4kB and the other at about 0.9kB. 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Restriction enzyme digest of pCMV.SPORT6 containing FABP7 insert 
The vector was subjected to a single digest with SalI and double digest with SalI and XholI. The 
undigested vector was also run alongside on the gel; this resulted in a band at around 3.8kB.  The 
single digest resulted in a product of over 5kB and the double gave 2 products of sizes of about 
4kB and 0.9kB. 
 
The single digest resulted in a band at over 5kB for the vector with FABP7 and a band between 
4kB and 5kB for the empty vector.  The double digest resulted in 2 products for the FABP7 vector, 
one at around 0.9kB the other between 4 and 5kB.  There was one visible product for the double 
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digest of the Empty vector at around 4kB. The bands of both the FABP7 and empty pCMV.SPORT6 
digests were of the expected sizes from the restriction sites on the vector map. 
An empty vector was synthesised for use as a negative control.  From figure 5.2 both the 
restriction enzyme digests for the FABP7 pCMV.SPORT6 vector and the empty pCMV.SPORT6 
vector resulted in the expected size bands.  In the first digest in figure 5.1 there are ‘ghost’ bands 
present; these are likely to be denatured or nicked plasmid.  Denatured or damaged plasmid DNA 
may have resulted in detrimental effects during transfection; to minimise this each new plasmid 
preparation was subjected to gel electrophoresis to ensure ‘ghost’ bands were minimal as in 
figure 5.2 
 
 
 
 
 
 
 
 
 
Figure 5.2 Restriction enzyme digest of pCMV.SPORT6 with FABP7 and Empty pCMV.SPORT6 
vector to verify empty vector generation. 
The vectors were subjected to a single digest with SmaI and double digest with SmaI and HindIII.  
For the FABP7 vector the single digest resulted in a product of over 5kB and the double gave 2 
products of sizes of about 4kB and 0.9kB. For the single and double digest of the empty vector a 
band for each was seen at around 4kB. 
Empty pCMV.SPORT6pCMV.SPORT6 with FABP7
10kB
0.5kB
1kB
3kB
4kB
5kB
SMAI        SMAI
HINDIII
SMAI       SMAI
HINDIII
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5.4.5 Over expression of FABP7 in BT-20 cells 
The BT-20 cell line was transfected with the pCMV.SPORT6 vector containing the FABP7 gene; 
RNA and protein were collected at 24, 48 and 72 hours post transfection.  For use as controls BT-
20 cells remaining un-transfected, treated with FugeneHD alone and transfected with a control 
pCMV.SPORT6 vector. Results are shown in figure 5.3, both protein and mRNA (approx 100 fold) 
were significantly increased after 24 hours (p=0.0041).  The highest amount of protein and mRNA 
was seen at 48 hours post transfection with around a 400-430 fold increase in mRNA relative to 
untreated BT-20 cells (p=0.001).  At 72 hours there was a drop in FABP7 mRNA to around 200 fold, 
compared to 48 hours, though this was still significant (p=0.001) compared to non-transfected 
cells.  FABP7 protein levels were not notably different between 48 and 72 hours post transfection.  
There were no significant changes in FABP7 mRNA at any time point for the controls and FABP7 
protein was not detected in the controls with western blotting. 
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Figure 5.3 Over-expression of 
FABP7 in BT-20 cells 
BT-20 cells were transfected 
with control or FABP7 containing 
pCMV.SPORT6 vector or left un-
transfected or treated with 
Fugene alone.  qPCR results are 
presented as fold change relative 
to non-transfected cells.  FABP7 
mRNA was increased in FABP7 
transfected BT-20 cells at all 
time points. A) 24 hours approx 
100 fold **(p=0.0041).  B) 48 
hours 400-430 fold 
***(p=0.001).  C) 72 hours 
approx240 fold ***(p=0.001).  A 
western blot was carried out (D) 
on each condition at each time 
point; FABP7 protein detected in 
FABP7 over-expressing cells at all 
time points with maximal 
protein at 48-72 hours. Results 
are representative of 3 
independent experiments with 
mean ±SEM as appropriate.  The 
U251 FABP7 positive control was 
imaged separately. 
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5.4.6 FABP7 over-expression leads to a reduction in cell death relative to control vector 
transfection 
Dead and live cells were counted post transfection as in figure 5.4 A) 24 hours, B) 48 hours and C) 
72 hours.  Results are expressed as percentage cell death and D) total cell number of transfected 
BT-20 cells across all time points.  At 24 hours there were significant increases in percentage cell 
death with the control vector (15% p=0.002) and with FABP7 (11% p=0.007) compared to non-
transfected cells.  There was a significant decrease in percentage cell death in FABP7 transfected 
cells compared to control vector transfected cells (p=0.028).  At 48 hours the only significant 
change in percentage death was between the untreated cells and the control vector transfection 
(11.8% p=0.0462).  At 72 hours percentage cell death was again significantly increased between 
the untreated cells and the control vector and in FABP7 transfected cells to 24% (p=0.046) and 
17.8% (p=0.049) respectively.  There was also a significant difference between percentage cell 
death of control vector and FABP7 transfected cells (p=0.0307).  Fugene HD treatment did not 
significantly alter percentage cell death at any time point.  The treatments with Fugene HD, 
control vector and FABP7 transfection resulted in fewer total cells than the untreated cells across 
all time points. 
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Figure 5.4 Percentage cell death after transfection 
Live cells were trypsinized and counted with dead cells using Trypan blue, post transfection, after 
A) 24 hours [significant differences: no treatment vs control vector **(p=0.002); no treatment vs 
FABP7 vector **(p=0.007); control vector vs FABP7 vector *(p=0.028)], B) 48 hours and 
[significant differences: untreated vs control vector **(p=0.0462)] C) 72 hours [significant 
differences: untreated vs control vector *(p=0.046); untreated vs FABP7 vector *(p=0.049); 
control vector vs FABP7 vector *(p=0.0307)].  Results are expressed as percentage cell death. D) 
Total cell number of transfected BT-20 cells across all time points are included to gauge changes 
in cell growth. Results shown represent 3 independent experiments carried out in triplicate with 
mean ±SEM.  
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5.4.7 FABP7 over-expression lead to increased cell viability compared to control vector cells 
assessed with an MTT assay 
An MTT assay was used to investigate cell viability post transfection.  The MTT assay results are in 
figure 5.5; there was no significant change in mitochondrial activity/cell viability between the non-
transfected cells and the FABP7 transfected cells.  There was a significant decrease in cell 
viability/mitochondrial activity in the control vector transfected cells compared to both non-
transfected (p=0.0039) and FABP7 transfected BT-20 cells (p=0.0002). 
 
 
 
 
 
 
 
 
Figure 5.5 MTT assay of transfected BT-20 cells 
BT-20 cells were transfected and the mitochondrial/cell viability measured with an MTT assay.  
There was no significant change in mitochondrial activity/cell viability between the untreated cells 
and the FABP7 transfected cells.  There was a decrease in cell viability/mitochondrial activity in 
the control vector transfected cells compared to the non-transfected cells **(p=0.0039) and the 
FABP7 transfected cells **(p=0.0002).  Results shown represent the mean of 3 independent 
experiments that were carried out in quintuplicate ±SEM. 
MTT assay of BT-20 cells 48 hours post transfection
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5.4.8 FABP7 transfected BT-20 cells are more resistant to death by FAs than control vector 
transfected cells 
Considering that there were changes in cell death and viability as a result of the transfection, 
another question to answer was whether transfection with FABP7 conferred more or less 
sensitivity to cell death by FAs.  The results are shown in figure 5.6.  A control experiment was 
carried out in conjunction to ensure serum starvation did not impact significantly on cell death 
post transfection; the percentage cell deaths were very similar to the original transfection cell 
count experiments as in figure 5.4. There was a significant increase in percentage cell death with 
50µM of palmitate in the control vector transfection relative to non-transfected cells (p=0.0006) 
and there was a trend for the FABP7 transfected cells to have lower percentage cell death 
compared to the control vector but this was not significant.  A dose of 200µM palmitate resulted 
in a significant increase in percentage cell death in the control vector (55.6%) compared to both 
the non-transfected cells (34.1% p=0.0213) and the FABP7 transfected cells (41.1% p=0.046) 
though there was no difference between the non- and FABP7 transfected cells.  Oleate doses used 
were 50µM and 100µM; a significant increase in cell death was noted for 50µM in the control 
vector transfected cell (31.9%) compared to both the non- (9.6%, p=0.010) and FABP7 (21.1%, 
p=0.011) transfected cells. The percentage cell death in the FABP7 transfected cells was higher 
than the cells with only oleate but this did not reach statistical significance.  With 100µM oleate 
the same trend was present with 42.5% cell death in the control vector transfected cell compared 
to 15.6% (p=0.0014) for non-transfected and 14.3% in FABP7 over-expressed cells (p=0.0027). 
Doses of AA used were 10µM and 50µM; the only significant difference in percentage cell death 
was for 10µM between the non-(12.4%) and control (22.9%) vector transfected cells (p=0.0049); 
however there was a trend for the percentage cell death in FABP7 over-expressing cells to be 
lower than both the non- and control vector transfected cells with 50µM AA.  DHA was used at 
doses of 10µM and 50µM; there was a significant reduction in cell death between the control 
vector and FABP7 transfection with both doses (10µM: 24.6% vs 15.4% p=0.0473; 50µM: 25.4% vs 
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15.9% p=0.0156); there was also a trend FABP7 transfected cells to have a lower percentage cell 
death than the non-transfected BT-20 cells. 
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Figure 5.6 Treatments of FA on transfected BT-20 cells 
A) No fat was used as a control to ensure the lack of serum did not impact on cell death; the 
percentage cell deaths were very similar to the original transfection cell count experiments (figure 
5.4). B) There was a significant increase in percentage cell death with 50µM palmitate in the 
control vector transfection relative to untreated cells **(p=0.0006); 200µM palmitate caused a 
significant increase in percentage cell death in the control vector (55.6%) compared to both the 
non-transfected cells *(34.1% p=0.0213) and the FABP7 transfected cells *(41.1% p= 0.046). C) An 
increase in cell death was noted for 50µM oleate in the control vector transfected cell (31.9%) 
compared to both the non- **(9.6%, p=0.010) and FABP7 *(21.1%, p=0.011) transfected cells.  
With 100µM oleate the same trend was present with 42.5% cell death in the control vector 
transfected cell compared to 15.6% **(p=0.0014) for untreated cells and 14.3% in FABP7 over-
expressed cells **(p=0.0027). D) The only significant difference in percentage cell death after AA 
treatment was for 10µM between the non-(12.4%) and control (22.9%) vector transfected cells 
***(p=0.0049). E) There was a significant reduction in cell death between the control vector and 
FABP7 transfection at both doses (10µM: 24.6% vs 15.4% *p=0.0473; 50µM: 25.4% vs 15.9% 
*p=0.0156).  Results shown represent the mean of 3 independent experiments carried out in 
triplicate with ±SEM.  A one-way ANOVA was used with a Bonferroni post-hoc test; a student’s 
paired t-test was used to determine any specific differences. 
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5.4.9 Transfection with FABP7 in BT-20 cells did not alter FA accumulation 
Considering that FABP7 binds the FAs used in this study, oil red O staining was carried out on 
transfected cells that had been treated with each of the FA to see if there were any changes in FA 
accumulation or lipid droplet formation.  The stained cells were assessed visually with 
representative results displayed in figure 5.7; there was no noticeable change in FA accumulation 
as a result of the transfection.  Oleate was the only FA that accumulated in the BT-20 cells. 
 
 
 
 
 
 
 
 
 
 
 
  
 
178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Oil red O staining of FA uptake in transfected BT-20 cells 
Control and transfected BT-20 cells were treated with either oleate, palmitate, AA or DHA and 
then stained with oil red O; staining was assessed by eye using a microscope.  Oleate resulted in 
FA accumulation in the BT-20 cells leading to strong staining.  AA and DHA treatment did not give 
any oil red O positivity.  There was no visible difference in FA accumulation as a result of 
transfection with FABP7 compared to both control vector transfected and untreated cells.  Results 
shown are representative of 3 independent experiments. 
Palmitate
Non transfection Control vector FABP7 over-expression
No fat
Oleate
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5.4.10 FABP7 over-expression did not confer resistance to apoptosis induced by STRP 
In addition to treatment with fat, BT-20 cells were treated with STRP post transfection to 
investigate whether FABP7 reduced apoptosis by STRP.  Non-transfected cells were treated with 
and without STRP to show that STRP induced death; there was 14.6% cell death in untreated cells 
compared to 39.3% with the addition of STRP (p=0.0001).  As previously, there was a lower 
percentage cell death in untreated cells (14.6% p= 0.0004) and FABP7 transfected cells (14.6% 
P=0.0002) compared to the cells transfected with the control vector (23.5%).  There was a 
significant increase in cell death in the control vector transfected cells treated with STRP (45.6%) 
relative to the non-transfected cells with STRP (39.3% p=0.0334) however there was no significant 
change in percentage cell death for the FABP7 transfected cells treated with STRP (43.5%) relative 
to the non-transfected cells with STRP (39.3%).  Results are in figure 5.8 
 
 
 
 
 
 
Figure 5.8 Transfected BT-20 cells treated with STRP 
Transfected and control BT-20 cells were treated with STRP to look for changes in sensitivity to 
cell death.  STRP induced 39.2% in non-transfected cells compared to 14.6% without 
***(p=0.0001).  Control vector transfection (23.6%) resulted in higher percentage cell death than 
non-transfected ***(14.6% p=0.0004) and FABP7 transfected cells ***(14.6% p=0.0002).  STRP 
treatment resulted in a higher percentage cell death in control vector transfected cells (45.6%) 
than cells treated with STRP alone *(39.3 p=0.0334). A one-way ANOVA was used with a 
Bonferroni post-hoc test; a student’s paired t-test was used to confirm any differences.  Results 
shown represent the mean of 3 independent experiments carried out in triplicate ±SEM 
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5.4.11 There was no significant difference in the ratio of expression of bcl-x splice variants in 
BT-20 cells transfected with FABP7 
Changes in BCL-X splice variant expression were assessed by PCR and band densitometry 24, 48 
and 72 hours post transfection.  Results are in figure 5.9; A is an example of bcl-x bands on a gel at 
the 24 hour time point, B is the band densitometry ratio for each treatment at each time point 
and represents the mean of three independent experiments ±SEM.  The ratio of the two bands 
was calculated by dividing the intensity of the 350bp anti-apoptotic band by the 160bp pro-
apoptotic band so that the larger the ratio the less apoptotic potential.  There were no significant 
changes in BCL-X expression as a result of transfection with either the control vector or FABP7 at 
any time point.  The greatest change was at 48 hours where the ratio for FABP7 transfected cells 
was 2.06 compared to the untreated and control vector transfected cells which both had a ratio 
of around 2.5. 
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Figure 5.9 Expression of BCL-X mRNA does not change significantly as a result of transfection 
with FABP7 
An example of the PCR BCL-X gel at the 24 hour time point. B) Band densitometry of BCL-X splice 
variants; a larger ratio indicates less apoptotic potential.  There were no significant differences in 
bcl-x mRNA expression at anytime point for any treatment. A one-way ANOVA was used with a 
Bonferroni post-hoc test; a student’s paired t-test was used to confirm any differences.  Results 
represent the mean of 3 independent experiments carried out in triplicate ±SEM. 
 
 
5.4.12 FABP7 transfected cells tended to have higher expression of the anti-apoptotic splice 
variant ΔEx3 survivin 
BT-20 cells were transfected with a control vector or FABP7 and RNA was extracted after 24, 48 
and 72 hours.  Standard PCR and band densitometry was initially carried out on survivin splice 
variants; there was a trend noted that FABP7 transfected cells tended to have higher expression 
of anti-apoptotic splice variants (figure 5.10) 
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Figure 5.10 Standard PCR and densitometry analysis of survivin splice variant expression 
This figure shows a gel representative of survivin splice variant expression in BT-20 cells after 
transfection (A).  Densitometry was carried out to give the expression ratio of survivin EX3 and 2B 
(B).  There were trends for FABP7 over-expressing cells to have more anti-apoptotic potential; to 
confirm these trends qPCR was carried out. 
 
To investigate these trends further qPCR was carried out, the results are in figure 5.11.  There 
were no-significant changes in total (A) or survivin splice variant expression (B&C) or the ratios 
(D&E) at any time point.  However there were consistent trends noted.  Full length survivin 
(survivin FL) expression tended to be higher in the FABP7 over-expressing cells compared to the 
control vector transfected and un-transfected cells; survivin FL expression was at its highest at 48 
hours where there was a 1.88 fold increase relative to un-transfected cells.  The control vector 
transfected cells had lower expression of survivin FL in relation to untreated cells at 24 and 48 
hours (both around 0.67 fold).  The same trends were present for the expression of survivin ΔEx3; 
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there was a 1.59 fold increase of survivin ΔEx3 in FABP7 transfected cells at 48 hours.  Survivin 
ΔEx3 in control vector transfected cells did not differ from the un-transfected cells until 72 hours 
where it fell to 0.56 fold.  In contrast to this there were not any notable changes in survivin 2B as 
a result of control vector or FABP7 transfection until 72 hours where there was a reduction for 
both, 0.56 fold and 0.77 fold respectively.  To investigate changes in apoptotic or survival 
potential the ratio of the splice variant relative to survivin FL was calculated; the smaller the ratio 
the less the anti-apoptotic properties and vice versa.  The survivin ΔEx3 to survivin FL ratio 
calculation showed that there was no change in anti-apoptotic properties as a result of control 
vector transfection compared to un-transfected cells; the ratios remained between 1.3 and 1.5.  
There were trends for the ratio of the splice isoforms in FABP7 over-expressing cells to be higher 
than both control and un-transfected cells; the highest ratio change was at 72 hours (ratio 2.3).  
The survivin 2B to survivin FL ratio changes did not change notably with the exception at 24 hours 
where both the ratio of control vector and FABP7 were lower than untreated cells (1.5), 0.9 and 
1.1 respectively.  The ratios for 48 and 72 hours were all between 1.0 and 1.3. 
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Figure 5.11 Survivin FL and ΔEx3 increase as a consequence of FABP7 over-expression 
A) Fold change in survivin FL mRNA. B) Fold change in survivin ΔEx3 mRNA. C) Fold change in 
survivin 2B mRNA. D) The ratio of survivin ΔEx3 to survivin FL. D) The ratio of survivin 2B to 
survivin FL.  There were no statistically significant changes in expression or ratio of the splice 
variants, though there was a trend for FABP7 over-expressing cells to have a higher expression of 
survivin FL and survivin ΔEx3 compared to both non- and control vector transfection. Results 
shown represent the mean of 3 independent experiments carried out in triplicate ±SEM. A one-
way ANOVA was used with a Bonferroni post-hoc test; a student’s paired t-test was used to 
confirm any differences. 
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5.4.13 FABP7 transfection did not alter the ratio of caspase 9 splice variants significantly, but 
there were changes in overall splice variant expression 
Standard PCR and band densitometry was initially carried out for caspase 9 splice variants in 
transfected BT-20 cells.  Changes were inconsistent over time as seen in figure 5.12. 
 
 
 
 
 
 
Figure 5.12 Standard PCR and band densitometry analysis of caspase splice variant expression 
This figure shows a gel representative of survivin splice variant expression in BT-20 cells after 
transfection (A).  Densitometry was carried out to give the expression ratio caspase splice variant 
expression (B).  The trends over time were inconsistent so qPCR was carried out to further 
investigate changes in expression. 
 
To further investigate changes in caspase 9 splice variant expression qPCR was carried out (figure 
5.13).  There were no statistically significant changes in caspase 9A expression as a result of 
transfection with either the control or FABP7 vector transfection.  Caspase 9A fold expression in 
control vector transfected cells were consistently lower relative to non-transfected cells, 0.44, 
0.54 and 0.64 at 24, 48 and 72 hours respectively.  In contrast the fold change in expression, 
relative to non-transfected cells, did not alter in FABP7 transfected cells until after 72 hours 
where it fell to 0.45.  At 24 hours there was a reduction in caspase 9B expression (0.49 fold).  
Forty-eight hours post transfection levels of caspase 9B were similar across treatments.  Caspase 
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9B fold change decreased for both transfected cells sets at 72 hours to 0.42 (control vector) and 
0.49 (FABP7).  To confirm any differences the ratio of expression of the 2 splice variants was 
calculated.  There was little difference in the ratios for each treatment and across each time point.  
The largest difference was a reduction in the ratio in FABP7 transfected cells to 0.96 compared to 
1.3 for both non- and control vector transfected cells after 24 hours. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Changes in expression of caspase 9 splice variants after transfection 
A) Fold change in caspase 9A expression relative to untransfected cells. B) Fold change in caspase 
9B expression relative to untransfected cells.  C) The ratio of caspase 9A to 9B expression.  There 
were no significant differences in overall caspase 9 splice variant expression or ratio of splice 
variant expression.  Results shown represent the mean of 3 independent experiments carried out 
in triplicate ±SEM. A one-way ANOVA was used with a Bonferroni post-hoc test; a student’s paired 
t-test was used to confirm any differences. 
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5.5 Discussion 
Transfection was successful with no increases in FABP7 mRNA or protein as a result of FugeneHD 
alone or control vector transfection.  FABP7 mRNA was maximal after 48 hours and then dropped 
slightly at 72 hours.  Protein was present after 24 hours with bands being comparable at 48 and 
72 hours.  This is as predicted as it would take time for cells to produce the protein after 
transfection and as the transfection is only transient levels of both protein and mRNA would be 
expected to decrease beyond 72 hours. 
 
5.5.1 FABP7 over-expression reduced cell death and increased cell viability relative to 
control vector transfected cells 
Live and dead cell counting after trypan blue staining has been shown to give comparable results 
to other methods such as flow cytometry and PARP cleavage assessment by western blotting 
(Thomas et al., 2010; Fowler et al., 2000; Gill et al., 1997).  However counting dead cells with 
trypan blue can have limitations due to disintegration of dead cells.  The results showed that 
percentage cell death was minimal at 24 and 48 hours but at 72 hours percentage cell death in 
both transfected sets of cells increased dramatically indicating that the transfection was 
beginning to have adverse effects on cell viability.  The cell counts also showed that the control 
vector transfected cells consistently had higher percentage cell death compared to both the 
untreated cells and the FABP7 transfected cells.  This is unlikely to be a result of experimental 
error, for instance due to seeding densities; seeding densities were the same across all wells 
verified by the total cell count results.  In addition nicked DNA assessed by restriction enzyme 
digest of plasmid, was minimal so unlikely to cause cell death.  The differences noted in the total 
cell counts between the untreated versus the FugeneHD, control vector and FABP7 transfected 
conditions are more likely to reflect changes in growth although changes were not significant.  
The MTT assay results further confirmed statistically significant differences in cell viability 
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between the control vector and FABP7 transfected cells; however there was no difference in 
mitochondrial activity between FABP7 over-expression and non-transfected cells.  One possible 
reason for this is that BT-20 cells may not cope well being transfected, perhaps the plasmid DNA 
activates certain pathways to cause death similarly to immune responses to viruses (Hornung & 
Latz, 2010; Atianand & Fitzgerald, 2013).  FABP7 may activate pathways that are protective 
against death or deactivate apoptotic pathways; this theory has further evidence from the 
percentage cell death in FABP7 over-expressing cells reducing after 48 hours, relative to control 
vector transfected cells and cell death at 24 hours, when FABP7 expression is at its highest. 
 
5.5.2 FABP7 over-expression conferred resistance to cell death by FAs relative to control 
vector transfected cells. 
Transfected BT-20 cells were treated with 2 doses of palmitate, oleate, AA and DHA to investigate 
whether FABP7 was protective against cell death.  Interestingly the control vector transfected 
cells consistently had a significantly higher percentage cell death compared to non-transfected 
cells for all FAs at both doses with the exception of 50µM AA and both doses of DHA.  This could 
be due to the fact the cells are porous post-transfection so the FAs more readily enter the cells 
than usual.  Moreover, cells over-expressing FABP7 had significantly lower cell death than control 
vector transfected cells for both doses of oleate, 200µM palmitate and for both doses of DHA.  
Again this is indicative that FABP7 protects against cell death and in this case death from FAs; 
however there were no differences in cell death between non-transfected BT-20 cells and those 
over-expressing FABP7.  DHA has previously been shown to promote apoptosis and inhibit growth 
in breast cancer cell lines  (Siddiqui et al., 2005; Sun et al., 2008).  One study found that by 
knocking down FABP7, the MDA-MB-435 cell line became sensitive to the effects of DHA; growth 
inhibition became apparent (Liu et al., 2012).  In this study the approach was the opposite, FABP7 
was over-expressed and the effect of DHA on cell death compared to controls was negated.  This 
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was particularly apparent for 50µM DHA, although not significant, cell death in FABP7 transfected 
cells was 16% compared to 22% in non-transfected BT-20 cells.  It was postulated that this effect 
could be a result of excess FABP7 sequestering DHA and thus limiting its availability or directing it 
to enzymes for degradation (Liu et al., 2012).  In contrast to this, another possibility is that FABP7 
transports DHA to the nucleus to trigger survival and proliferation pathways (Liu et al., 2012).  This 
is in conjunction with work by Mita et al (2010); the role of FABP7 with DHA in growth, apoptosis 
and proliferation was studied in glioma cell lines.  The findings of the study led them to come up 
with a suggested pathway (figure 1.13).  FABP7 binds to AA or DHA depending on the relative 
abundance and the shuttles DHA into the nucleus which then binds to PPAR-γ resulting in down-
regulation of promigratory genes or it binds to AA to transfer it to the COX2 pathway in the 
cytoplasm to activate promigratory genes downstream of the pathway (Mita et al., 2010).  The 
reasons for the different documented effects of DHA on proliferation and apoptosis are probably 
due to the cell lines being of different origin and having different gene expression profiles, in 
particular differing basal levels of FABP7.  It is therefore probable that in the present study, FABP7 
inhibits death induced by DHA by sequestering it and preventing gene activation.  In light of the 
work by Mita et al (2010) it could be predicted that AA has the opposite effect however there 
were no significant changes in cell death with AA treatment in FABP7 transfected cells.  Perhaps 
higher doses were required to see a difference in cell death with AA and a more marked effect 
with DHA.  Oleate and palmitate have been demonstrated to have opposite effects on cell 
proliferation and apoptosis; therefore it was interesting that FABP7 transfected cells had a lower 
percentage cell death than control vector transfected cells with both oleate and palmitate 
treatments.  Again, this could be due to FABP7 sequestering the FAs to prevent FAs causing cell 
death.  The higher doses of oleate and palmitate did not reveal any significant differences 
between FABP7 transfected and non-transfected cells.   
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5.5.3 FABP7 over-expression did not alter FA accumulation 
To ascertain if FABP7 had any impact on FA accumulation BT-20 cells were transfected and then 
treated with the FAs for staining with oil Red O.  There was not any noticeable difference in FA 
accumulation as assessed by oil red O.  Oleate was the only fatty acid that accumulated in the 
cytoplasm and therefore was strongly positive with oil red O staining however the degree of 
staining was not different between FABP7 over-expressing and control BT-20 cells.  It is a 
possibility that AA and DHA do not accumulate in BT-20 cells or that the dose was not high 
enough to see an effect; higher doses would have been detrimental to the cells and perhaps there 
would not be any cells remaining to stain for after a higher dose of FA.  In light of this FABP7 may 
not be involved with FA accumulation in breast cells and its role may be in solubilising and 
transporting FA when they have entered or are synthesised in the cells so that they are 
metabolised. 
 
5.5.4 Over-expression of FABP7 did not alter sensitivity to apoptosis by STRP 
To investigate whether FABP7 over-expression conferred resistance to apoptosis, BT-20 cells were 
transfected and then treated with STRP.  STRP successfully induced apoptosis however only the 
control vector transfected cells were more susceptible to STRP compared to non-transfected cells 
treated with STRP.  This increase in death could be viewed as the additive effect of the control 
vector transfection causing death with STRP rather than the cells being more sensitive particularly 
as the control vector transfection had a higher percentage cells death in the group without STRP 
treatment.  It is not known how STRP induces apoptosis but it is thought that it does this through 
several different mechanisms (Weil et al., 1996).  It is possible that a difference in sensitivity was 
not seen because of this; FABP7 could confer resistance or sensitivity in apoptosis but only 
through 1 or 2 mechanisms and these would not be noticeable due to the multi-target effect of 
STRP.  One way to overcome this is to use agents that induce apoptosis in a more specific manner 
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but clues would be needed as to which mechanisms FABP7 works with as the use of each agent 
would need to be justified.  For these reasons different genes involved in apoptosis and survival 
were looked at for changes in expression as a result of FABP7 transfection. 
 
5.5.5 Over-expression of FABP7 altered the expression of splice variants involved in 
apoptosis and survival 
The genes in the present study were chosen for the reason that the splice variants could give 
information on changes in both anti- and pro-apoptotic properties at the same time.  Standard 
PCR was carried out to initially look for changes and then qPCR was carried to confirm and 
changes.  There were no significant changes in either of the bcl-x splice variants as a result of 
FABP7 over-expression.  The bcl-xL protein has been found to be the variant that is predominantly 
over-expressed in breast cancer and it is associated with high tumour grade (Olopade et al., 
1997).  If FABP7 had been found to increase bcl-xL or decrease bcl-xs it could be indicative that it is 
of poor prognostic value.  Interestingly there were changes in survivin expression.  The survivin 2B 
splice variant changed the least in terms of overall expression and the ratio with survivin FL with 
transfection; therefore FABP7 expression did not lead to reduced anti-apoptotic properties.  In 
contrast there were increases in survivin FL and survivin ΔEx3 in FABP7 over-expressing BT-20 
cells, the ratio of survivin EX to FL also increased particularly at 24 and 48 hours.  Although not 
significant the trends in the changes of splice variant ratio were consistent.  There has been 
conflicting result as to the role of survivin in breast cancer, perhaps due to the expression of the 
different splice variants.  For example one study looked at survivin with IHC and found that 
nuclear staining for survivin was an independent predictor of favourable prognosis (Kennedy et 
al., 2003).  Another study found that survivin was associated with a poor prognosis but nuclear 
and cytoplasmic localisation were not assessed separately (Hinnis et al., 2007).  In contrast 
another study found that survivin ΔEx3 was correlated positively with apoptosis (Ryan et al., 
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2005).  Due to the differing evidence it is plausible that FABP7 can have a detrimental or improved 
effect on prognosis depending on the role of survivin FL and ΔEx3 in breast cancer; further 
investigations are required to understand this.  It is possible that FABP7 is shuttling various fats 
around the cell that lead to increased or decreased expression of the genes involved in apoptosis 
in the present study (Mita et al., 2010; Liu et al., 2012).  The results for caspase 9 expression 
showed that there was little change in the ratio at any time point as a result of transfection, an 
indication that there is not a change in apoptotic properties.  There were overall decreases in 
both caspase 9A and 9B mRNA though there was not a pattern as to whether they decreased as a 
result of the transfection or as result of FABP7 over-expression.  Caspase 9 protein is an initiator 
caspase that is downstream of survivin; survivin interacts with caspase 9 through a 
phosphorylated domain to inhibit caspase 9 action/activation (Reed, 2001; Boatright & Salvesen, 
2003).  If survivin protein increased as mRNA did with FABP7 over-expression, this could result in 
a block on the apoptotic action of caspase 9.  Alternatively FABP7 could inhibit apoptosis 
independently of caspase 9; for instance, considering the increased mitochondrial activity 
(measured by a MTT assay) in FABP7 over-expressing cells, FABP7 could alter mitochondrial 
activity and pathways involved in apoptosis perhaps by decreasing reactive oxygen species (ROS) 
that affect the mitochondrial membrane (Ott et al., 2007; Fleury et al., 2002).  Without further 
investigation it is not possible to fully ascertain the relationship of FABP7 with apoptosis. 
 
In the current study, evidence is presented to show that short term over-expression of FABP7 
increases cell viability of breast cancer cells. Whether long term over-expression of FABP7 will 
confer the same effect remains to be investigated. Further studies using cell line models that 
enable long term investigation of FABP7 and patient cohorts with clinical follow up data will 
further aid understanding on whether FABP7 may be a novel prognostic marker in breast cancer.  
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5.6 Conclusions  
FABP7 transfected BT-20 cells have increased viability compared to control vector transfected 
cells.  FABP7 transfected cells are more resistant to death induced by FAs than control vector 
transfected cells.  FABP7 transfection results in changes in survivin expression but further work is 
required to ascertain whether this is of prognostic value.  
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6 IGFBP-2 and PTEN expression in triple negative 
breast cancer 
 
6.1 Introduction 
IGFBP-2 is a member of the IGF-axis and modulates the action of insulin like growth factors (IGF-I, 
IGF-II) that principally signal via the type 1 IGF receptor (IGF-IR) (Perks et al., 2007).  The IGF axis 
has important roles in metabolism.  IGFs, particularly IGF-II, have been found to be essential in 
foetal growth (Duan, 2002); links with the growth hormone axis and epidemiological studies have 
shown that IGFs are important in determining height and individuals who are taller are more at 
risk of developing cancer particularly in the breast or prostate (Okasha et al., 2002).  This axis 
plays a critical role in the development and progression of many epithelial cancers, including 
breast cancer (Meinbach & Lokeshwar, 2006).  At the cellular level the IGF-I receptor appears to 
play a fundamental role in maintaining the transformed phenotype (Baserga et al., 2003).  Recent 
prospective epidemiology has consistently shown strong associations between circulating IGF-I 
levels and the subsequent risk of developing a number of epithelial cancers, including breast 
cancer (Roddam et al., 2008).  Whilst IGFBPs can act to either inhibit or enhance IGF-induced cell 
signalling they can also exert effects in an IGF-I-independent manner, indicating that IGFBPs can 
intrinsically modulate aspects of cell growth and survival (Holly & Perks, 2006).  Busund et al. 
reported that in breast cancer, IGFBP-2 abundance was markedly higher in invasive breast 
carcinoma and carcinoma in situ when compared to normal breast tissue or benign hyperplastic 
lesions that had very little IGFBP-2 expression (Busund et al., 2005).  A study by Wang et al. 
showed that tumour expression of IGFBP-2 could predict tumours most likely to metastasise.  
IGFBP-2 clearly appears to play a role in breast cancer progression (Gebauer et al., 1998; McGuire 
et al., 1994; Wang et al., 2000; Busund et al., 2005; So et al., 2008) and interestingly high levels of 
IGFBP-2 expression have also been identified in a number of additional cancers including those of 
the prostate (Degraff et al., 2009), ovary (Yan et al., 2009), stomach (Zhang et al., 2007), adrenal 
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gland (Shi et al., 2007) and bladder (Miyake et al., 2005) suggesting that IGFBP-2 generally plays 
an important role in tumourigenesis.  Although there has been much work investigating IGFBP-2 
in general breast cancer cohorts and cell lines little if any work has investigated the relevance of 
IGFBP-2 in a cohort of TN breast cancer cases.  However one study found that IGFBP-2 expression 
was associated with ER negativity in a general cohort (So et al., 2008); further illustrating the 
importance of investigating IGFBP-2 in TN breast cancer.  PTEN is a tumour suppressor gene that 
is lost or mutated in many types of cancer, including breast, prostate and lung cancer (Salmena et 
al., 2008).  PTEN dephosphorylates PIP3, a product of the PI3K pathway, thereby inactivating the 
Akt signalling pathway, inhibiting cell growth and promoting apoptosis (Salmena et al., 2008).  
More recently, PTEN has been postulated to have an important role in DNA repair, as mutation or 
loss of PTEN results in a deficiency to repair DNA double strand breaks (Shen et al., 2007).  Whilst 
one previous study has reported PTEN loss in 48% of unselected breast cancer cases, other 
studies have reported lower incidence of PTEN loss (8% (Panigrahi et al., 2004), 15% (Perren et al., 
1999), 28% (Lopez-Knowles et al., 2009)), though these differences may reflect methodological 
differences in testing and reporting PTEN loss. In contrast, a recent study suggests that up to 66% 
of basal like breast cancers have loss of PTEN and that PTEN loss may occur more frequently in 
this phenotype, compared to other subtypes of breast cancer (Lopez-Knowles et al., 2009).  An 
unbiased screen of human prostate and glioblastoma samples, using microarray-based expression 
profiling, identified IGFBP-2 as the most significant marker of PTEN loss (Mehrian-Shai et al., 2007) 
and whilst the mechanism of loss of expression of PTEN in breast cancer has yet to be fully 
elucidated in cell lines PTEN activity is down-regulated by the interaction of IGFBP-2 with the beta 
1 integrin receptor (Perks et al., 2007) (section 1.7 and 1.8).   
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6.2 Aim and hypotheses 
6.2.1 Aim 
i) The purpose of the current study was to investigate for the first time the association 
between PTEN loss and IGFBP-2 expression in a cohort of TN breast cancer cases and 
relate this expression to basal cytokeratin expression and the clinicopathological features 
of stage, histological grade, patient age and overall survival. 
6.2.2 Hypotheses 
i) Loss of the PTEN gene is a frequent event in TN breast cancer and is associated with 
IGFBP-2  expression. 
ii) IGFBP-2 expression and PTEN loss are associated with a worse prognosis in TN breast 
cancer. 
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6.3 Materials and Methods 
Tissue blocks of all accessible triple negative breast carcinomas diagnosed between 2004 and 
2009 at the University of Malaya Medical Centre, were used in this study, with a total of 101 
identified as having adequate invasive tumour tissue for evaluation and were negative after re-
assessment for ER, PR and Her2. All tissues had been fixed in 10% neutral buffered formalin 
between 6 to 72 hours, and processed to paraffin wax blocks, from which sections were cut at 
3µM thickness on a rotary microtome and mounted onto Tissue Tek Plus glass slides to ensure 
maximum adhesion. 
 
6.3.1 Assessment of Tumour Grade and Stage 
Grading was according to the modified Bloom and Richardson criteria (Elston & Ellis, 1991) and all 
slides were reviewed and re-graded for this study by the histopathologists in the team.  Clinical 
data on patient age, ethnicity and stage (American Joint Commission on Cancer, 2003), were 
extracted from the database for this series of cases.  Patients were staged according to the 6th 
edition of the American Joint Commission on Cancer (AJCC) (Singletary & Connolly, 2006). 
 
6.3.2 Immunohistochemistry 
Expression of ER, PR, Her2, IGFBP-2, PTEN, cytokeratins 5/6 and cytokeratin 14 were tested for by 
IHC and staining assessed as described in section 2.1. 
 
6.3.3 Statistical analysis 
Continuous variables (age) were described using medians and compared using the Mann-Whitney 
U test, while categorical variables (ethnicity, stage, grade, IGFBP-2 expression, PTEN loss, CK5/6 
expression and CK14 expression) were expressed as proportions and compared using either Chi 
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square test or Fisher’s Exact test. Variables that were significantly associated with PTEN loss and 
IGFBP-2 expression were simultaneously entered into a multivariate logistic regression model 
with PTEN loss and IGFBP-2 as the outcome variables, to determine the independent predictors of 
PTEN loss and IGFBP-2 expression.  Considering that information on cause of death was not 
available for the majority of patients, the relative survival rates (RSRs) were calculated to estimate 
the excess mortality among the patient population due to breast cancer.  Population mortality 
data for Malaysia was used to compute these estimates. The relative survival adjusts for the 
general survival of the Malaysian population for the given sex, age and year, and thus is a 
measure of net survival attributed to breast cancer independent of other causes of death.  P 
values of less than 0.05 and 95% confidence interval (CI) for odds ratio (OR) which does not 
include 1.0 were considered as statistically significant. All statistical analyses were carried out 
using SPSS IBM Statistics (Version 20) and Stata MP (Version 14).  Analysis for the study was 
carried out by Dr. Nirmala Boo Pathy. 
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6.4 Results 
Following re-testing of ER, PR and Her2 and confirmation of the triple negative status of the 
breast cancers, a total of 89 cases were available for analysis of PTEN loss and basal cytokeratin 
expression and a total of 100 available for analysis of IGFBP-2 and basal cytokeratin expression.  
The age of onset of breast cancer in the patients ranged from 23 to 83 years old with a median of 
53 years.  The majority of cases (93%) were invasive ductal carcinomas, with the remaining being 
either medullary or metaplastic cancers.  
 
6.4.1 IGFBP-2 
IGFBP-2 staining was predominantly confined to the cytoplasmic compartment of the invasive 
cancer cells with little stromal staining or expression in normal glands. Heterogeneity of staining, 
with some invasive tumour cells showing strong expression for IGFBP-2 and other cells showing 
little or no expression was a common feature. Addition of the IGFBP-2 blocking peptide resulted 
in complete absence of staining in cases shown to be strongly positive for IGFBP2 (figure 6.4.1).   
 
One hundred TN cases were assessable for IGFBP-2 staining with 32% showing high levels of 
IGFBP-2 expression (Allred score >5).  Univariate analysis revealed no significant differences in 
high IGFBP-2 expression and age, stage, or CK5/6 but there was an association between IGFBP-2 
expression and lack of staining for CK14 (p=0.004) (table 6.1).  In the multivariate analysis, 
independent predictors of high levels of IGFBP-2 expression were lack of positivity for CK14 
(p=0.005) (figure 6.2) and PTEN loss (p=0.047) (figure 6.3).  There was also a trend for lympho-
vascular invasive cases to have high levels of IGFBP-2 expression but this trend was not significant 
(p=0.064) (table 6.2). 
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Figure 6.1 IGFBP-2 staining pattern and the specificity of the IGFPB-2 antibody 
Top:  Immunohistochemical cytoplasmic staining for insulin like growth factor binding protein-2 
(IGFBP-2) in a triple negative invasive ductal carcinoma. Bottom:  The addition of the IGFBP-2 
blocking peptide resulted in complete absence of cytoplasmic staining for IGFBP-2 of this tumour. 
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Table 6.1 Factors associated with IGFBP-2 expression 
 
 
Key:  
a) Compared using Mann-Whitney-U test  
b) Compared using Fisher’s Exact test  
c) No patients with grade 1 tumour 
d) Defined as an Allred Score >5. 
 
 
 
 
 
 
Overall  
N (%) 
IGFBP2 
positive 
N (%) 
IGFBP2 
negative 
N (%) 
P for X2 test 
No. of patients 100 32  68   
Age (median, years) 53 52 53 0.685a 
Ethnicity    0.215 
Chinese 63 (63.0) 19 (59.4) 44 (64.7)  
Malay 21 (21.0) 6 (18.8) 15 (22.1)  
Indian 13 (13.0) 7 (21.9) 6 (8.8)  
Others 3 (3.0) 0 (0.0) 3 (4.4)  
Tumour size (median, cm) 3.0 3.3 3.0 0.445a 
Lymph node involved    0.866   
Yes 44 (44) 15 (42.9) 29 (44.6)  
No 56 (56)  20 (57.1) 36 (55.4)  
     
Stage    0.837b 
Early 65 (65) 24 (68.6) 41 (63.0)  
Late 35 (35) 11(31.4) 24 (37.0)  
Grade c    0.855 
Grade 2 19 (19.6) 7 (20.6) 12 (19)  
Grade 3 78 (80.4) 27(79.4) 51 (81)  
Unknown 3 1 2  
Lymphovascular invasion    0.176 
Present 34 (34.3) 16 (47.1) 18 (32.7)   
Absent 55 (65.7) 18 (52.9) 37 (67.3)  
Unknown 11 1 10  
CK14 status    0.004 
Negative 55 (56.7) 26 (76.5) 29 (46)  
Positive 42 (43.3) 8 (23.5) 34 (54)  
Unknown 3 1 2  
CK 5/6 status    0.368 
Positive 26 (29.5) 11 (35.5) 15 (26.3)  
Negative 62 (70.5) 20 (64.5) 42 (73.7)  
Unknown 12 4 8  
PTEN loss    0.073 
Yes 43 (48.3) 19 (61.3) 24 (41.4)  
No 46 (51.7) 12 (38.7) 34(58.6)  
Unknown 11 1 10  
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Table 6.2 Factors associated with IGFBP-2 expression in multivariate analysis 
 
 
 
 
 
 
KEY:  (a) derived using a multivariable logistic regression model including all variables with p value 
< 0.20 in univariable analysis, lymphovascular invasion, CK 14 expression, and PTEN loss, (b) 
reference category, (c) statistically significant (p< 0.05) 
 
 
 
 
 
 
Factors Odds ratio for IGFBP2 
positivity a 
(95% confidence interval) 
95% confidence interval  
for odds ratio 
Significance (p) 
Lower Upper 
Lympho-vascular 
invasion 
    
Absent  1.00 b    
Present 2.56 c 0.95 6.93 0.064 
CK 14 expression     
No 1.00 b    
Yes 0.23 c 0.08 0.64 0.005 
PTEN loss     
No 1.00    
Yes 2.74 c 1.02 7.39 0.047 
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Figure 6.2 The association of IGFBP-2 expression and absence of CK14 expression 
Top: x20 A triple negative infiltrating ductal carcinoma immunohistochemically stained for insulin 
like growth factor binding protein-2 (IGFBP-2). Bottom: x40 The same tumour 
immunohistochemically stained for Cytokeratin 14 whilst the normal glands stain positively ◀, the 
invasive tumour component is negative .  
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Figure 6.3 The association of IGFBP-2 expression and PTEN loss 
Top Left: x20 A triple negative IDC stained with Haematoxylin and 
Eosin Top Right: x20 the same IDC showing loss of PTEN staining in 
tumour cells  and positive surrounding stromal tissue ◀.  Bottom: x20 
Strong cytoplasmic staining for IGFBP-2 in tumour cells of the 
same case. 
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6.4.2 PTEN 
PTEN staining occurred in both the nucleus and cytoplasm of cancer cells.  Loss of nuclear and 
cytoplasmic immunostaining for PTEN occurred in 48.3% of triple negative cases; the remaining 
cases had weak PTEN staining or stronger staining of PTEN equal to that of the surrounding 
stromal tissue (figure 6.4).  Univariable analysis showed that loss of PTEN immunostaining was 
associated with younger age of onset; the median age of patients at diagnosis with tumours 
showing PTEN loss was 47 years old, compared with 57 years in those without PTEN loss 
(p=0.005).  PTEN loss was also associated with CK5/6 expression and IGFBP-2 expression, though 
these trends were not statistically significant in univariable analysis (p=0.097 and p=0.073 
respectively) (table 6.3).  In multivariable analysis, independent predictors of PTEN loss were 
younger age of onset (p=0.041), late stage (p=0.026), CK5/6 positivity (p=0.028) and IGFBP2 
expression (p=0.042) (table 6.4) (figures 6.3 & 6.5). 
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Figure 6.4 The types of PTEN staining 
Patterns of immunohistochemical staining for PTEN in three triple 
negative invasive breast carcinomas (IDC).  Top left:  x10 Cytoplasmic and 
nuclear staining of PTEN in the IDC tumour cells  and positive 
surrounding stromal tissue ◀.  Top right:  x10 Weak cytoplasmic and 
nuclear staining for PTEN in the IDC cells  compared to strong staining in 
the surrounding stromal tissue ◀.  Bottom:  x10 Absence of staining for 
PTEN in the IDC, indicating total loss of PTEN in the tumour compartment 
, with strong staining for PTEN in the adjacent stromal tissue ◀. 
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Figure 6.5 The association of PTEN loss with CK5/6 expression 
Top: x20 Loss of immunohistochemical staining for PTEN  in a triple negative IDC with PTEN 
positivity in surrounding stromal tissue ◀.  Bottom: x20 Strong cytoplasmic staining for cytokeratin 
5/6  in the same tumour with negative staining in surrounding stromal tissue◀. 
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Table 6.3 Factors associated with PTEN expression 
 
 
 
Key:  
a) Statistically significant (p less than 0.05) 
b) Compared using Mann-Whitney-U test 
c) Compared using Fisher’s Exact test 
d) There were no patients with grade 1 tumour 
e) Defined as an Allred Score of >5. 
 
 
 
 
 
Overall 
N (%) 
PTEN loss 
N(%) 
No PTEN loss 
N(%) 
P for X2 test 
No. of patients 89 43  46   
Age (median, years) 53 47 57 0.005 a b 
Ethnicity,     0.518 c 
Chinese 53 (59.6) 27 (62.8) 26 (56.5)  
Malay 21 (23.6) 10 (23.3) 11 (23.9)  
Indian 12 (13.5) 6 (14.0) 6 (13.0)  
Others 3 (3.4) 0 (0.0) 3 (6.5)  
Tumour size (median, cm) 3.0 3.5 3.0 0.236 b 
Lymph node involved,    0.250 
Yes 42 (47.2) 23 (53.5)           19 (41.3)   
No 47 (52.8) 20 (46.5) 27 (58.7)  
Stage,     0.078 
Early (Stage 1-2) 55(61.8) 23(53.5) 32(69.6)  
Late (Stage 3-4) 34(38.2) 20(46.5) 14(30.4)  
Grade d,     0.145 
Grade 2 16 (18.6) 5 (12.2) 11(24.4)  
Grade 3 70 (81.4) 36 (87.8) 34 (75.6)  
Unknown 3  2 1  
Lymphovascular invasion,     0.780 
Present 32 (40.5) 16 (42.1) 16 (39)  
Absent 
Unknown 
47 (59.5) 
10 
22 (57.9) 
5 
25 (61) 
5 
 
 
CK14 status,     0.354 
Negative 47 (54) 20 (48.8) 27 (58.1)  
Positive 40 (46) 21 (51.2) 19 (41.3)  
Unknown 87 2 0  
CK 5/6 status,    0.097 
Negative 23 (29.1) 8 (20.5) 15 (37.5)  
Positive 56 (70.9) 31 (79.5)  25 (62.5)  
Unknown 10 4 6  
IGBFP2,     0.073 
Positive e 31 (34.8) 19 (44.2) 12 (26.1)  
Negative 58 (65.2) 24 (55.8) 34 (73.9)  
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Table 6.4 Factors associated with PTEN expression in multivariate analysis 
 
 
 
 
 
 
 
KEY:  (a) Derived using a multivariable logistic regression model including all variables with p value 
< 0.20 in univariable analysis; age, stage, grade, CK 5/6, and IGBFP2 status, (b) Statistically 
significant (p<0.05), (c) Reference category 
 
 
 
 
Factors Odds ratio for PTEN lossa 
(95% confidence interval) 
95% confidence interval  
for odds ratio 
Significance (p) 
Lower Upper 
Age (years) 0.95 b 0.91 1.00 0.041 
Stage     
Early (Stage 1-2) 1.00 c    
Late (Stage 3-4) 3.76 b 1.17 12.10 0.026 
Grade     
Grade 2 1.00 c    
Grade 3 2.95 0.81 10.77 0.101 
CK 5/6 expression     
No 1.00 c    
Yes 3.94 b 1.16 13.34  0.028 
IGBFP2 expression     
No 1.00 c    
Yes 3.26 b 1.04 10.21 0.042 
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6.4.3 Survival analysis 
Triple negative cases with PTEN loss tended to have a worse  survival compared to cases without 
PTEN loss; 4-year relative survival rate (RSR) for patients with PTEN loss was 65.0% (95%CI: 45.2-
79.7%) as compared to 77.8% (95%CI: 60.8-89.0%) in those without PTEN loss; though this was 
not significant (figure 6.6). Similarly, cases with high levels of IGFBP-2 experienced marginally 
lower survival than their counterparts with low or negative IGFBP-2; 4-year RSR; 68.4% (95%CI: 
44.5-84.5) compared to 74.9% (95%CI:60.8-85.1) (figure 6.7), however this was not significant.  
 
 
 
 
 
 
 
 
 
 
Figure 6.6 PTEN expression and patient samples 
Kaplan Meier survival analysis was carried out for PTEN negative versus PTEN positive cases.  
Results show that PTEN positive cases had better survival than cases that were PTEN negative. 
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Figure 6.7 IGFBP-2 expression and patient survival 
Kaplan Meier survival analysis was carried out for IGFBP-2 negative versus IGFBP-2 positive cases.  
Results show that IGFBP-2 positive cases had poorer survival than cases that were IGFBP-2 
negative. 
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6.5 Discussion 
6.5.1 IGFBP-2 expression in TN breast cancer 
The IGFBP-2 staining pattern in the present study was similar to that noted by Busund et al. 
(2005) who also looked at IGFBP-2 expression in breast cancer.  An Allred score of 5 was used as a 
cut off point for IGFBP-2 positivity; using this cut off point 32% of cases were positive for IGFBP-2.  
This is a similar percentage to another study using an unselected breast cancer cohort; 37% of 
cases were moderate to strongly positive for IGFBP-2 So et al. (2008).  As the percentages are 
similar in both TN and unselected breast cancer cohorts, IGFBP-2 positivity may not be related to 
hormone receptor or Her2 status.  IGFBP-2 positivity was associated with lymphovascular invasion 
and worse breast cancer survival though neither of these trends reached statistical significance; 
possibly due to the small number of cases in the current study.  This data is consistent with that of 
So et al., who showed that of 3117 breast tumours that were assessable for both ERα status and 
IGFBP-2 expression, IGFBP-2 was not prognostic among the ERα positive tumours, but a trend was 
revealed towards worse breast cancer disease-specific survival in the ER negative tumours.  
However the study did not distinguish between Her2 positive and TN cases within in the ERα 
negative group.  Busund et al., (2005) also found that IGFBP-2 expression was higher in benign 
hyperplasia compared to normal tissue and that IGFBP-2 expression was highest in malignant 
breast cancer.  Furthermore, in vitro studies have demonstrated that over-expression of IGFBP-2 
in ER negative breast cancer cell lines and cell lines of other cancer types to include those of 
prostate, glioma and bladder, conferred a growth advantage, enhanced invasion and migration 
and chemoresistance (Kiyama et al., 2003; Miyake et al., 2005; So et al., 2008; Wang et al., 2008).  
Interestingly IGFBP-2 expression in tumours was linked to lack of staining for CK14. TN breast 
cancers are enriched for characteristics of epithelial mesenchymal transition (EMT) or 
mesenchymal epithelial transition (MET); changes in CK14 expression can be indicative of EMT or 
MET (Hugo et al., 2007; Mani et al., 2008; Savagner, 2010).  It can be speculated that these 
tumours may be undergoing EMT or MET and that IGFBP-2 may be involved.  However, further 
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studies would be required to confirm this.  Perhaps using additional cytokeratin markers would 
help further understand the relationship between IGFBP-2 and basal like phenotype.  A recent 
study showed that IGFBP-2 promotes angiogenesis in neuroblastoma cells via direct activation of 
the VEGF promoter (Azar et al., 2011) and anti-VEGF therapy of gliomas, infiltrating tumour was 
associated with increased levels of IGFBP-2 (de Groot et al., 2010).  VEGF can be targeted and 
clinical trials have taken place using such drugs against VEGF in TN breast cancer.  For example 
bevacizumab a monoclonal antibody against VEGF has shown promise when used with cisplatin 
against TN breast cancer (Ryan et al., 2009); perhaps co-targeting IGFBP-2 and VEGF might be of 
benefit in TN breast cancer if IGFBP-2 is further demonstrated to be associated with poor 
prognosis.  In addition over-expression of EGFR and IGFBP-2 has been observed in high grade 
astrocytomas and co-expression of these genes was strongly associated with high grade gliomas 
and lower survival. This report suggested that co-expression of these genes had a more important 
clinical and biological impact than the expression of each individual gene alone (Scrideli et al., 
2007).  EGFR is strongly associated with TN breast cancer and is a potential target for therapy 
(Sarrio et al., 2008; Gluz et al., 2009); there may now be rationale for assessing EGFR status in 
relation to IGFBP-2 expression in TN breast cancers as perhaps co-targeting both of IGFBP-2 and 
EGFR for example with, monoclonal antibody therapy, would provide a better outcome. 
 
6.5.2 PTEN loss of expression in TN breast cancer 
Loss of PTEN staining in the invasive tumour compartment was readily assessable, as strong 
positive staining of the adjacent non-tumour stroma serves as an excellent internal positive 
control, as previously reported (Perren et al., 1999).  In the current study, PTEN expression in 
tumour cells is lost in nearly half of TN breast cancers using the antibody clone 6H2.1.  Notably, 
the extent of PTEN loss in triple negative breast cancer was significantly higher than that reported 
utilising the same PTEN antibody in an unselected breast cancer cohort (Lopez-Knowles et al., 
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2009).  Clone 6H2.1 is the recommended marker for immunohistochemical analysis of PTEN loss 
as it is the only antibody that exhibits a correlation with molecular alterations in PTEN (Pallares et 
al., 2005) and shows correlation between western blot analysis and PTEN mutational and allelic 
status (Perren et al., 1999).  Another reason for the extent of PTEN loss could be due to 
differences in the type of cohort.  The cohort in the present study was of Asian origin; breast 
cancers in Malaysia tend to be more aggressive than in other countries (section 1.9).  Dietary and 
lifestyle factors have been suggested as reasons for these differences.  However with respect to 
PTEN loss a study looking at PTEN loss and mutations in colorectal cancer found no correlation 
with dietary factors (Naguib et al., 2011).  One way of investigating whether the frequency of 
PTEN loss is high in TN breast cancer or associated with Malaysian breast cancer would be to use 
IHC staining for PTEN on a local UK TN breast cancer cohort.  Interestingly, loss of PTEN was 
significantly associated with a younger age at diagnosis.  This reflects the findings by Anders et al. 
(2008) where PTEN expression and genes involved in related signalling pathways were altered in 
breast cancers that occurred in patients 45 years old and younger.  Collaborative work has led to 
publication of the association of PTEN loss with age and has also demonstrated that PTEN status 
assessed by IHC increases the sensitivity of the Manchester score analysis.  The Manchester score 
analysis uses criteria including grade, hormone and Her2 receptor status to predict BRCA1 and 
BRCA2 mutations (Phuah et al., 2012).   
There was a significant association of PTEN loss with CK5/6 positivity.  This probably reflects the 
association of PTEN loss with basal-like phenotype and is in conjunction with other studies (Marty 
et al., 2008; Neto et al., 2012).  Although not significant, there was an association between PTEN 
loss and reduced breast cancer survival; this is in agreement with significant findings by Depowski 
et al (2001) in a cohort of breast cancers not selected on the basis of TN status. TN cohorts 
generally tend to have poorer survival than unselected cohorts of breast cancer cases.  
Consequently, it is probably necessary to study larger TN cohorts with PTEN loss in order to 
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establish whether the trend observed in the current study becomes significant, when larger 
numbers of cases are included.  
 
6.5.3 IGFBP-2 expression is associated with PTEN loss 
This is the first immunohistochemical study to show an association  between IGFBP-2 expression 
and PTEN loss and supports the evidence from in vitro cell line studies that show IGFBP2 down-
regulates PTEN (Perks et al., 2007) and conversely that over-expression of PTEN has been shown 
to reduce IGFBP-2 expression (Levitt et al., 2005). These studies indicate IGFBP-2 plays a role in 
the PI3K signalling pathway that is known to be involved in promoting survival and growth (Hers 
et al., 2011).  A recent study has investigated the relationship between PTEN loss and IGFR-1 
expression in TN breast cancer cases; it was found that PTEN loss was associated with IGFR-1 
over-expression and that together these markers may be useful in predicting reoccurrence in TN 
breast cancer and may prove useful targets of therapy.  This provides further evidence of the 
overlap between the IGF axis, PTEN and the PI3K pathways (Iqbal et al., 2012).  There are several 
potential pathways that could be behind this inverse relationship; one is that increased IGFBP-2 
expression by breast cancer cells could partially diminish or ablate the expression of PTEN protein, 
potentially via interaction with integrin receptors (Perks et al., 2007).  Further work could also 
investigate how IGFBP-2 impacts on the catalytic activity of PTEN.  PTEN possesses a carboxy-
terminal, non-catalytic regulatory domain with three phosphorylation sites (Ser380, Thr382 and 
Thr383) that regulate its biological activity (Vazquez et al., 2000; Torres et al., 2001). Antibodies 
are available that recognize phosphorylation at these sites and may prove useful in further studies 
to investigate the relationship between IGFBP-2 expression and PTEN phosphorylation and thus 
activity.  
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6.6 Conclusions 
In summary this chapter has shown that IGFBP-2 over expression is a frequent event in TN breast 
cancer and was associated with poor prognosis, though this trend was not significant.  It has 
shown that loss of PTEN can be readily assessed by immunohistochemistry and that PTEN loss is a 
frequent event in triple negative breast cancers.  PTEN loss is significantly associated with a 
younger age of onset of breast cancer and late stage of presentation.  This is the first 
immunohistochemical study to show an association between IGFBP-2 expression and PTEN loss 
and supports the evidence from in vitro cell line studies that show IGFBP2 down-regulates PTEN. 
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7 General Discussion 
 
Breast cancer is the most common type of cancer in the UK and current guidelines recommend 
that all cases be tested for expression of the biomarkers of ER, PR and Her2 (Wolff et al., 2007; 
Hammond et al., 2010).  These subtypes of breast cancer can be treated with targeted therapies 
such as tamoxifen and trastuzumab for ER and Her2 positive breast cancer, respectively.  
However, some breast cancers do not express ER, PR or Her2 and are consequently classified as 
triple negative breast cancer and targeted therapy is not available for this type of disease.  To 
define any cancers by the markers they do not express will never be completely satisfactory.  One 
aim of this research was to investigate new biomarkers of relevance in TN breast cancer and 
relate biomarker expression to patient and clinicopathological features.  A further aim was to 
investigate the expression of a particular biomarker of interest, FABP7, in cell line models and 
relate expression of FABP7 to features such as survival and apoptosis in cell lines. 
 
Expression profiling and IHC studies have identified FABP7 to be over-expressed in basal-like 
breast cancer, and consequently TN breast cancer, as over 80% of basal like breast cancer have 
been found to lack expression of ER, PR and Her2.  However the significance of FABP7 with 
prognosis in breast cancer is unclear and studies have given conflicting evidence (Zhang et al., 
2010; Tang et al., 2010).  The in vivo patient sample work (chapter 3) sought to investigate the 
association of FABP7 with clinicopathological features in a cohort of Malaysian TN breast cancer 
cases.  It was found that FABP7 expression was associated with lower breast cancer stage and the 
basal-like phenotype.  There was also a trend for cases with high levels of FABP7 to have 
improved survival, though this trend was not significant, they are in agreement with an earlier 
study in an unselected cohort (Zhang et al., 2010).  The results also suggest that the role of FABP7 
218 
 
expression is similar in both Malaysian and western breast cancer cohorts.  One way of confirming 
any similarities is to compare FABP7 staining frequency in the Malaysian cohort to a UK breast 
cancer cohort, using the same FABP7 antibody; work has been undertaken to begin this 
investigation.  A longer follow-up period and perhaps larger cohorts, comparing the UK and 
Malaysian cohorts, may help confirm the relationship between FABP7 expression and breast 
cancer survival.   
 
In the current study, interestingly FABP7 and FAS expression were positively associated suggesting 
a link between fatty acid metabolism and FABP7 expression; further work would involve 
investigating the relationship in a UK TN breast cancer cohort and to use cell line models to 
investigate whether the expression of FAS is influenced by FABP7 expression or vice versa.  The 
aim of the study was also to investigate FABP7 mRNA and protein in breast cancer cell lines in 
order to choose an appropriate model for further investigation of FABP7.  BT-20 cells were found 
to express the highest amount of FABP7 mRNA and protein out of the breast cancer cell lines 
investigated; BT-20 cells are of basal like phenotype so this was anticipated.  However, mRNA 
expression was lower overall than expected and FABP7 protein was not detectable without a 
highly modified western blot protocol.  Whilst expression was highest in the BT-20 cell line, it was 
not expressed at high enough levels suitable for knock-down experiments.  Given the high level of 
FABP7 expression amongst the TN cases with the basal like phenotype, it was expected that at 
least one of the cell lines expressing a similar phenotype (BT-20, MDA-MB-231, MCF10A, and 
HS578T) may have levels of FABP7 at sufficient level to allow knock-down.  This may explain the 
paucity of in vitro cell line studies utilising a breast cancer cell line that naturally expresses FABP7.  
Other studies have had similar findings; one study used the MDA-MB-435 cell line to knock-down 
FABP7 (Liu et al., 2012) though evidence suggests that this cell line may be of melanoma origin 
rather than breast cancer origin (Rae et al., 2007; Lacroix, 2009).  A limiting factor may be the 
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number of cell lines tested; each cell line would have been originally derived from one patient; 
nine cell lines may not be a large enough selection to be representative of FABP7 expression in 
clinical cases.  Though notably based on IHC results it was expected that at least one of the basal-
like cell lines investigated would express FABP7.  Alternatively, there might be factors absent in 
vitro that are essential for FABP7 expression; for example, fat exposure or the epigenetic status of 
FABP7 may be different in the cell lines used in the present study compared to patient samples. 
 
Another aim was to more fully understand the mechanisms that regulate FABP7 expression and 
thus identify factors that may or may not be occurring in vitro; this was investigated by treating 
BT-20 and MDA-MB-231 cells with AZA, TSA and the FAs oleate, palmitate, AA and DHA (chapter 
4).  There is an abundance of evidence suggesting that FABP7 is regulated by epigenetic 
mechanisms (reviewed in section 1.6.1) but little if any work has looked at whether methylation 
or acetylation are factors associated with FABP7 expression in breast cancer cell lines.  AZA 
significantly increased FABP7 mRNA expression but not to a level that was expected.  If FABP7 was 
methylated directly then larger fold changes may have been expected, perhaps similar to fold 
changes of ER re-expression with AZA treatment in breast cancer cell lines (Yang et al., 2001).  It 
was therefore concluded that FABP7 was indirectly regulated by methylation and acetylation.  A 
combined bisulfite restriction analysis (COBRA) assay may have been useful in confirming whether 
FABP7 was methylated but CpG islands could not be identified in the FABP7 promoter region.  
However methylation can occur at other regions of the gene and at regions other than CpG 
islands (Wozniak et al., 2007).  Possible mechanisms for the increased expression of FABP7 with 
AZA treatment are outlined in figure 7.1; a transcription factor of FABP7, for instance STAT3 could 
be methylated or a regulator of the transcription factor such as cAMP response element binding 
protein (CREB) could be methylated thus preventing FABP7 expression in both instances. 
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Figure 7.1 The indirect mechanisms by which methylation could alter FABP7 expression 
A transcription factor, such as STAT3, NF-1 or ERG-4, upstream of FABP7 is re-expressed after AZA 
treatment resulting in an increase in FABP7 expression.  Alternatively a regulator of a 
transcription factor such as cAMP response element binding protein (CREB) for STAT3, E2 factor-5 
(E2F-5) for NF-1 and activating transcription factor-1 (AFT-1) for ERG-4, is demethylated after AZA 
treatment leading to increased expression of both the transcription factor (e.g. STAT3) and in turn 
FABP7. 
 
The results of chapter 3 also showed that FA treatments on their own resulted in small but 
significant changes of FABP7 mRNA expression.  However when FAs were combined with AZA 
treatment significant increases in FABP7 expression resulted.  Firstly, the double dose of AZA 
significantly increased FABP7 mRNA expression and it was postulated that this was due to the 
indirect nature of methylation impacting on FABP7 expression; longer time of exposure and a 
higher dose of AZA is required to activate and re-express targets upstream of FABP7.  When AZA 
was combined with FA treatment palmitate synergistically increased FABP7 expression and 
oleate, AA and DHA decreased FABP7 mRNA compared to AZA treatment alone.  The reasons that 
have been put forward in light of these results are that palmitate may facilitate the binding of 
transcription factors or co-activator to genes that are re-expressed after AZA treatment.  Oleate, 
AA and DHA prevent binding of co-activators and transcription factors to genes after 
demethylation by AZA treatment.  This hypothesis is summarised in figure 7.2 
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Figure 7.2 The potential mechanisms by which FAs and methylation interact to alter FABP7 
expression. 
AZA treatment demethylates genes that regulate the expression of FABP7 such as STAT3, NF-1 
and ER-4. Additional treatment with palmitate could lead to the facilitation of transcription of 
FABP7 or genes upstream of FABP7 by increasing transcription or co-activator binding.  Oleate, AA 
and DHA have the opposite effect of palmitate and may prevent binding of transcription factors 
and co-activators. 
 
Further work would involve identifying transcription factors of FABP7; genecards identifies STAT3 
as one potential candidate.  A chromatin immunoprecipitation (chIP) assay would be useful in 
identifying whether STAT3 binds to FABP7 in breast cancer cell lines.  If STAT3 is a transcription 
factor to FABP7 or others were identified, methylation studies could be carried out to further 
investigate how AZA alters FABP7 expression.  An alternative to epigenetic mechanisms and FAs 
being absent in vitro compared to in vivo, is the 3D tumour microenvironment.  For instance there 
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is no stromal tissue present within the cell line culture environment; therefore interactions that 
may stimulate FABP7 expression would not occur.  3D spheroid culture or animal models may 
help further understand in vivo expression of FABP7 and any interaction with stromal tissue. 
 
Over-expression experiments (chapter 5) set out to understand the role of FABP7 and alterations 
in the phenotype of BT-20 cells, when FABP7 is over-expressed.  To summarise, part of the work 
demonstrated that FABP7 over-expression increased mitochondrial activity/cell viability and 
reduced cell death.  It is unlikely that FABP7 over-expression altered the result of the MTT assay 
by increasing cell turnover and thus number of mitochondria per well of the culture vessel, 
because total cell numbers were unchanged between transfection conditions.  In relating this 
finding to the in vivo patient sample work (chapter 3), it seems counterintuitive that increased 
mitochondrial activity/cell viability as a result of FABP7 over-expression relates to FABP7 
expression being associated with a better prognosis.  If FABP7 positive breast cancer cells in vivo 
were more metabolically active and/or viable, than FABP7 negative counterparts, it seems logical 
to assume that FABP7 positivity may indicate a poor prognosis.  This study has suggested that 
FABP7 may increase cell viability by decreasing the production of ROS; ROS have been implicated 
to contribute to tumourigenesis and metastasis by causing damage to mitochondrial DNA and 
thus disrupting mitochondrial function (Ishikawa et al., 2008).  A very recent study has shown that 
mitochondrial complex I activity is important in regulating breast tumour growth and metastasis 
through regulation of the balance between NADH and NAD+ (oxidised NADH) and also through 
generation of ROS (Santidrian et al., 2013).  It can be theorised that FABP7 may restore or 
maintain the energy balance of mitochondrial complex I either by directly making FAs available to 
the energy pathways or by shuttling the FAs for conversion to molecules that enter the pathway.  
Alternatively FABP7 may prevent the production of ROS either by preventing or making FAs 
available to metabolic pathways.  In both instances this could explain how FABP7 over-expression 
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is associated with an improved patient prognosis and increased cell viability/mitochondrial 
activity.  Further work is required to understand the relationship between FABP7 and 
mitochondrial activity. 
 
FABP7 over-expression did not alter cell death induced by STRP, possibly due to the multiple 
pathways through which STRP induces apoptosis.  This could indicate that FABP7 does not alter 
sensitivity to cell death.  This phenotype may be useful, as chemotherapy drugs used to treat TN 
breast cancer, induce cell death through a number of pathways.  For instance chemotherapy 
drugs can induce apoptosis through activation of caspases or mitochondrial death pathways, or 
can induce cell death by necrosis and autophagy (Fulda & Debatin, 2006).  This shows that 
chemotherapy drugs, like STRP, have multiple mechanisms of action; it also could be postulated 
that FABP7 is not involved with resistance to chemotherapy drugs though further research is 
required in order to understand FABP7 expression in relation to sensitivity to chemotherapy drugs 
for TN breast cancer.  To investigate the role of FABP7 in sensitivity to cell death, BT-20 cells were 
treated with FAs post transfection.  Relative to the control vector transfected cells, FABP7 over-
expression reduced cell death caused by FA treatment.  It was postulated that this could be due to 
FABP7 sequestering the FAs so they are not available to activate apoptotic pathways; for instance 
palmitate can induce death through conversion to ceramide; FABP7 may bind palmitate and 
prevent ceramide synthesis so apoptosis is not activated.  An alternative is that FABP7 shuttles 
the FAs to the nucleus so that anti-apoptotic pathways are activated and pro-apoptotic pathways 
are inhibited.  As a result of this theory it is possible that the combination of both FABP7 
expression and the intake of various FAs in the diet, play a role in breast cancer development and 
progression; it would be interesting to investigate further the combined effect of FABP7 and fatty 
acids on the cell line characteristics, for instance cell migration and invasion.  FABP7 over-
expression did not alter FA accumulation, as demonstrated with oil red O staining, suggesting that 
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the role of FABP7 in breast cancer cell lines is to shuttle FAs and solubilise them so that various 
metabolic and viability pathways are activated or inhibited. 
 
A further aim of the FABP7 over-expression studies (chapter 4) was to investigate whether over-
expression of FABP7 altered the expression of bcl-x, survivin and caspase 9 splice variants; these 
genes are involved in the regulation of apoptosis and survival and the ratio of splice variant 
expression can give an indication on both anti- and pro- apoptotic properties.  There were no 
changes in the expression of bcl-x splice variants in FABP7 over-expressing BT-20 cells.  Bcl-xL is 
the variant predominantly over-expressed in breast cancer and is associated with high tumour 
grade (Olopade et al., 1997).  Considering that FABP7 in the present study was associated with a 
better patient survival, it could be speculated that there would be a reduction in expression of 
bcl-xL and/or an increase in the expression of bcl-xs; however the results indicate that FABP7 does 
not play a role in bcl-x signalling pathways.  There were also no changes in the ratio of caspase 9 
splice variants nor any obvious patterns in expression of individual splice variant expression in 
relation to FABP7 expression.  One suggested reason for this was that FABP7 inhibits apoptosis 
independently of caspase 9; perhaps through inhibition of ROS production in mitochondria or 
increased mitochondrial activity; this is supported by the MTT assay results in FABP7 over-
expressing BT-20 cells.  Interestingly there was a trend for FABP7 over-expressing BT-20 cells to 
have increased expression of survivin ΔEX3, survivin FL and increased ratio of survivin 
ΔEX3:survivin FL.  Although not significant this trend was of note as the increased survivin 
expression was in line with results showing decreased apoptosis after FA treatment and increased 
mitochondrial activity/cell viability.  It was hypothesised that FABP7 could be shuttling various FAs 
to the nucleus of cells and alter gene expression, or to the mitochondria to alter mitochondrial 
activity, energy production and in turn cell viability; in both cases leading to alterations in survivin 
expression.  It is interesting that FABP7 increased survivin expression; as with the increased 
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mitochondrial activity, it seems counterintuitive that this should be the case considering that in 
patient samples there is a trend for FABP7 expression to be associated with better survival.   
There is conflicting evidence as to the role of survivin in breast cancer.  For example one study 
looked at survivin with IHC and found that nuclear staining for survivin was an independent 
predictor of favourable prognosis (Kennedy et al., 2003).  Another study found that survivin was 
associated with a poor prognosis but nuclear and cytoplasmic localisation was not distinguished 
(Hinnis et al.,; 2007).  One study even found that survivin ΔEx3 was correlated positively with 
apoptosis (Ryan et al., 2005).  Further work is required to understand the role of FABP7 in relation 
to apoptosis and survival and expression of genes in these pathways.  A limitation of transient 
over-expression is that only short term effects of FABP7 over-expression could be studied.  
Further work could investigate the long term effects of FABP7 expression, possibly using a stable 
transfection; perhaps trends such as changes in survivin expression may become clearer. 
 
Figure 7.3 was compiled based on the findings of this research.  It shows the potential 
mechanisms that could regulate FABP7 and shows how FABP7 may alter gene expression and cell 
survival.   
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Figure 7.3 The potential roles of FABP7 in TN breast cancer cell lines 
This diagram was produced based on the findings of this research.  FABP7 is regulated indirectly 
by methylation, perhaps by the transcription factor STAT3.  FABP7 can interact with FAs perhaps 
and shuttle them to the nucleus.  The FAs may then activate or inhibit the transcription of FABP7 
directly or indirectly in conjunction with epigenetic mechanisms.  FABP7 may shuttle FAs around 
the cell to impact upon gene expression and mitochondrial activity. 
 
The role of IGFBP-2 and PTEN in TN breast cancer patient samples was investigated (chapter 6).  
IGFBP-2 is a member of the IGF-axis and is involved in regulating the action and binding of IGFs to 
the IGF receptor.  Similarly to FABP7, IGFBP-2 is involved in aspects of metabolism and breast 
cancer development and progression.  This information is reviewed in section 1.7.  IGFBP-2 has 
actions that are independent of the IGF-axis; figure 1.15 shows that IGFBP-2 down-regulates the 
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expression of the tumour suppressor gene PTEN in cell line models (Perks et al., 2007).  However 
studies have yet to investigate the expression of IGFBP-2 in TN breast cancer and no study until 
now has investigated the relationship between IGFBP-2 and PTEN expression in patient samples.  
The main finding of chapter 6 was that IGFBP-2 expression is significantly associated with loss of 
PTEN expression in TN breast cancer cases.  Loss of PTEN expression was also found to be a 
frequent event in TN cancer when compared to other studies using the same PTEN antibody for 
IHC on breast cancer cohorts not selected on the basis of their TN status (Lopez-Knowles et al., 
2009).  Further studies would investigate whether the relationship found in the current study 
between IGFBP-2 and PTEN in a Malaysian TN breast cancer cohort, is present in a UK TN cohort 
and also whether the frequency of PTEN loss found in the present study is comparable to that in a 
UK TN cohort.  
 
7.1 Conclusions 
To summarise, this research has shown that FABP7 expression in patient samples is associated 
with lower stage of breast cancer, the basal-like phenotype and expression of FAS.  There was also 
a trend for FABP7 positive patient samples to have better survival than FABP7 negative cases.  
This is the first study to show that FABP7 protein and mRNA is expressed in low but detectable 
levels in breast cancer cell lines and expression of FABP7 mRNA may be indirectly regulated by 
epigenetic mechanisms such as methylation.  FABP7 over-expression leads to increased 
mitochondrial activity/cell viability and prevented death after FA treatment.  FABP7 over-
expression did not significantly alter the expression of bcl-x, survivin and caspase 9 splice variants 
but there were trends.  FABP7 over-expressing BT-20 cells tended to have increased survivin FL 
and ΔEX3 expression.  Both increased mitochondrial activity and survivin expression have been 
found to be associated with improved prognosis in breast cancer and this may explain some 
mechanisms by which FABP7 results in better prognosis in the TN breast cancer cases in this 
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study.  This is the first study that demonstrates the significant relationship between IGFBP-2 
expression and PTEN loss in patient samples.  PTEN loss is a frequent event in TN breast cancer.  
IGFBP-2 and PTEN loss may be useful markers of prognosis in TN breast cancer. 
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9 Appendix I: Fatty acid dosing method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40mM stock  
solution 
0.2mM 
Take 50µl of 
4mM stock and 
950µl of 20% 
BSA SFM 
1µM 
Take 1ml of 
 5µM solution 
and 4ml of BSA 
free SFM 
5µM 
Take 75µl of 
0.2mM solution 
and 2925µl of 
BSA free SFM 
0.2mM 
Take 50µl of 
4mM stock and 
950µl 4% BSA  
SFM 
5µM 
Take 1ml of 
25µM solution 
and 4ml of BSA 
free SFM 
25µM 
Take 375µl of 
0.2mM solution 
and 2625µl of 
BSA free SFM 
2mM 
Take 50µl of 
40mM stock and 
950µl of 20% 
BSA SFM 
10µM 
Take 1ml of 
50µM solution 
and 4ml of BSA 
free SFM 
50µM 
Take 75µl of 
20mM solution 
and 2925µl of 
BSA free SFM 
2mM 
Take 50µl of 
40mM stock and 
950µl of 10% 
BSASFM 
20µM 
Take 1ml of 
100µM solution 
and 4ml of BSA 
free SFM 
100µM 
Take 150µl of 
20mM solution 
and 2850µl of 
BSA free SFM 
2mM 
Take 50µl of 
40mM stock and 
950µl of 4% BSA 
SFM 
50µM 
Take 1ml of 
250µM solution 
and 4ml of BSA 
free SFM 
250µM 
Take 375µl of 
20mM solution 
and 2625µl of 
BSA free SFM 
Dilute 40mM 1:10 with ETOH 
to make 4mM 
Arachidonic Acid Dose Volumes 
Final concentration of BSA for all doses is 0.1%    Final concentration of ETOH for all doses is <0.1%   ETOH is filter steralised 
Fatty acid free BSA is made up then filter steralised   All solutions are heated and mixed thoroughly at each stage 
400mM stock  
solution 
2mM 
Take 50µl of 
40mM stock and 
950µl of 4% BSA 
SFM 
50µM 
Take 1ml of 
250µM solution 
and 4ml of BSA 
free SFM 
250µM 
Take 375µl of 
2mM solution and 
2625µl of BSA 
free SFM 
20mM 
Take 50µl of 
400mM stock and 
950µl of 20% 
BSA SFM 
100µM 
Take 1ml of 
500µM solution 
and 4ml of BSA 
free SFM 
500µM 
Take 75µl of 
20mM solution 
and 2925µl of 
BSA free SFM 
20mM 
Take 50µl of 
400mM stock and 
950µl of 10% 
BSA SFM 
200µM 
Take 1ml of 
1000µM solution 
and 4ml of BSA 
free SFM 
1000µM 
Take 150µl of 
20mM solution 
and 2850µl of 
BSA free SFM 
20mM 
Take 50µl of 
400mM stock and 
950µl of 5% BSA 
SFM 
400µM 
Take 1ml of 
2000µM solution 
and 4ml of BSA 
free SFM 
2000µM 
Take 300µl of 
20mM solution 
and 2700µl of 
BSA free SFM 
20mM 
Take 50µl of 
400mM stock and 
950µl of 4% BSA 
SFM 
500µM 
Take 1ml of 
2500µM solution 
and 4ml of BSA 
free SFM 
2500µM 
Take 375µl of 
20mM solution 
and 2625µl of 
BSA free SFM 
Dilute 400mM 1:10 with 
ETOH to make 40mM 
Oleate and Palmitate Dose Volumes 
Final concentration of BSA for all doses is 0.1%    Final concentration of ETOH for all doses is <0.1%   ETOH is filter steralised 
Fatty acid free BSA is made up then filter steralised   All solutions are heated and mixed thoroughly at each stage 
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40mM stock  
solution 
2mM 
Take 50µl of 
4mM stock and 
950µl of 20% 
BSA SFM 
10µM 
Take 1ml of 
 50µM solution 
and 4ml of BSA 
free SFM 
50µM 
Take 75µl of 
2mM solution and 
2925µl of BSA 
free SFM 
2mM 
Take 50µl of 
4mM stock and 
950µl 10% BSA  
SFM 
20µM 
Take 1ml of 
100µM solution 
and 4ml of BSA 
free SFM 
100µM 
Take 150µl of 
2mM solution and 
2850µl of BSA 
free SFM 
2mM 
Take 50µl of 
40mM stock and 
950µl of 4% BSA 
SFM 
50µM 
Take 1ml of 
250µM solution 
and 4ml of BSA 
free SFM 
250µM 
Take 375µl of 
2mM solution and 
2625µl of BSA 
free SFM 
2mM 
Take 50µl of 
40mM stock and 
950µl of 2% BSA 
SFM 
100µM 
Take 1ml of 
500µM solution 
and 4ml of BSA 
free SFM 
500µM 
Take 750µl of 
2mM solution and 
2250µl of BSA 
free SFM 
2mM 
Take 100µl of 
40mM stock and 
1800µl of 1% 
BSA SFM 
200µM 
Take 1ml of 
1000µM solution 
and 4ml of BSA 
free SFM 
1000µM 
Take 1500µl of 
2mM solution and 
1500µl of BSA 
free SFM 
Docosahexaenoic Acid Dose Volumes 
Final concentration of BSA for all doses is 0.1%    Final concentration of ETOH for all doses is <0.1%   ETOH is filter steralised 
Fatty acid free BSA is made up then filter steralised   All solutions are heated and mixed thoroughly at each stage 
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